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Cytosolic glutathione transferases (GSTs) are a large family of enzymes that 
play an important role in detoxification of xenobiotics. They catalyse the conjugation 
of the glutathione tripeptide (GSH) to a wide range of toxic electrophilic acceptors. 
The overall 3D folds and architectures of the catalytic sites of many GSTs are 
conserved. They are composed of a well conserved glutathione binding site (G-site) 
and a promiscuous hydrophobic binding site (H-site). The 3D structure and ligand 
specificity has allowed the sub-classification of the multiple isoforms within the 
soluble GST superfamily. GSTs are involved in the drug detoxification and so are the 
target of medicinal chemistry programmes but it has proven difficult to generate 
isoform-specific inhibitors due to their inherent promiscuity. 
In this project, Venughopal Bhat (University of Edinburgh, laboratory of Dr. 
Mike Greaney) and I have explored a new platform to probe enzyme specificity. 
Protein-directed dynamic combinatorial chemistry (DCC) allows the assembly and 
amplification of a ligand within the confines of a binding site. DCC was used as a tool 
to explore the promiscuous H-site of four eukaryotic GSTs. I purified recombinant 
forms of SjGST, hGST P1-1, mGST M1-1 and mGST A4-4 from E. coli and assayed 
them with the universal, synthetic GST substrate 1-chloro-2,4-dinitrobenzene (CDNB). 
Venughopal Bhat prepared a ten-member, thermodynamically-controlled, dynamic 
combinatorial library (DCL) of acyl hydrazones from a 1-chloro-2-nitrobenzene 
aldehyde and ten acylhydrazides. This DCL was incubated with each of the four GST 
isozymes (spanning diverse classes) and distinct amplification effects were observed 
for SjGST and hGST P1-1. I subsequently carried out several biophysical experiments 
in an attempt to rank each of the ligands. These experiements, coupled with molecular 
modelling, provided insight into the basis of the observed selectivity. 
Bacterial GSTs are thought to play a role in primary metabolism and display a 
different GSH-conjugation mechanism compared to the eukaryotic GSTs. A 
recombinant form of the beta-class GST from the pathogenic bacterium Burkholderia 
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cenocepacia was isolated, purified and biochemically characterised. The same ten-
member acylhydrazone DCL was interfaced with the bacterial GST which was shown 
to amplify a hydrophobic library member that shared structural features with the 
known substrate 2-hydroxy-6-oxo-6-phenyl-2,4-dienoate (HOPDA).  
With the collaboration of Venughopal Bhat, I attempted to explore the 
putative active site of a GST-like protein with an unknown function using the same 
DCL. Although no amplification was observed, a new aldehyde template was 
suggested for future DCC experiments on this protein. 
GSTs are widely employed in biotechnology as protein fusion tags to enhance 
target protein solubility coupled with a facile enzyme assay. Manish Gupta and Juan 
Mareque-Rivas (University of Edinburgh) used the N-terminal, hexahistidine-tagged 
SjGST to demonstrate that quantum dots (QDs) coated with nitrilotriacetic acid (NTA) 
bound to Ni2+ ions can be used to reversibly and selectively bind, purify, and 
fluorescently label a His6-tagged GST in one step with retention of enzymatic activity. 
For this prupose, I purified and characterized both the untagged and hexahistidine-
































Chapter 1: Probing the active site of four eukaryotic 









1.1. Introduction  
1.1.1. Introduction to glutathione transferases 
1.1.1.1. Glutathione transferases – role in cellular detoxification 
 
All living organisms are open systems constantly interacting with their 
environment. They can take up various nutrient compounds required for growth which 
are metabolised through catabolic pathways which degrade these molecules to liberate 
their energy and produce small building blocks. Anabolic pathways integrate them into 
newly synthesized macromolecules. All these biochemical reactions are rigorously 
controlled by various enzymes. Waste and heat are released back to the environment.  
A xenobiotic is a chemical which enters a cell but has no physiological 
function, or an endogenously produced substance (endobiotic) present in a higher 
concentration than expected. Drugs, some food constituents, cosmetics, toxins, 
pollutants are considered as xenobiotics in humans because they are not synthesized by 
the human body, nor are they essential nutrients. The body removes xenobiotics by 
detoxication and secretion of the resulting substances through urine, feces, sweat or 
breath [1]. The metabolism of xenobiotics can be divided into three phases: (I) 
activation, (II) conjugation and (III) excretion. Phase I and phase II involve the 
conversion of a hydrophobic xenobiotic molecule to a relatively more water-soluble and 
therefore less toxic metabolite, which can then be easily eliminated from the cell (phase 
III). In phase I, a variety of enzymes, mainly cytochrome P450 systems, creates or 
modifies a functional group on their substrates. These reactions include reduction, 
oxidation, hydrolysis and hydration [2]. In phase II, which can also occur without or 
before phase I, xenobiotics are conjugated to endogenous more water-soluble substrates 
such as glutathione (GSH), glucuronic acid or glycine. These reactions are catalysed by 
several groups of transferases [1, 3-7]. Glutathione Transferases (also known as 
Glutathione S-Transferases; GSTs) constitute the most important group of transferases, 
and catalyse the conjugation of glutathione to a wide range of electrophilic substrates. 
Once conjugated, xenobiotics can be further metabolized: in particular, glutathione 
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conjugates are processed to acetylcysteine conjugates through the mercapturic acid 
pathway (MAP) [8]. In phase III, transformed xenobiotics are released from cells 
through a variety of membrane ATP-dependant pump systems [9].  
 
1.1.1.2. The mercapturic acid pathway  
 
The body can detoxify many xenobiotics via the glutathione-dependant 
mercapturic acid pathway (Figure 1.1.), through inter-organ cooperation between the 
liver, kidney and intestine. This starts with the formation of a thioether of glutathione, 
which is ultimately converted to a mercapturic acid (S-substituted N-acetylated-L-
cysteine). Mercapturic acids are organic acids, and are therefore more water-soluble than 
the entering xenobiotics. Their higher solubility facilitates their excretion [8].  
Firstly, whereby an electrophilic molecule is attacked by the tripeptide 
glutathione, is catalysed by GSTs. These enzymes are found in all tissues and cell types 
but are more abundant in the liver. They bring together the electrophilic centre of a 
xenobiotic with the activated thiolate of glutathione. Their glutathione binding site is 
well conserved throughout the family but they have a broad specificity towards the 
hydrophobic xenobiotics [8, 10-12]. The GST super-family will be presented and 
discussed further in the following sections. 
The conjugated compound is exported from the cell by an ATP-dependent 
transport and is either excreted in the biliary canniculae or transported to the kidney. 
Here the glutathione moiety is degraded to a cysteine in a two-step mechanism. γ-
glutamyl transpeptidase – an extra-cellular membrane-bound enzyme – catalyses the 
first step by removing a glutamate. The isopeptide bond between the γ-carboxyl of 
glutamate and the amino group of cysteine is cleaved, and the γ-glutamyl is either 
hydrolysed or transferred to an acceptor amino-acid and a cysteinylglycine conjugate 
remains [8, 13-16].  
The second step in the degradation of the glutathione moiety is also thought to 
happen extracellularly in the biliary canniculae and kidney and is catalysed by a 
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membrane-associated cysteinylglycine dipeptidase. The glycyl is hydrolised, leaving an 
S-substituted cysteine conjugate [8, 17]. 
The remaining conjugate is N-acetylated to give an N-acetylated-S-cysteine 
conjugate (mercapturic acid). This reaction occurs intracellularly mainly in the kidney 
and is catalysed by a microsomal cysteine S-conjugate N-acetyltransferase that transfers 
an acetyl group from acetylcoenzyme A to the amino group of the cysteine conjugate. 






















Figure 1.1. Sequence of enzymatic steps in mercapturic acid pathway 
 
RX + γ-Glu-Cys(SH)-Gly 
γ-Glu-Cys(SR)-Gly  
       
Glutathione Transferase 
Cys(SR)-Gly 















1.1.1.3. Glutathione: an unusual peptide 
1.1.1.3.1. The structure of glutathione 
 
Glutathione – γ-L-glutamyl-L-cysteinylglycine, GSH (Figure 1.2.) – is a natural 
antioxidant which plays a crucial role in detoxification processes; in particular, it largely 




Figure 1.2. The structure of L-glutathione  
 
This tripeptide was first isolated in 1921 by Hopkins [19] and its structure was 
determined by Nicolet in 1930 [20]. It is widely distributed throughout animal tissues 
and plants at high cellular concentrations (~1-10 mM) and is especially concentrated in 
the liver (~5-10 mM), which makes GSH the principal cellular non-protein thiol and the 
most abundant low molecular weight peptide in eukaryotes. In bacteria, GSH is mostly 
present in Gram-negative aerobic species (~3.5-6.6 mM in E. coli) but very rarely in 
anaerobes and Gram-positive strains which have developed other low molecular weight 
thiols such as mycothiol produced by Actinobacteria or bacillithiol found in Bacilli [21-
23].  
GSH presents some unique properties which are closely related to its functions: 
 - Its characteristic structural features, including the unusual peptide linkage 
between the amine group of L−cysteine and the carboxyl group of the L−glutamate side 
chain, provides for intra-cellular stability and specificity in glutathione-dependent 
enzymes, particularly with GSTs; 
- Its cysteinyl residue (pKa of GSH = 9.2) provides a nucleophilic thiol which 






- Its overall negative charge and hydrophilicity increase the solubility of the 
xenobiotics to which it becomes conjugated [12, 24-27]. 
 
1.1.1.3.2. Glutathione metabolism 
 
GSH metabolism occurs through the γ-glutamyl cycle which can be divided in 
six steps.  
GSH synthesis takes place in the cytoplasm and involves two ATP-dependant 
enzymatic steps (Figure 1.3.). The first step is rate-limiting and consists in the 
condensation of an L-glutamate and an L-cysteine. This step is limited by the feedback 
of competitive inhibition by glutathione and by the availability of L-cysteine. This 
reaction is catalysed by a glutamate cysteine ligase (GCL) which requires either Mg2+ or 
Mn2+ and coupled ATP hydrolysis. L-glutamate and ATP first react to give a tightly 
bound γ-glutamyl phosphate which reacts with L-cysteine. Therefore an amide bond is 
formed between the γ-carboxyl group of glutamate and the amino group of cysteine. 
GCL is a dimeric enzyme composed of a heavy unit with competent but low catalytic 
activity and a modulatory activity light subunit lowering the Km for glutamate and 
increasing the Ki for glutathione. GSH cell levels are closely related to GCL expression 
and activity. Oxidative stress caused by diverse agents can transcriptionally and post-
transcriptionally activate the GCL subunits. Increases in GSH levels, GCL mRNA levels 






Figure 1.3. Glutathione biosynthesis mechanism 
 
The second step of glutathione biosynthesis is catalysed by a glutathione 
synthase for which chemical mechanisms are similar to those of GCL: L-g-glutamyl-L-
cysteine and ATP first react to form tightly bound L-g-glutamyl-L-cysteinylphosphate, 
and that intermediate then reacts with glycine to form GSH [24, 26, 28-30, 33].  
The breakdown of GSH begins outside of the cell and is catalysed by the γ-
glutamyl transpeptidase involved in the MAP. The γ-glutamyl moiety is transferred to 
acceptors such as amino acids, certain dipeptides and water. γ-glutamyl amino acids are 
then transported into the cell where they become substrates of γ-glutamyl 
cyclotransferase, which converts these products into 5-oxo-L-proline. The ATP 
dependant conversion of 5-oxo-L-proline to L-glutamate is catalysed by the intracellular 
enzyme 5-oxo-prolinase.  
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The cysteinylglycine formed in the transpeptidase reaction is split by 
dipeptidase to generate cysteine and glycine [24, 28]. Most cells readily take up cysteine 
and the majority is incorporated into GSH, while the rest is either incorporated into 
proteins or degraded into sulphate and taurine. The γ-glutamyl cycle allows GSH to be 
used as a continuous cellular source of cysteine [26]. 
 
1.1.1.3.3. Glutathione functions  
 
In eukaryotic cells, GSH is mostly stored in the cytoplasm (almost 90%) where 
it serves several vital functions, 10% is found in mitochondria and a small percentage is 
in the endoplasmic reticulum [34, 35].  
 
 
1.1.1.3.3.1. Antioxidant function 
 
The main function of glutathione is to protect cells against reactive oxidants. 
All aerobic organisms are subject to oxidative stress from the respiration metabolism. 
Reactive oxygen species, including free radicals such as superoxide, hydroxyl radicals 
and non-radical species like hydrogen peroxide are formed and can lead to lipid 
peroxidation and cellular damage. 
GSH primarily exists in two redox forms: reduced and oxidised glutathione 
disulfide (GSSG). The latter only represents less than one percent of the total 
glutathione, it can be reduced back to GSH at the expense of NADPH through the action 
of a glutathione reductase. When this reduction is overcome by a severe oxidative stress, 
GSSG can be actively exported out of the cell to prevent a shift in the redox equilibrium. 
The presence of a sulfhydryl group makes GSH function as an antioxidant; thiols react 
rapidly and non-enzymatically with oxidising species and some of their oxidation 
products can be reversibly reduced by various redox-active enzymes such as thioredoxin 




1.1.1.3.3.2. Detoxifying function 
 
As described previously in section 1.1.1.2., glutathione plays a major role in the 
detoxification of many exogenous and endogenous compounds through the mercapturic 
acid pathway. Conjugation to xenobiotics irreversibly consumes GSH [26]. 
 
1.1.1.3.3.3. Maintenance of the intracellular redox state and cell signalling 
 
GSH is the most abundant intracellular low-molecular-mass thiol and therefore 
is an important mediator in the maintenance of the intracellular redox state and the 
essential thiol status of proteins. It may be thought of as an intracellular redox buffer 
which can act as an electrophile scavenger as well as an electron donor via the 
sulfhydryl group of a cysteine residue.  
Glutathione undergoes protein disulfide exchange as follows: 
 
Protein-SSG + GSH    Protein-SH + GSSG 
 
This reversible reaction is catalysed by a thiol transferase and therefore the 
equilibrium depends on the concentrations of GSH and GSSG. During oxidative stress, 
disulfide exchange between proteins and glutathione constitutes a protective mechanism 
for thiols, preventing further oxidation, and plays roles in cell signaling. In particular, 
protein S-glutathionylation is known to regulate several metabolic processes including 
redox homeostasis, ion channel activity, protein folding, cell growth and apoptosis [21, 
26, 30, 36-42]. 
 
1.1.1.4. The glutathione transferase super-family 
 
Glutathione Transferases (EC 2.5.1.18, GSTs) are a large family of phase II 
detoxification enzymes which catalyses the first step in the mercapturic acid pathway. 
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The general chemical mechanism of these enzymes is thought to involve nucleophilic 




Figure 1.4. Glutathione conjugation to a generic xenobiotic substrate (X) catalysed by 
GST results in the formation of a glutathione-S-X conjugate. 
 
Typical GST-catalyzed reactions are varied, and include Michael-type addition 
with ethacrynic acid (EA), nucleophilic addition to the epoxide phenantrene 9,10-oxide, 
hydroperoxide reduction with cumene hydroperoxide, and thiolysis of 4-nitrophenyl 






Figure 1.5. Examples of reactions catalysed by GSTs: a) Michael-type addition; b) 




Most GSTs can catalyse the conjugation of GSH to 1-chloro-2,4-dinitrobenzene 
(CDNB; Figure 1.6.), which is considered as the ‘universal GST substrate’. It has been 
used since 1974 to monitor the enzymatic activity of various GST by visible 






Figure 1.6. Conjugation of glutathione and CDNB catalysed by many GSTs. 
 
GSTs were discovered in 1961 by Booth et al., who partially purified and 
characterised a cytosolic GST isolated from rat liver [45]. Since then, GSTs have been 
extensively studied and classified according to a variety of criteria including protein 
sequences, kinetic and ternary/quaternary structural properties. There are four families 
of GSTs:  two of those, cytosolic and mitochondrial, are soluble and distantly related. 
The third family, microsomal, is referred to membrane-associated enzymes involved in 
eicosanoid and glutathione metabolism (MAPEG). The fourth family is less related than 
the three other and is represented by the bacterial fosfomycin resistance proteins FosA 
and FosB [46-50]. Recent, detailed reviews have been published on the GST family so 
in this thesis I will highlight GSTs of interest to this study. 
 
 
1.1.1.4.1. Cytosolic glutathione transferases 
 
Cytosolic GSTs represent the largest family and are found in a wide range of 
species including mammals, plants, invertebrates, insects, fungi and bacteria. 
Historically, mainly based on amino-acid sequence similarity, they have been divided 
into seven classes: Alpha, Mu, Omega, Pi, Sigma, Theta, Zeta. The letter designation of 
the enzymes (A, M, O, P, S, T and Z, respectively) shows their assignments to one of 
these classes and their subunit composition or isoenzyme type is designated by Arabic 
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numerals. Single-letter prefixes denote species of origin (e.g. m, mouse; h, human). For 
instance, a homodimer of type 4 alpha subunits from the mouse is mGSTA4-4. Other 
classes: Beta, Delta, Epsilon, Lambda, Phi, Tau and the “U” class have been identified in 
plants, insects and bacteria. The plant and bacterial enzymes often serve more 
specialised functions than detoxification, for instance they can take part in the transport 
of pigments or dehalogenation of hydrocarbons [46-53].  
 
1.1.1.4.1.1. Protein architecture of cytosolic glutathione transferases 
 
In general, GST monomers are ~25-30 kDa and the amino acid sequence 
identity within a class is high (more than 40%) whereas the identity between classes is 
much lower (less than 30%). Cytosolic GSTs are mostly homodimers with a common 
three–dimensional structural fold. Each monomer contains two main domains connected 



























































Figure 1.7. Crystal structure of a ligand-free hGSTP1 monomer (PDB 1EOG). α helices 
and β strands are represented in red and yellow, respectively. The peptide linker 
connecting the two domains is shown in blue.  
 
 
The N-terminal domain or domain 1 constitutes roughly one-third of the protein 
and is classified as part of the thioredoxin superfamily fold [54]. It is composed of three 
 helices and a mixed  sheet of the sequence 1-1-2-2-3-4-3. These elements 
fold so that the  strands are in the order of 4-3-1-2 with strand 3 antiparallel to the 
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others. The  sheet is almost planar with 1 and 3 helices below this plane and 2 
above it. There is a loop with a proline residue in the cis conformation between 2 and 
3 which helps to maintain the correct structure for catalytic activity [55]. Most GSTs 
present a SNAIL/TRAIL motif (i.e. Ser-Asp-Ala-Ile-Leu/Thr-Arg-Ala-Ile-Leu) in the 
α3 helix, which includes residues contributing to the GSH binding site.  
The larger C-terminal domain or domain 2 is an all--helical domain, the core 
of which generally consists of a group of five helices (the number of α helices varies 
widely between the classes). This domain is less conserved at the sequence and 
structural levels, with the helices varying in number, length, curvature, and orientation.  
The dimeric structures of GSTs (~ 50 kDa) are very stable and class-specific. 
The subunits are non-covalently bound and are related by a two-fold axis (C2 
symmetry). Interactions between the two subunits are mainly hydrophobic but differ 
between the classes. GST dimerisation allows for the construction of two fully 
functional active sites which are partly located at the dimer interface [47, 49, 50, 56].  
 
 
1.1.1.4.1.2. G- , H-  and L- sites 
 
GSTs are highly specific towards GSH and relatively more flexible with the 
electrophilic substrate. Each GST active site can be divided into a GSH binding site or 





















Figure 1.8.  A. Structure of hGSTM1-1 with one molecule of glutathionyl-S-
dinitrobenzene bound in each active site (grey: monomer 1; orange: monomer 2; green: 
glutathione moiety; red: dinitrobenzene moiety).  Structure of the same GST illustrating 
the G- and the H- sites (grey: monomer 1; orange: monomer 2; green: G-site; red: H-site; 
PDB 1XWK) [57]. This Figure was generated using PyMOL. 
 
 
G-site and activation of glutathione 
 
The G-site is located in a cleft between the N-terminal domain of one subunit 
and the C-terminal domain of the other subunit, so it is only completed after 
dimerisation. Most of the G-site residues are located in domain 1 and involve a specific 
network of polar bonds with GSH (Figure 1.9.). Amino-acids contributing to binding of 
GSH at the G-site are generally well conserved within classes. The tripeptide binds 
GSTs in an extended conformation with its main chain forming hydrogen-bonds with the 
peptide-loop connecting α2 to β3. This interaction is important for the recognition and 
orientation of GSH in the active site. The γ-glutamyl moiety anchors the tripeptide in the 
G-site by interacting extensively with a hydrophilic pocket located near the subunit 
interface. The glycyl resides near the solvent-accessible surface of the protein, with its 
carboxyl group strongly sequestered at the G-site. Finally, the cysteinyl sulfur points 
toward the subunit to which it is bound. Depending on the class of GST, the thiol of 




(Figure 1.10.). Within the π and α classes, it was found that mutation of a tyrosine to a 
phenylalanine dramatically decreased the catalytic activity but did not significantly 
reduce the ability to bind GSH, suggesting that this interaction does not have an essential 











Figure 1.9. Representation of the hGSTM1-1 G-site residues interacting with 
glutathione (PDB 1XW6) through polar bonds. (black: amino acids from domain 1 of 
monomer 1;  orange: Asp105 from domain 2 of monomer 2; violet: glutathione) [57]. 
This Figure was generated using PyMOL. 
 
As GSH binds to the G-site, the pKa value of the thiol drops from ~9.5 to ~6.8 
units, which promotes deprotonation of the GSH at physiological pH (~7.4). Proton 
release and extrusion from the active site takes place via an initial conformational 
rearrangement of GSH, followed by a water-assisted proton transfer between the thiol 
group of GSH cysteinyl residue and the GSH glutamyl α-carboxyl group. When the 
catalytic residue is a tyrosine or a serine, the anionic form of GSH is stabilised by the 
available hydroxyl group, and can subsequently react more readily with electrophilic 
substrates [56, 60]. GSTs possessing this tyrosine have higher activity toward the GSH 
conjugation reaction than GSTs containing a serine [61] as the hydroxyl group of a 
tyrosine is more acidic (pKa ~10.5) than the hydroxyl group of a serine (pKa ~13). 
Therefore, the anionic form of GSH would make stronger interaction with the tyrosine, 












A theta-class GST (hGSTT2-2) with a catalytically active serine residue has 
been demonstrated to act as a sulfatase with menaphthyl sulphate, which generates 
menaphthyl-GSH and free sulphate [62]. Although the enzymes residues involved in this 
catalysis have not been clearly identified, it has been shown that the active site serine is 
not essential in this reaction. The architecture of the active site could contribute to 
catalysis in this isozyme. Therefore, these enzymes may have evolved to specifically 









Figure 1.10. Catalytic residues in GSTs. In most GST classes, a tyrosine residue (a: 
hGSTM1 crystal structure complexed with glutathione; 1XW6) interacts with GSH to 
stabilize the thiolate anion, with a consequent decrease in pKa. In the theta, kappa and 
the zeta classes, this role is carried out by a serine residue (b: hGSTK1 crystal structure 
complexed with glutathione sulfinate; 1YZX), while in the omega and beta classes a 
mixed disulphide is formed with a cysteine residue (c: hGSTO1 crystal structure 
complexed with glutathione; 1EEM). This figure was generated using PyMOL. 
 
 
The mechanism of GSH activation by a catalytic tyrosine is not well 
understood. Nishida and co-workers [63] highlighted the presence of an additional 
conserved histidine residue in the active sites of beta-class GSTs. They suggested that 
the sulphur atom of the GSH thiol group makes hydrogen bonds with the backbone NH 
and the SH group of the essential cysteine and with the imidazole ring of the nearby 
histidine (His106 in the E. coli GST; [63]). The deprotonation of the GSH thiol group 
would be accelerated by either the imidazole ring of the histidine or by the sulphur atom 
of the cysteine.  
a b c 
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GSTs containing a cysteine in their active site often show dehalogenation 
activity. In general, this reaction is a two-step mechanism [64]: 
(1)  A molecule of GSH is added to a halogenated substrate, and the halogen 
atom is eliminated. The dehalogenated molecule is released by nucleophilic attack of the 
active site cysteine thiolate on the sulphur of the GSH moiety, yielding a mixed disulfide 
linkage; 
(2) Regeneration of the enzyme is initiated by the binding of a second GSH at 
the H-site for a final disulfide exchange. The result is a reduced catalytically active 
cysteine thiol and the release of GSSG from the active site. 
 
H-site and the binding of electrophiles 
 
In contrast to GSH binding to domain 1, residues from domain 2 are mainly 
responsible for binding of the electrophilic substrates. The H-site is highly hydrophobic 
and includes the active-site loop connecting β1 to α1, the C-terminal region of α4 and 
the C-terminal segment of the peptide linker. The great diversity of H-site topologies 
would explain the differences in electrophilic substrate specificity between GST classes 
[46, 56].   
 
L-site or ligandin binding site 
 
In addition to their enzymatic properties, GSTs are able to bind hydrophobic 
molecules, including hemin, bilirubin, bile salts, steroids, thyroid hormones, fatty acids 
and drugs. This ligandin property was observed in early work and suggests a role of 
storage or transport [65, 66]. The ligandin binding site or “L-site” has been observed in 
many GST isoforms. Its location remains uncertain and seems to be variable among the 
classes. For instance, McTigue et al. have shown that the drug Praziquantel could bind 
to the dimer interface of a GST from the parasitic worm Schistosoma japonicum, 




1.1.1.4.2. Glutathione transferases as therapeutic targets 
1.1.1.4.2.1. Mammalian cytosolic glutathione transferases and cancer 
 
Development of acquired drug resistance is a major problem in chemotherapy 
treatment. Exposure to anti-cancer agents can lead to an induction and expression of 
gene products that protect the cells. In particular, over-expression of GST isozymes has 
been reported in a number of different human cancers when compared to normal tissues, 
and it has been demonstrated that it is correlated with clinical drug resistance. GSTs can 
serve two distinct roles in the development of drug resistance: they can increase the rate 
of direct drug detoxification; and they can regulate the mitogen-activated protein kinase 
pathway that participates in cellular survival and apoptosis signalling [70-73].  
 
1.1.1.4.2.1.1. Mammalian cytosolic glutathione transferases 
 
Three-dimensional ribbon structural representations of the mammalian GSTs 
discussed below are shown in Figure 1.12. Isoform-specific features are summarised in 
Table 1.1. 
 
1.1.1.4.2.1.1.1. Alpha-, mu- and pi-classes 
 
The Alpha, Mu and Pi classes are the most abundant in mammals and the most 
extensively studied GSTs. Based on sequence alignments and substrate specificity 
criteria, several isoenzymes were recognized as belonging to Alpha, Mu or Pi class. In 
humans, four distinct subunits have been characterized in the Alpha class (A1 to A4), 
four in the Mu class (M1 to M4) and only one belongs to the Pi class (P1). Mammalian 
Alpha/Mu/Pi overall structures are very similar, they share 26 conserved residues (pair-
wise sequence identity: alpha-mu 20%, pi-mu 30 % and alpha-pi 32 %), but they show 
some important points of difference in the detailed structure, in particular in domain 2 
[46, 49, 53, 56].  
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The three classes share the same type of hydrophobic “lock and key” 
interaction between the subunits 1 and 2. The ‘key’ is an aromatic residue (Phe-52 in 
Alpha, Phe-56 in Mu and Tyr-49 in Pi) extending from the loop preceding -3. It fits 
into a hydrophobic ‘lock’ composed by helices -4 and -5 of the other subunit (Figure 
1.11.). The interface creates a V-shape crevice which is solvent-accessible. Mu-class 
enzymes have a characteristic mu-loop which is located between -2 and -2, creating a 
deeper active-site cleft. This additional loop is not essential in GST activity but it plays a 













Figure 1.11. View of a class mu dimer (hGSTM2-2, PDB: 3GUR) down the two fold 
axis relating the two subunits, showing the ‘lock and key’ interaction of an aromatic 
residue (Phe-56) from domain 1 between α-4 and α-5 from domain 2 of the opposite 
subunit. This Figure was generated using PyMOL. 
 
The -Glu moiety of GSH interacts with a hydrophilic complementary pocket 
near the subunit interface. The α and π class structures contain a salt bridge between an 
arginine (Arg-14 in Alpha, Arg-13 in Mu) and a glutamate (Glu-103 in Alpha, Glu-95 in 
Mu) which stabilizes the protein conformation at the -Glu site. A conserved tyrosine 
residue in -1 (Tyr-8 in Alpha, Tyr-6 in Mu and Tyr-7 in Pi) has been proposed to 
activate the thiol group of GSH. Estimated pKa values for the thiol group of glutathione 
are 5.7 – 6.9 for class mu, 6.7 – 7.0 for class alpha and 6.3 for class pi. In the alpha class 
structure, the sulfur atom of bound glutathione is also hydrogen-bonded to the guanidine 
group of Arg-14. In the mu class, GSH cysteinyl carboxyl group is not sequestered by 
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the protein backbone peptide loop connecting α-2 to β-3 as in the alpha and pi classes, 
but by a Trp-7. This disparity is responsible for the difference in GSH conformation 
taking place mostly at the Cys-Gly peptide bond in the mu class G-site, compared to the 
alpha and pi classes [46, 49, 53, 56].  
In domain 2, only the interaction with a conserved aspartic residue of -4 (Asp-
100 in Alpha, Asp-105 in Mu and Asp-96 in Pi), which is part of the G-site, is common 
to all structures. The Alpha-class domain contains an extra C-terminal -helix (-9) 
which packs onto the hydrophobic site and contributes to a smaller and more 
hydrophobic active site. This extra helix is important for GST dimer stabilization and 
non-substrate ligand binding, and lowers both the rate of GSH binding and the pKa value 
of the catalytic residue Tyr9 [46, 49, 53, 56, 75]. 
 
1.1.1.4.2.1.1.2. Theta-class  
 
Theta-class GSTs are widespread in nature, they have been found in a diverse 
range of organisms including bacteria, plants and insects. Three main structural features 
distinguish this class from the Alpha, Mu and Pi classes, with which they only share 7% 
of similarity: theta class enzymes lack a “lock and key” interaction between their 
subunits; the cleft at their dimer interface is less pronounced; and their catalytic residue 
is a serine rather than a tyrosine. Substrate affinity has also been used to differentiate 
Alpha/Mu/Pi GSTs from those of the Theta class. Theta GSTs have the particularity not 
to bind affinity matrices such as GSH-agarose or S-hexyl-GSH-agarose, and most of 
them lack activity with CDNB. Two subunits (T1 and T2) were identified in human, 
sharing only 55% sequence identity and showing distinct substrate specificity.  In 
particular, hGST T1-1 can conjugate GSH to halogenated organic compounds such as 
1,2-epoxy-3-(p-nitrophenoxy)propane and shows some peroxidase activity with organic 
hydroperoxides; whereas hGST T2-2 is able to transfer GSH to sulfate esters, unlike 
other GSTs, and is believed to play an important role in the prevention of 




1.1.1.4.2.1.1.3. Omega-class  
 
A new class of GST was identified ten years ago by analysis of human 
expressed sequence tag sequences, and the crystal structure of hGST O1-1 was 
determined [80]. Since then, other omega GSTs have been found in varied organisms 
such as pig, rat, nematodes and insects. Omega class enzymes present several marked 
structural differences compared to the other classes: they have an unusual 19-20 proline-
rich N-terminal extension; their domain 2 is composed of seven α-helices instead of the 
usual five; their inter-subunit interface is considerably more open; and their catalytic 
residue is a cysteine, unlike other eukaryote GSTs. GST O1-1 has low activity with most 
GST substrates, including CDNB but has a high thiol transferase activity. This isoform 
is strongly expressed in both skeletal and cardiac muscle and is thought to play a role in 
protecting cells from apoptosis by Ca2+ channel modulation [53, 80, 81].  
 
 
1.1.1.4.2.1.1.4. Sigma-class  
 
The Sigma class was identified by protein sequence alignments and crystal 
structural analysis revealed some important distinctive features, especially at the dimer 
interface and in the active site. Sigma class GSTs usually show hydrophilic interactions 
between the two monomers and lacks the ‘lock and key’ motif. Although GSH binds to 
the active site, Sigma class GSTs lack GST activity, which is thought to be due to 
insertion of eleven residues between the conserved α-4 and α-5 helices. This insertion 
closes up the conformation around the active site. Sigma GSTs also contain a third 
binding site for GSH conjugates which may play a role in conjugate transport [53, 82]. 
Hematopoietic Prostaglandin D-Synthases (H-PGDSs), which are involved in 
prostaglandin D (PGD) biosynthesis by catalysing the isomerisation of prostaglandin 
PGDH to PGD2, belong to the GST Sigma class. Although they share more than 35 % of 
similarity with Sigma GSTs, H-PGDSs have a hydrophilic dimer interface with a lock 
and key interaction similar to that found in Alpha/Mu/Pi classes [83-85]. 
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1.1.1.4.2.1.1.5. Zeta-class  
 
The Zeta class was identified by phylogenetic analyses and was found in plants, 
worms and mammals. Zeta GSTs are also known as maleylacetoacetate isomerase 
(MAAI) and catalyse the glutathione-dependant cis-trans isomerisation of 
maleylacetoacetate to fumarylacetoacetate, which is the penultimate step in the catalysis 
of phenylalanine and tyrosine. MAAI is also involved in the detoxication of carcinogen 
dichloroacetic acid to glyoxylic acid. Zeta GSTs have low GSH-conjugating activity 
with CDNB. It can be explained by the presence of a very small, polar active site. Zeta 
class GSTs possess a hydrophobic dimer interface, lacking a ‘V shape’, as in the Theta 
class GSTs. There is a ‘lock and key’ motif where an unusual methionine residue plays 
the role of the key, and the catalytically essential residue is thought to be a serine 





















































Figure 1.12. Crystal structures of alpha (hGST A2 complexed with GSH; PDB: 2WJU), 
mu (hGST M2 complexed with GSH; 3GUR), pi (hGST P1 complexed with nitrosyl 
glutathione; 2A2R), theta (hGST T1 complexed with 1-menaphthyl glutathione 
conjugate; 3LJR), omega (hGST O1 complexed with GSH; 1EEM), sigma (hGST S1 
complexed with GSH; 3EE2) and zeta (hGST Z1 complexed with GSH; 1FW1). The 
views are of a single subunit perpendicular to the twofold axis of each dimer. Proteins 
are shown in grey, ligands are in blue, essential active residues (Tyr, Ser or Cys) are in 
yellow and isoform-specific structural features are coloured in red. This Figure was 
generated using PyMOL. 
alpha mu pi 




Table 1.1. Isoform-specific features of mammalian GSTs 
 






Alpha 5 Tyr/Arg Extra -helix (-9) 
 
Mu 6 Tyr Mu loop between -2 and -2 
 
Omega 1 Cys Proline-rich N-terminal extension 
Open dimer interface 
Two extra -helices in domain 2 
 
Pi 1 Tyr Unknown 
 
Sigma 1 Tyr Lack of a ‘lock and key’ motif at 
the dimer interface  
Hydrophilic dimer interactions 
3rd binding site for GSH conjugates 
Prostaglandin D synthase activity 
 
Theta 2 Ser Lack of a ‘lock and key’ motif at 
the dimer interface  
Small active site    
Lack of a V-shaped dimer interface 
No binding to GSH affinity 
matrices 
 
Zeta 1 Ser Very small polar active site  
Lack of a V-shaped dimer interface  
Low GSH-conjugating activity 
with CDNB  
Maleylacetate isomerase activity  











1.1.1.4.2.1.2. Drug detoxification 
 
Several anti-cancer agents such as busulfan, melphalan, chlorambucil or 
thiotepa are substrates of GSTs and can be directly inactivated through catalytic 
conjugation to GSH. For instance, GST- from human colon adenocarcinoma cells are 
40-fold more expressed in the presence of the anti-cancer drug chlorambucil (CMB), and 
catalyse its conjugation with GSH to form monochloromonoglutathionyl CMB. This 
conjugate is more water soluble and thus more easily removed from the cells (Figure 




Figure 1.13. Conjugation of Chlorambucil and GSH via GST-.  
 
 
1.1.1.4.2.2. SjGST as a drug target in schistosomiasis treatment 
1.1.1.4.2.2.1. Schistosomiasis 
 
Schistosomiasis is a parasitic disease found in tropical and subtropical areas, 
caused by several species of platyhelminths of the genus Schistosoma. It is the second 
most serious parasitic disease after malaria. More than 200 million people are affected 
and around 200,000 deaths are caused annually. Three main species of flatworms are 
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responsible for schistosomiasis: Schistosoma mansoni, Schistosoma japonicum and 
Schistosoma haematobium. S. mansoni and S. japonicum cause the intestinal form of 
schistosomiasis, while S. haematobium causes the urinary form. Symptoms are varied 
depending on the species of infected schistosome but include abdominal pain, diarrhea, 
fever, haematuria and egg granulomas [94-96]. 
Resistance is developing to the leading anti-schistosomal drug – Praziquantel 
(PZQ; Figure 1.14.) – currently available for treatment. Although its mode of action is 
not exactly known at present, it is thought that PZQ increases the permeability of the 
parasite tegument for calcium ions. The drug thereby induces muscle contractions of the 












1.1.1.4.2.2.2. The 26 kDa GST from Schistosoma japonicum 
 
GSTs present a major defense mechanism for the schistosomes as they contain 
very low levels of other detoxification enzymes. Therefore, they are under investigation 
as targets for antischistosomal drugs to replace or to combine with those currently used. 
GSTs from helminthes are mostly expressed in the cytoplasm but secretory GSTs are 
also commonly expressed. The latter feature makes helminth GSTs tempting targets for 
vaccine development. S. japonicum possesses two GST isozymes, of 26 kDa and 28 kDa 
monomeric molecular weight. The 26 kDa enzyme has had great impact in 
biotechnology and is widely used as a fusion protein, allowing expression of proteins 
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which otherwise would have poor expression levels and simplifying purification through 
the use of immobilized glutathione [53, 95, 99-101].  
The S. japonicum 26 kDa GST (SjGST) structure resembles the Mu-class 
GSTs. Domain 1 adopts the usual thioredoxin fold involving a four-stranded -sheet 
surrounded by 3 -helices. Between -2 and -2, sjGST shows a shortened version of 
the mu loop. Domain 2 contains five helices. There is a coil at the C-terminal end 
(residues 195-218) with a unique hairpin loop (211-218) exposed to the solvent. The C-
terminal tail is close to the loop between -2 and 2, helping to enclose the G site. As 
observed for the alpha, mu and pi mammalian isoforms described previously, the sjGST 
homodimer shows a ‘lock and key’ interaction. The essential catalytic residue is a 













Figure 1.15. Crystal structure of homodimer (a: one monomer is shown in grey, the 
other monomer in orange) and G-site (b: catalytic tyrosine 7 is shown in blue, GSH in 
pink) of the 26 kDa SjGST in complex with GSH (PDB 1UA5). This Figure was 
generated using PyMOL. 
 
To understand the mode of action of PZQ a crystal structure of the 26 kDa GST 
from S. japonicum bound to the drug has been determined. At therapeutic 
concentrations, PZQ binds one drug per GST homodimer in the intersubunit cleft 
adjoining the two catalytic sites (Figure 1.16.). Contacts are made with Gln67, Gly-97, 
Leu100, Asp101, Tyr104, and Arg108 from one subunit and with Tyr-104 of the second 




same position. However, in contrast to its perceived mode of action, PZQ does not seem 
to inhibit sjGST enzyme activity. Its binding site is about 9.6 Å from the G site’s 













Figure 1.16. Crystal structure of the sjGST homodimer (one monomer in grey, the other 
monomer in yellow; PDB: 1GTB) showing PZQ (in pink) bound in the intersubunit 
cleft. The two catalytic tyrosine residues are shown in blue to indicate the positions of 
the active sites [68]. This Figure was generated using PyMOL. 
 
 
1.1.1.4.2.3. Glutathione transferase inhibitors and pro-drugs 
1.1.1.4.2.3.1. Inhibitors 
 
Several approaches are currently used to synthesize GST inhibitors, including 
GS-R conjugates, GSH peptide analogs and nonpeptide analogs, bivalent inhibitors and 
ligandin-type inhibitors. A broad class of GST potential inhibitors exists, but they are 
therapeutically limited regarding their toxicity, carcinogenicity, or unsuitability as a drug 
for human use. Moreover, as GST up regulation in cancer cells often concerns certain 








1.1.1.4.2.3.1.1. GS-R conjugates 
 
The highly conserved G-site and the H-site versatility in GSTs have been used 
to design GSH-conjugate inhibitors. The GSH moiety allows anchoring of the ligand 
into the active site, whereas the variability of the H-site among the isoforms provides a 
source for isoform specificity. However, the fact that substrates can adopt different 
orientations within the H-site makes the drug rational design complicated.   
An example of this is Ethacrynic acid (EA) a diuretic drug, commercially 
known as Edecrin, which is used to treat high blood pressure and the swelling caused by 
various medical problems such as congestive heart failure, liver failure and kidney 
failure. It acts by inhibiting a sodium-potassium-chloride transporter in the kidneys 
[106]. EA was also found to form a conjugate with GSH via Michael addition on its ,-
unsaturated ketone moiety, both spontaneously and by GST-driven catalysis. EA and its 
glutathione conjugate inhibit the GST-, - and - classes by direct binding to the 
isozymes active sites [107]. The crystal structure of human GSTP1-1 in complex with 
EA has been solved, showing that EA can bind GSTs in two different modes (Figure 
1.17.) [108, 109]. After in vitro and animals studies, EA has been reported to potentiate 
the cytotoxic effects of anti-cancer agents such as chlorambucil and melphalan in human 
colon carcinoma cell lines [110].  
Figure 1.17. Crystal structures of hGSTP1-1 (PDB files: left 3GSS; right 11GS) 
showing the two binding modes of EA glutathione conjugate. hGSTP1-1 surface is 
shown in grey, EA conjugate in pink, the catalytic tyrosine residue in blue [108, 109]. 
This Figure was generated using PyMOL. 
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Other glutathione conjugates such as S-alkyl and S-benzyl GSH are used in 




Figure 1.18. Chemical structures of EA, S-hexylglutathione and S-benzylglutathione. 
 
 
1.1.1.4.2.3.1.2. Bivalent inhibitors 
 
A new type of tight binding and isoform-selective inhibitors was developed by 
Atkins and co-workers in 2003 [112]. In their approach, the presence of two active sites 
separated by an accessible cleft in GSTs allowed them to design molecules with multiple 
binding domains. These inhibitors interact with active sites of each GST monomer 
simultaneously. As the distance between the actives sites vary among the isoforms, the 
length and nature of the linker connecting the inhibitor extremities interacting with the 
active sites allows for isoform selectivity [113]. Several bivalent compounds with 
different binding elements and linkers were synthesised. For instance, an inhibitor based 
on the EA-GSH conjugate was found to be 75 times more selective for GSTA1-1 over 
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GSTP1-1 (Figure 1.19.) [114]. The development of drugs based on this approach is 















Figure 1.19. Bivalent inhibitor based on the GS-EA conjugate [114]. 
 
1.1.1.4.2.3.2. Glutathione transferase - activated pro-drugs 
 
A pro-drug is a designed pharmacological substance which is administered in 
an inactive form and is activated by enzymes that are specifically elevated in target 
tissues. As GST levels are particularly high in cancer cells, they are good candidates for 
activating pro-drugs and releasing anti-cancer chemotherapeutic drugs in tumours. This 
approach allows an increased delivery of anticancer agents in a tumour tissue, and a 
minimized toxicity toward normal tissues [44, 73]. There are currently three types of 
GST targeted pro-drugs which are metabolized to turn into nitrogen mustards [115, 116], 
cytolytic nitric oxide [117] or thiopurine [118]. The most advanced of the GST-activated 
pro-drug candidates is TLK286, which is currently in phase 3 clinical trials. TLK286 is a 
GSH analogue sulfone derivative, activated by GST P1-1 and GST A1-1. The active site 
tyrosine would act as a base and promote a -elimination reaction that cleaves the 
prodrug into a GST inhibitor (GS-vinyl-sulfone) and a DNA alkylating agent (nitrogen 




Figure 1.20. Activation of TLK286 (-glutamyl--amino--(2-ethyl-N,N,N’,N’-
tetrakis(2-chloroethyl)phosphorodiamidate)-sulfonyl-propionyl-(R)-(-) phenylglycine) 
by hGST P1-1.  
 
 
1.1.2. Dynamic combinatorial chemistry as an exploring tool in isoform 
specificity 
 
Dynamic combinatorial chemistry (DCC) is based on the reversibility of the 
reaction that links building blocks together. A dynamic combinatorial library (DCL) is 
governed by thermodynamics rather than kinetics and is therefore able to respond to 
external influences. According to Le Châtelier’s principle: ‘If a chemical system at 
equilibrium experiences a change in concentration, temperature, volume, or partial 
pressure, then the system alters in order to minimize, or counteract the effect of 
disturbance’. Therefore, stabilisation of a library member through molecular recognition 
will generate a change in the equilibrium composition that will favour the formation of 






1.1.2.1. Protein-directed dynamic combinatorial chemistry 
 
Under thermodynamic conditions, a biological target such as an enzyme is used 
to select, stabilise and therefore amplify an active ligand or an inhibitor, which 
assembles within the confines of a binding site, directly from the library pool. The 
reaction between the components is then frozen, and the best binders identified and 
isolated through analysis of the DCL population (Figure 1.21.). Protein-directed DCC 
therefore constitutes a new efficient approach for studying, discovering, and ranking 
novel protein ligands, where chemical synthesis of drug candidates and biological 













Figure 1.21. The principle of protein-directed DCC. 
 
The utilisation of proteins requires the DCC to work at physiological 
conditions: pH, temperature and the nature of the reaction medium are three important 
parameters that have to be taken into account. Two typical DCC reactions fulfilling 




1.1.2.1.1. Imine bond formation 
 
The use of imine bond formation in protein-directed DCC was first described by 
Lehn and Huc in 1997 [125]. In their study, they generated a DCL composed of imines to 
probe the active site of the enzyme Carbonic Anhydrase (CA), which is a drug target in 
the treatment of various diseases including neurological disorders and osteoporosis. The 
initial building blocks were composed of four amines and three aldehydes (Figure 1.22.) 
and were selected so that all the DCL components had structural features in common with 
known CA inhibitors. The functional groups creating the imine linkage had comparable 













































































































































1a 1b 1c 1d
2a 2b 2c 2d
3a 3b 3c 3d
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Amines were in excess to create pseudo-first order behaviour with respect to 
the aldehydes, and to limit cross-reactivity between the aldehydes and any nucleophilic 
amino acid residues on the protein surface. The use of NaBH3CN then converted the 
imines into amines which are more stable and therefore easier to analyse by HPLC 
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Figure 1.23. Reversible imine transamination reaction.  
 
This experiment was the first proof of principle of DCC involving a biological 
target. However, there are two major problems associated with the utilisation of imines: 
first, because they are reduced to amines, imines are not represented in the final analysis; 
there is also a side reaction where starting aldehydes are reduced to benzylic alcohols, 
their concentration is therefore biased. 
 
Lehn and co-workers also studied acylhydrazone formation (Figure 1.24.) as a 
method for DCL generation for inhibition of acetylcholine esterase (ACE) [126], which 
is a drug target in the treatment of glaucoma and Alzheimer’s. The use of acylhydrazone 
formation in DCC in abiotic systems was introduced by Sanders and co-workers [127]. 
 
 
Figure 1.24. Reversible acyl hydrazone formation. 
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As the reaction takes place under conditions unsuitable for most enzymes and 
ACE in particular, the DCL, composed of thirteen building blocks (aldehydes and 
hydrazides, Figure 1.25.), was pre-equilibrated and frozen before ACE was added to the 
solution. A deconvolution approach was developed to identify the best ACE inhibitor. 
The pre-equilibrated 13-member DCL was frozen and assayed with ACE. Then, thirteen 
sub-libraries were prepared containing all building blocks minus one hydrazide or one 
aldehyde, frozen and assayed. The absence of the most active constituent would result in 
an increase in ACE activity. In parallel, each library component was re-synthesised and 
assayed individually. The results of these two experiments were in agreement, validating 
the DCC technique. The same approach was also used by Lehn and co-workers in a 
higher scale (440-member DCL) to identify a cationic inhibitor of a phosphotransfer 
protein kinase from Bacillus subtilis [128]. 
 
 
Figure 1.25. Hydrazide and aldehyde components for acyl hydrazone DCL 
 
Following this proof of concept, the reversible acylhydrazone formation was 
applied to DCC by other groups, such as Eliseev and co-workers [129] and Beau and co-
workers [130-132] who used this technique to generate new enzyme inhibitors.   
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1.1.2.1.2. Disulfide bond exchange 
 
The disulfide bond exchange reaction was introduced to DCC in the late 1990s 
by Still, Sanders and Lehn in separate reports [133-135]. Given the fundamental role 
played by disulfide formation and cleavage in biology, this reaction is highly compatible 
with protein targets as disulfide exchange readily proceeds in water and at mildly basic 
pH. Unlike imines, disulfide bonds are stable enough to undergo HPLC analyses and 
isolation from aqueous solutions. For instance, Hunter and Waltho used disulfide 
exchange in peptidic DCLs to target the calcium transducer calmodulin (CaM) [136]. 
The DCL building blocks were composed of cystine dimers containing hydrophobic 
amino acid residues (Figure 1.26.) and the DCL was equilibrated for 48 hours. After 
equilibration with CaM, one dimer was significantly amplified and revealed to be a 






























































Figure 1.26. Cystine dimer components for calmodulin DCL. 
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1.1.2.1.3. Enzymatic methods 
 
Enzymes have been used to catalyse reversible reactions in DCC. They present 
advantages such as being able to work within physiological conditions and can be 
applied to a variety of C-C and C-X bond-forming reactions. For instance, thermolysin 
was used in protease-catalysed amide-bond synthesis/hydrolysis [137-139].  
Gleason and Kazlauskas introduced the concept of pseudo-dynamic 
combinatorial chemistry by combining compartmentalised irreversible synthesis of 
library with an irreversible destruction step [140, 141]. A pseudo-DCL of peptides was 
used to inhibit CA. The system was consisted of two dialysis bags suspended in a 
surrounding solution (Figure 1.27.). One of the bags was a synthesis chamber where 
dipeptide binders were irreversibly created through addition of amino acids to 
immobilised active esters. These dipeptides could diffuse to the solution – or screening 
chamber – containing the targeted CA and where a binding equilibrium was established. 
Dipeptides further diffused into the second dialysis tube – or destruction chamber – 
where they were hydrolysed back to amino-acid building blocks which could migrate to 































Figure 1.27. Enzymatic pseudo-DCL experiment. 
 
1.1.2.2. Dynamic combinatorial chemistry and SjGST 
 
In recent work by the Greaney and Campopiano groups, the 26 kDa GST from 
S. japonicum has been used as a template in DCC [142]. The reaction was based on the 
reversible conjugate addition of thiols to Michael acceptors, which is well suited for 
biological DCL synthesis as it takes place in water at room temperature and under 
mildly basic conditions [143]. Acidification easily switches the reaction off. A first DCL 
was constructed with GSH, three GSH analogues modified on the γ-glutamyl moiety and 
the Michael acceptor EA (Figure 1.28.). After one hour of equilibration, the library was 
analysed and the four EA adducts could be characterised by LC-MS. Upon addition of 




















































































1a X = SO2NH
1b X = H
2a R1 = CH2Ph, R
2 = H
2b R1 = R2 = H
2c R1 = CH2CH(CH3)2, R
2 = H













binding assays, giving IC50 values of 0.32 µM for 7 and 88 µM for 10, suggested a 
correlation between the observed amplification and binding affinities of the DCL 
components toward the enzyme.  
 
 
Figure 1.28. Thiol conjugate addition DCL template by sjGST: (a) DCL without 
enzyme, (b) DCL after 10 minutes in the presence of SjGST, (c) DCL after equilibration 
and subsequent addition of the target, after 2 days, (d) the same system after 6 days. 
 
The work was extended to a larger library constituted of GSH and fourteen EA 
analogues (Figure 1.29.). In the presence of SjGST, three glutathione conjugates were 
amplified (12a, 12m, 12n) as they exhibited the strongest binding affinities for the 
enzyme. Both amplified GSH conjugates and their corresponding enone starting 
materials were assayed for inhibitory activity against SjGST and showed slightly higher 









Figure 1.29. Thiol conjugate addition DCL templated by SjGST: (a) DCL without 
enzyme, (b) SjGST template DCL. IC50 values for 12-a, b, f and n are indicated in bold. 








1.1.3. Aims and research strategy 
 
The purification and biochemical characterization of the recombinant forms of 
four potential drug target GSTs from human (hGST P1-1), mouse (mGST A4-4; 
mGSTM1-1), and the parasitic worm S. japonicum (SjGST) were carried out prior to 
their application in a DCL study. The reversible acyl hydrazone formation, in the 
presence of aniline as nucleophilic catalyst, was used by Venugopal Bhat (University of 
Edinburgh, laboratory of Dr. Mike Greaney) to generate a DCL based on the CDNB 
scaffold in order to explore the active site of each purified GST. I consequently tested 
the DCL members in inhibition and binding studies with SjGST and hGST P1-1, in an 
attempt to correlate the amplification of a ligand and its affinity for the GST templating 





















1.2. Results and Discussion 
1.2.1. Structural comparison of the four glutathione transferase isoforms  
 
The four GST genes from the plasmids in our possession (pGEX-6P-1-SjGST, 
pET-15b-6His-mGSTM1, pET-15b-6His-hGSTP1 and pET-9a-mGSTA4) were all 
sequenced and aligned with the protein sequence database. The GST from pGEX6P-1 
was identical to the S. japonicum 26 kDa GST (UniProt accession number: P08515). The 
two GSTs from the plasmids donated by Prof. John Hayes, University of Dundee – pET-
9a-mGSTA4 and pET-15b-6His-mGSTM1 – were similar to GST A4 (gene ID: 14860, 
UniProt accession number: P24472) and GST M1 (gene ID: 14862, UniProt accession 
number: P10642) respectively, both isolated from Mus musculus. The GST from the 
plasmid given by Dr. Sylvie Blond – pET-15b-6His-hGSTP1 – corresponded to the 
human GST P1 (gene ID: 2950, UniProt accession number: P09211). SjGST from the 
commercial pGEX6P-1 plasmid contained an extra 26 amino acid sequence at the C-
terminus, corresponding to the pre-scission protease and multiple cloning sites allowing 
the fusion of a protein. Analyses on the protein sequences revealed lengths varying 
between 222 and 244 amino acids and molecular weights of 23 to 28.5 kDa (Table 1.2.). 
 
Table 1.2. Lengths and molecular weight of the four forms of GST  
 
 Length (aa) Molecular weight (Da) 
SjGST 244 28,428 
His6-mGST M1 238 28,131 
His6-hGST P1 232 25,759 





The protein sequences were then compared pair wise and the percentage of 
identity between each of them was determined. These data were incorporated into a 
matrix represented in Figure 1.30. 
 
 SjGST mGST M1 mGST A4 hGST P1
SjGST 100 44.2 28.4 29.1 
mGST M1 44.2 100 22.3 31.7 
mGST A4 28.4 22.3 100 32.6 
hGST P1 29.1 31.7 32.6 100 
 
Figure 1.30. Matrix representing the percentage of identity between each isozyme. 
Alignments were made with LALNVIEW, using a BLOSUM62 matrix [144]. 
 
 
The four isoforms presented low sequence similarities (from 22% to 44% identity). It is 
generally accepted that GSTs share greater than 40% identity within a class, and below 
30% for GSTs belonging to different classes [53, 145, 146]; a low level of identity can 
be expected between homologous enzymes that catalyse a wide range of reactions on 
electrophilic substrates [146, 147]. Since SjGST is structurally very close to the mu class 
enzymes, it was not surprising to find the highest percentage of identity (44%) between 
SjGST and mGST M1-1 protein sequences [103, 104]. 
In order to identify the similarities between the GST isoforms, we aligned their ternary 
spatial conformations. Since the 3D-structure of mGST M1-1 has never been solved, a 
structural model was generated with the protein structure homology-modeling server 
SWISS-MODEL [148, 149]. The analysis was based on the high protein sequence 
resemblance with GST M1 from Rattus norvegicus (92.6% identity) [150], for which a 
macromolecular structure was already available in the Protein Data Bank (PDB file 
6GSV_A). The backbone conformations of the monomeric isoforms SjGST [102], 
mGST M1, mGST A4 [151], and hGST P1 [152] were superimposed, and are illustrated 
in Figure 1.31. As reported by Dirr et al.[56], we observed that the four spatial structures 
follow a similar canonical fold despite a low sequence identity across the classes. Each 
monomer consists of two distinct domains connected through a small peptide linker. The 
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N-terminal domain 1, which constitutes roughly one third of the protein, consists of four 
β-sheets and three α-helices (βαβαββα), similar to that of the thioredoxin fold [54]. The 
four β-sheets are essentially in the same plane, two helices (α1 and α3) are below this 
plane and one (α2) is above it, exposed to the solvent. The C-terminal domain 2 is an all 












Figure 1.31. Ternary structural alignment of hGSTP1, mGSTA4, SjGST and the 
structural model of mGSTM1 generated with SWISS-MODEL. β-sheets are coloured in 
yellow, α-helices in red, inter-specific region in green and the inter-domain linker 
peptide in violet. This Figure was generated using PyMOL. 
 
 
A protein sequence alignment based on both sequence homology and structural 
information was performed (Figure 1.32.). After highlighting the α-helices and β-sheets, 
we observed that the regions corresponding to the secondary-structure elements in the 
sequences of the GST enzymes could be aligned with confidence. Each subunit 
polypeptide chain folds into two structurally distinct domains that have a total secondary 
structure content of about 48-59% α-helix and 8-10% β-strands. The oligopeptide 
linking the two domains is composed of seven residues. Dirr et al. reported a number of 
26 invariant residues between the alpha, mu and the pi classes, all located around the 
active site and mostly contributing to GSH binding, catalysis and conformational 
stability [56]. Similarly here, 22 conserved residues and 37 homologous residues were 
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SjGST         MSP--ILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERD-----EGDKWRNKKFELGLEFP 
hGSTP1-1      MPP-YTVVYFPVRGRCAALRMLLADQGQSWKEEVVT--------VETWQEGSLKASCLYG 
mGSTA4-4      MAAKPKLYYFNGRGRMESIRWLLAAAGVEFEEEFLE-------TREQYEKMQKDGHLLFG 
mGSTM1-1      MPM--ILGYWNVRGLTHPIRMLLEYTDSSYDEKRYTMGDAPDFDRSQWLNEKFKLGLDFP 
              :       *:  :*     * **      : *               : :        :  
                                               β−1                        α−1                      β−2       extra mu-loop    α−2 
 
SjGST         NLPYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSK 
hGSTP1-1      QLPKFQDGDLTLYQSNTILRHLGRTLGLYGKDQQEAALVDMVNDGVEDLRCKYISLIYT- 
mGSTA4-4      QVPLVEIDGMMLTQTRAILSYLAAKYNLYGKDLKERVRIDMYADGTQDLMMMIAVAPFKT 
mGSTM1-1      NLPYLIDGSHKITQSNAILRYLARKHHLDGETEEERIRADIVENQVMDTRMQLIMLCYNP 
              ::*        : *: :*: ::     : *   :*     :      *         :   
                                          β−3       β−4             α−3         linker peptide                        α−4 
 
SjGST         --DFETLKVDFLSKLPE-MLKMFEDRLC----HKTYLNGDHVTHPDFMLYDALDVVLYMD  
hGSTP1-1      --NYEAGKDDYVKALPG-QLKPFETLLSQNQGGKTFIVGDQISFADYNLLDLLLIHEVLA 
mGSTA4-4      PKEKEESYDLILSRAKTRYFPVFEKILKDH--GEAFLVGNQLSWADIQLLEAILMVEELS 
mGSTM1-1      --DFEKQKPEFLKTIPE-KMKLYSEFLG----KRPWFAGDKVTYVDFLAYDILDQYRMFE 
                : *      :       :  :   *        :: *::::  *    : :     :  
                                                                       α−5                                                                                 α−6 
 
SjGST           PMCLDAFPKLVCFKKRIEAIPQIDKYLKSS-KYIAWPLQGWQATFGGGDHPPK 
hGSTP1-1        PGCLDAFPLLSAYVGRLSARPKLKAFLASP-EYVNLPINGNGKQ--------- 
mGSTA4-4        APVLSDFPLLQAFKTRISNIPTIKKFLQPGSQRK-PPPDGPYVEVVRTVLKF- 
mGSTM1-1        PKCLDAFPNLRDFLARFEGLKKISAYMKSS-RYIATPIFSKMAHWSNK----- 
                   *  ** *  :  *:     :  ::         *         
                                                                α−7       α−8               α−9 
                                                               
Figure 1.32. Alignment of topologically equivalent amino acid residues of the four 
GSTs. Catalytically active tyrosines are shown in red. Residues assigned to major 
secondary structure elements are underlined (beta strands) and squared (alpha helices). 
The seven-residue linker peptides are shown in grey. Invariant residues are indicated by 
an asterisk; residues with the same chemical properties are indicated by a double dot. α 




Within the 22 conserved residues, three of them directly interact with GSH: 
Tyr7 (Sj) / 8 (P1) / 9 (A4) / 7 (M1) activates GSH and stabilizes the thionate anion; 
Gln66 (Sj) / 62 (P1) / 67 (A4) / 72 (M1) located between β−3 and α−3 and Asp100 (Sj) / 
96(P1) / 101(A4) / 106(M1) both interact with the glutamyl moiety of GSH, their 
mutation provokes a considerable decrease in activity and GSH affinity [56]. Gly12 (Sj) 
/ 13 (P1) / 14 (A4) / 12 (M1) and Pro55 (Sj) / 53 (P1) / 56 (A4) / 61 (M1) are both 
located in the active site and maintain a functional backbone conformation. Asp151 (Sj) 
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/ 152 (P1) / 157 (A4) / 157(M1) is located in α−6, in the hydrophobic pocket and plays a 
role in protein stability. Five leucine residues are involved in the hydrophobic core at the 
dimer interface: Leu19 (Sj) / 20 (P1) / 22 (A4) / 20 (M1); Leu20 (Sj) / 21 (P1) / 23 (A4) 
/ 21 (M1); Leu136 (Sj) / 133 (P1) / 140 (A4) / 141(M1) makes Van der Waals contacts 
with Leu169 (Sj) / 170 (P1) / 175 (A4) / 175 (M1) and Leu175 (Sj) / 176 (P1) / 181 (A4) 
/ 181 (M1). The twelve remaining conserved residues all play essential roles in protein 






















Figure 1.33. Three-dimensional structures of individual GST subunits. Helices are 
coloured in red, β-strands in yellow. The linker regions connecting the two domains are 
shown in violet. The extra mu-loop in mGST M1 and α-9 in mGST A4 are represented 
in blue. Protein database codes and references are given between parentheses: (a) SjGST 








Despite the similarities between the protein sequences, comparing each 
individual three-dimensional structure allowed us to point out some obvious differences 
in their backbones (Figure 1.33.). Each of mGST M1-1 and mGST A4-4 presents a 
unique structural feature, typical from the mu and the alpha class, respectively. M1-1 has 
a characteristic “mu loop” which is located between β−2 and α−2. A4-4 N-terminus has 
an extra α-helix (α−9), which packs on to the H-site. Both of these specific structural 
elements are located close to the substrate binding sites and contribute to a more 
constricted and less solvent-exposed active site of these two isoforms compared to the 
other GSTs. SjGST contains a smaller version of the “mu loop” observed in mGST M1, 
which is not long enough to cover the binding sites.  
Differences in H-site topologies are correlated to the distinct substrate 
specificities observed in the GST family. As well as structural characteristics, kinetic 
properties constitute another important criterion in isozyme differentiation. I expressed, 
purified and kinetically characterised the four isoforms, using the GST-universal CDNB 
assay. A catalytically inactive mutant of SjGST – Y7F-SjGST – used later on as a 
control in the DCC experiments carried out by Venughopal Bhat, was also generated and 
characterised.  
 
1.2.2. Glutathione transferase purification and characterization 
1.2.2.1. Expression and purification 
 
SjGST, mGST A4-4, His6-mGST M1-1 and His6-hGST P1-1 proteins were 
expressed at 37°C in E. coli BL21 (DE3) host cells using prokaryotic expression vectors 
pET or pGEX. After induction with isopropyl -D-1-thiogalactopyranoside (IPTG) for 3 
to 5 hours, an obvious increase in expression of the recombinant proteins of the expected 
mass (~26 to 28 kDa) was observed using SDS-PAGE (Figure 1.34.). 
The conserved Tyr7 active site residue is known to play a critical role in GSH 
conjugation for SjGST, stabilizing the GSH thiolate anion through H-bonding from the 
phenol group, with enzymes lacking this residue being catalytically inactive. I prepared 










phenylalanine. pGEX-6P1 was used as a template for mutagenesis and the mutation was 
confirmed by DNA sequencing. Y7F SjGST was expressed in E. coli BL21 at 30˚C and 
induced with IPTG for 5 to 6 hours (Figure 1.34.).  
 
              SjGST     His6-mGST M1   His6-hGST P1    mGST A4      Y7F SjGST    







Figure 1.34. SDS-PAGE showing expression of proteins from E. coli before (-) and 
after (+) induction with IPTG. From comparison with the marker (M) bands it is 
possible to see a large increase in the concentration of proteins of approximately 26 kDa. 
 
All the plasmids, except pET9-a-mGST A4, contain a lacI gene so the 
recombinant proteins from these vectors should only be expressed in the presence of 
IPTG. The lac I repressor may not bind tightly enough to the lac O operator of pET15-b-
His6-mGST M1, allowing a slight expression of His6-mGST M1 without inducer. 
Purifications of SjGST, mGST A4-4 and mutant Y7F SjGST were performed 
by GSH affinity chromatography, using a 20 ml GSTPrep FF 16/10 column, followed by 
a gel-filtration chromatography using a 320 ml Sephacryl S-200 column. Proteins with a 
histidine tag – His6-hGST P1-1 and His6-mGST M1-1 – were isolated using a 5 ml 
Nickel column and a 320 ml Superdex S200 size exclusion column. Cell free extracts, 
affinity column flow-throughs (containing unbound proteins), washes and the eluted 
fractions were analysed by SDS-PAGE (Figures 1.35. to 1.39.). Specific activities were 
measured at each purification step (Tables 1.3. to 1.6.). The catalytic activity of the 
SjGST_Y7F mutant was also checked after purification and compared to the wild type 
SjGST (Figure 1.40).  Kinetic parameters of each purified GST are presented and 
discussed in section 1.2.2.2.  
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Figure 1.35. Elution profiles of sjGST from the GSTPrep column (A) and from the 
Sephacryl S-200 (B) showing the A280. Calibration markers are specified at the top of the 
gel filtration S-200 column UV trace, V0 is a void volume, VC is the column volume. 
Collected fractions were analysed by SDS-PAGE (M: low molecular weight marker; E: 
cell free extract; F: flow through; W: wash; collected fractions are represented by their 
number).  
 
Table 1.3. Purification of SjGST  


















Cell free extract 50 371 7.4 501.2 ± 59 67.7 ± 8 100 













M    E   F   W   7  10   13  18 
30 kDa 















































Figure 1.34. Elution profiles of mGST A4-4 from the GSTPrep column (A) and from 
the Sephacryl S-200 column (B) showing the A280 and SDS-PAGE analyses of the 
collected fractions.  
 
 






















Soluble cell lysate 50 295 5.9 20.3 ± 1.9 3.4 ± 0.3 100 
S-200 eluate 30 23 0.8 11.9 ± 1.2 14.9 ± 1.5 59 
M   E   F  W  11 12 13 14  15 16 
30 kDa 






























Figure 1.37. Elution profiles of His6-mGST M1-1 from the Nickel column (A) and from 
the Sephacryl S-200 column (B) showing the A280 and SDS-PAGE analyses of the 
collected fractions.  
 





















Soluble cell lysate 50 278 5.6 58.9 ± 0.6 10.5 ± 0.1 100 
S-200 eluate 40 61 1.5 40.8 ± 0.5 27.2 ± 0.3 69 
M   E   F   W   3   4    5   6 
30 kDa 
M  16 19 20 21 23 24 25 26 

































Figure 1.38. Elution profiles of His6-hGST P1-1 from the Nickel column (A) and from 


























Soluble cell lysate 50 284 5.7 353.1 ± 9.9 61.9 ± 1.7 100 
S-200 eluate 40 76 1.9 260.9 ± 7.4 137.3 ± 3.9 74 
M  E   F  W   7  9  11 13 14 15 
30 kDa 


























SjGST Y7F (0.15 nM)
SjGST (0.15 nM)

















Figure 1.39. Elution profiles of Y7F from the GSTPrep column (A) and from the 
















Figure 1.40. Comparative CDNB assays between SjGST WT and SjGST_Y7F, the 
mutant catalytic activity was reduced to 1.7%. 
30 kDa 
M   E   F   W   5   6   7   8    9  10 
M   14   15  16 
SjGST_Y7F Specific Activity: 






A yield of ~20 mg (mGST A4-4) to ~90 mg (SjGST) of recombinant protein 
was generally obtained from three liters of E. coli BL21 (DE3) culture. The SjGST_Y7F 
mutant was isolated in a yield of ~25 mg. 
The five GSTs eluted as homodimers from the gel filtration column in 
agreement with their predicted dimeric structures [103, 108, 151]. They were purified 
with total recoveries of about 60 and 70% of the total activity using CDNB as a substrate 
in a standard GST assay, for GSTs purified with GSH affinity chromatography (mGST 
A4-4 and SjGST) and GSTs purified with Ni2+ affinity chromatography (His6-mGST 
M1-1 and His6-hGST P1-1), respectively. In a previous study, Blond and co-workers 
expressed the His6-hGST P1-1 using the same plasmid, the same E. coli strain and a 
Co2+ affinity chromatography, with a total recovery of about 67% from the cell free 
extract [154].  
In order to identify the purity of each sample and to determine the mass of each 
purified GST, ESI LC-MS analysis was carried out. A preliminary LC-MS of SjGST 
after dialysis against 0.1 M KPhos buffer, pH 6.8 gave a result of 29,350 Da (Figure 








Figure 1.41. The mass spectrum of the purified sjGST. The ion envelope shows peaks 
ranging from 750 to 2000. The deconvoluted mass was determined using MassLynx. 
 
Two ion series was observed in the spectrum, the first ion corresponds to the 
theoretical mass (28,428 Da) of the monomeric protein bound to three molecules of 
glutathione (3 x 307 Da). Another set of peaks (Figure 1.41. B) indicated a mass of 
29,217 Da, which corresponds to the SjGST monomer lacking a methionine (132 Da). 
This suggests that a part of the proteins had their N-terminal methionine cleaved during 
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their synthesis. In order to obtain a ligand-free protein, the sample was dialysed against 
4 L of KH2PO4 buffer, containing 1.4 mM of -mercaptoethanol allowing the disulfide 
bonds to be reduced. LC-MS analysis of this sample gave results of 28,434 Da (Figure 
1.42. A) and 28,303 Da (Figure 1.42. B) which are in agreement with the theoretical 
masses of the monomer and the N-terminal truncated monomer respectively. Looking at 
SjGST’s crystal structure, I found that each monomer possesses four cysteines (Cys83, 
Cys135, Cys166 and Cys175) which are all solvent accessible [102]. These results 








Figure 1.42. Mass spectrum of the purified SjGST after dialysis with KPhos buffer and 
β-mercaptoethanol. The ion envelope shows peaks ranging from 650 to 2000. The 
deconvoluted mass was determined using MassLynx. 
 
mGST A4-4 does not contain any cysteine residues and therefore did not 
require any reducing agent in the dialysis buffer. LC-MS analysis on mGST A4-4 gave a 
result of 25,450 Da (Figure 1.43.), which is in agreement with the theoretical mass of the 


















Figure 1.43. Mass spectrum of the purified mGST A4-4. The ion envelope shows peaks 
ranging from 750 to 2000. The deconvoluted mass was determined using MassLynx. 
 
His6-hGST P1-1 and His6-mGST M1-1 were dialysed against KPhos and 
Tris/HCl buffers respectively, prior to MS analysis. A mass of 25,630.6 Da was obtained 
for His6-hGST P1-1 and is in agreement with the calculated theoretical mass of 25,630 
Da (Figure 1.44.). A MALDI-TOF analysis on His6-mGST M1-1 gave a major peak 
with a mass of 28,130.47 m/z, which corresponds to the theoretical mass of 28,131 Da 
(Figure 1.45.). A second peak, lower in intensity, was observed at 56,256 m/z and 















Figure 1.44. LC ESI-MS spectrum of the purified His6-hGST P1-1. The ion envelope 







The purified mutant was dialysed against Tris/HCl (20 mM) prior to MALDI-
TOF mass spectrometry analyses. As for SjGST, β-mercaptoethanol was added to the 
dialysis buffer to reduce any eventual disulfide bonds with GSH. The analysis gave a 
mass of 28,410.54 m/z, corresponding to the theoretical mass of SjGST_Y7F (28,412 
Da) (Figure 1.46.). A second peak with a mass of 56,821.94 m/z was observed and 
corresponds to the dimeric form of the mutant (56,824 Da). 
 
Figure 1.45. MALDI-TOF mass spectrum of the purified His6-mGST M1-1 from 20,000 
to 65,000 m/z.   
 
 






[His6-mGST M1+ H] 
56,256.45 Da 
[2His6-mGST M1+ H] 
28,410.54 Da 





1.2.2.2. Enzymatic analyses  
 
Using the CDNB assay specific activities of each enzyme were obtained; 105.1, 
14.9, 27.2 and 137.3 µmol/min/mg for SjGST, mGST A4-4, His6-mGST M1-1 and His6-
hGST P1-1 respectively. The data obtained for mGST A4-4 and His6-hGST P1-1 are 
comparable to those found in the literature (12.2 and 130 µmol/min/mg respectively 
[154, 155]). Specific activities for SjGST and His6-mGST M1-1 have not been reported 
in the literature. However, a value of 26 µmol/min/mg has been published for the rat 
GST M1-1 [74], which shares 92.6% sequence identity with mGST M1-1. Specific 
activity of the mutant was found to be 1.8 µmol.min-1.mg-1, representing only 1.7% that 
of the wild-type enzyme. In previous studies, García-Fuentes and co-workers generated 
the same mutant and found a specific activity varying between 8 and 12 µmol.min-1.mg-1 
and a kcat of 1.7% that of the wild type [156]. 
CDNB assays with variable concentrations of substrates (GSH: 1.0 µM to 2.0 
mM; CDNB: 0.5 µM to 1.0 mM) were performed. Data were plotted with the software 
SigmaPlot using the Michaelis-Menten, Lineweaver-Burk and Eadie-Hofstee equations 
and kinetic parameters such as kcat and KM were determined. Similar results were 
obtained with the three models; Michaelis-Menten plots are shown in Figures 1.47. and 























































































































































Figure 1.47. Michaelis-Menten representation of mGST A4-4 (1), His6-mGST M1-1 
(2) and His6-hGST P1-1 (3) activities towards the substrates GSH (a) and CDNB (b). 



























































Figure 1.48. Michaelis-Menten representation of SjGST (1) and SjGST_Y7F (2) 
activities towards the substrates GSH (a) and CDNB (b). GSH and CDNB 
concentrations were varied from 1 µM to 2 mM and 0.5 µM to 1 mM respectively 
when assaying SjGST and from 0.03 to 10 µM and 0.4 to 40 µM respectively when 
assaying the mutant.  
 
 
Table 1.7. Kinetic parameters for mGST A4-4, His6-mGST M1-1, His6-hGST P1-1, 













mGST A4-4 0.49 +/- 0.03 4.67 +/- 0.55 6.3 +/- 0.6 1.3 14.9 +/- 1.5 
His6-mGST M1-1 0.07 +/- 0.02 0.02 +/- 0.01 12.7 +/- 0.1 635 27.2 +/- 0.3 
His6-hGST P1-1 0.20 +/- 0.02 0.81 +/- 0.04 59.3 +/- 1.6 69.5 137.3 +/- 3.9 
SjGST 0.35 +/- 0.03 4.65 +/- 0.92 50.0 +/- 8.3 10.8 105.1 +/- 17.6 
SjGST_Y7F 0.09 +/- 0.01 2.75 +/- 0.19 0.7 +/- 0.1 0.3 1.8 +/- 0.1 
[CDNB] (µM)














































The optimum conditions for the CDNB assays were obtained with a maximum 
CDNB concentration of 1 mM in 2.5% ethanol. CDNB precipitates at higher 
concentrations and a higher percentage of ethanol resulted in a decrease of the enzymes 
activities. The same observation was made by Jakoby and co-workers who developed 
the assay in 1974 [43]. Because of low solubility, the CDNB substrate concentration was 
less than the KM when assaying SjGST and mGST A4-4. Therefore, the kinetic data are 
less accurate for these two isozymes showing higher error values.   
 
A general trend is observed for the GST isozymes SjGST, mGST A4-4 and 
His6-hGST P1-1 – the enzymes display a higher affinity to GSH than to CDNB. This is 
often seen with GSTs as their G-site is very well conserved and highly specific for GSH.  
SjGST and mGST A4-4 have similar KM values regarding the two substrates. 
Despite the fact that SjGST is most structurally similar to the mu class, it was found that 
its H-site bears a higher similarity to that of A4-4 [103]. These features could explain 
why these two enzymes have similar affinities for the same substrates.  
His6-mGST M1-1 differs from the other GSTs presented here by its relatively 
low affinity constants for both CDNB and GSH. By mutational experiments, Colman 
and co-workers have proved that the mu loop present in the rat GST M1-1 plays a 
crucial role in the specific recognition of CDNB [74]. Deletion of the loop substantially 
decreased the enzyme’s affinity for the xenobiotic substrate by a 34-fold factor, giving a 
KM
CDNB value close to the human GST P1-1’s. SjGST, mGST A4-4 and His6-hGST P1-1 
all lack this structural feature.  
Roberts and co-workers have shown that the extra C-terminal alpha helix (α-9) 
in hGST A1-1 is important for both binding and catalysis of CDNB, since its deletion 
induced a 26-fold increase in KM
CDNB and 160-fold decrease in kcat. Although A4-4 
displays the same structural characteristic, it has been shown that this isoform is more 
specific for lipid peroxidation product 4-hydroxynonenal (4-HNE) with a specific 
activity 17 times higher for this substrate [157].  
The relatively high affinity of His6-hGST P1-1 for CDNB is partly due to the 
presence of an isoleucine in the H-site (I-105) [158], which creates a narrow active site 
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where the small substrate is accommodated. Mutation of this isoleucine to a valine 
induced a 4-fold increase in KM
CDNB.  
Comparable KM values have been reported in the literature for SjGST (KM
GSH = 
0.43 mM, KM
CDNB = 2.68; [159]), mGST A4-4 (KM
GSH = 0.48 mM, KM
CDNB = 4.1 mM; 
[160]), rGST M1-1 (KM
GSH = 0.069 mM, KM
CDNB = 0.019 mM; [161]) and His6-hGST 
P1-1(KM
GSH = 0.13 mM, KM
CDNB = 0.86 mM; [154]). 
 
The turnover number kcat represents the number of substrate molecules that are 
converted to product per active site. In GSTs, nucleophilic aromatic substitution 
reactions are rate-limited by the formation of the transition state and by product release. 
For CDNB conjugation, the highest kcat values were found for His6-hGST P1-1 (59.3 s
-1) 
and SjGST (50.0 s-1) and were 5 to 10 times lower for His6-mGST M1-1 (12.7 s
-1) and 
mGST A4-4 (6.3 s-1). Similarly, Awasthi and co-workers found a kcat of 58.8 s
-1 for 
hGST P1-1 [162]; and Dirr and co-workers found a kcat of 18 s
-1 for the rat GST M1-1 
[163]. A slightly higher value was reported for mGST A4-4 (18.2 s-1) [160]. The close 
proximity of the mu loop and alpha helix in mGST M1-1 and mGST A4-4 respectively, 
is suggested to physically restrict the rate of product release from the active sites. 
Furthermore, in mGST M1-1, Tyr115 located in α-4 has also been shown to play an 
important role in catalysis. It seems that this residue interferes with product release 
through hydrogen-bonding with Ser209. Mutation of Tyr115 into a Phe in the rat mGST 
M1-1 resulted in a 3.6-fold increase in the turnover of CDNB [164].  
 
The catalytic efficiency of an enzyme is determined by the ratio between the 
rate of product release kcat and the dissociation constant KM between the enzyme and the 
substrate. His6-mGST M1-1 showed the highest kcat/KM value for the GSH conjugation 
of CDNB when compared to the three other isoforms, indicating that, for this class of 
compound, the overall reaction is the most efficiently catalysed by His6-mGST M1-1. 
 
Mutation of the catalytically active tyrosine 7 to a phenylalanine in SjGST 
resulted in almost complete loss of activity toward CDNB substrate and a kcat that was 
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1.4 % than that of the wild type. These observations show the importance of Tyr7 for the 
catalytic activity of this enzyme. The presence of the hydroxyl group of this tyrosine 
does not seem fundamental for the binding of GSH, but it would stabilize the thiolate 
group and give it the right orientation for the attack on the electrophilic substrate [165].  
Moreover, the mutant protein showed higher affinity to GSH than the wild type. 
This result is in agreement with those published in 2003 by Jara-Pérez and co-workers 
[166] who studied the thermodynamics of GSH binding to the same mutant. They 
proposed that SjGST has an additional water molecule in its G-site, forming a hydrogen 
bond with Tyr 7 and which needs to be displaced upon GSH binding. Therefore, the 
balance between the number of hydrogen bonds before and after substrate binding would 
account for the favourable enthalpy upon binding of the mutant. This would explain the 
enhanced affinity for the GSH substrate to SjGST_Y7F. 
     
With each recombinant, purified GST isoform isolated in high yield and with 
high catalytic activity we now proceeded to test the possibility of generating isoform-
specific GST inhibitors. Previously the promiscuity of the GST H-site made rational 
design difficult. Protein-directed DCC provides a new method which presents the 
advantage to not require any structural information on the enzyme. Venughopal Bhal 
used a dynamic combinatorial approach to explore the active sites of the four isozymes.  
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1.2.3.   Exploring glutathione transferase active sites  
1.2.3.1. Glutathione transferase – templated dynamic combinatorial 
chemistry 
 
A first dynamic combinatorial library was generated by Venughopal Bhat, 
based on acylhydrazone formation between an aldehyde having a CDNB scaffold and 
ten commercially available hydrazides. The reversible imine formation was catalysed by 
aniline, allowing the reaction to equilibrate rapidly at pH 6.2 [167]. Aniline functions as 
a nucleophilic catalyst via the formation of a Schiff base which then reacts with a 
hydrazone to yield an acyl hydrazone (Figure 1.49.). Without the aniline the equilibrium 
was achieved very slowly. However, in its presence it was clear that all 10 members of 
the DCL were observed by HPLC and mass spectrometry. Little of the initial aldehyde 











Figure 1.49. Two-step mechanism of the aniline-catalysed acyl hydrazone formation, 




After verifying that SjGST retained catalytic activity in the presence of up to 20 
mM of aniline, SjGST and His6-hGST P1-1 were targeted. The acylhydrazone DCL 
presented in Figure 1.50. was interfaced with the two isozymes and amplification of a 
particular peak corresponding was observed. Both DCLs demonstrated clear 
amplification of hydrazone components; thiophene acylhydrazone 3g was selected by 
SjGST and t-butylphenyl hydrazone 3c by His6-hGST P1-1 (Figure 1.51.). A control 
experiment was made synthesising the same DCL in the presence of bovine serum 
albumin (BSA) and produced no detectable amplification, indicating that GSTs 
isozymes were responsible for library component amplification [194]. The pH of the 
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Figure 1.50. Aniline-catalysed acyl hydrazone formation. Conditions: Aldehyde (5 µM), 
hydrazides (20 µM) in NH4OAc Buffer (50 mM, pH 6.2) containing 15% DMSO. 




















Figure 1.51. HPLC analyses of GST-templated DCLs (254 nm). A, DCL hydrazone 
composition in the absence of any target (blank). B, When the DCL is constituted in the 
presence of SjGST, the thiophene hydrazone 3g is clearly amplified. C, Changing the 
target protein to hGSTP1-1 produces a different distribution, in which the t-butylphenyl 
derivative 3c is amplified. Targeted DCL conditions: GST (1 equiv.), aldehyde (5 µM), 
hydrazides (20 µM) and aniline (10 mM) in NH4OAc buffer (50 mM, pH 6.2) containing 
15% DMSO for 16 h. 
 
 
The amplified components were individually synthesised. I carried out some 
inhibition assays against both GSTs with these compounds. However, due to their poor 
solubility (< 10 µM), it was not possible to determine their IC50 values. To solve this 
problem and simultaneously to increase the potency of the DCL components towards the 
GSTs, Venughopal Bhat chemically conjugated GSH to aldehyde 1, generating a new 
library composed of ten GS-conjugated hydrazones (Figure 1.52. A). We anticipated that 
the highly soluble GSH tripeptide motif would act as an anchor at the G-site, enabling 
exploration of the H-site with assorted hydrazide fragments. This approach, in which a 
known enzyme–substrate interaction is used for inhibitor discovery, is well exemplified 
in classical medicinal chemistry drug design, GST inhibition and DCC methods.  
Venughopal Bhat tested the new library with the four isoforms: SjGST, His6-
hGST P1-1, His6-mGST M1-1 and mGST A4-4. Equilibration was complete in 6 hours 
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in the presence of aniline at pH 6.2. As before, clear shifts in equilibrium could be 
observed for both SjGST and His6-hGST P1-1 targets: in each case the same hydrazide 
fragment was selected as the best binder, thiophene (5g) for SjGST and t-butylphenyl 
























































Figure 1.52. HPLC analyses of GST-templated DCLs of GSH conjugates. A, Acyl 
hydrazone DCL based on GSH-conjugated aldehyde 4 (GS-S-linked glutathione). B, DCL 
acyl hydrazone composition in the absence of target (blank), in the presence of SjGST and in 
the presence of hGSTP1-1. C, Changes in DCL component concentration for blank, SjGST 
and hGST P1-1 DCLs. The error bars represent the standard deviation over three 















































































24 ± 1 
119 ± 8 
34 ± 1 
84 ± 4   
37 ± 1; 61 ± 3 
40 ± 2 
87 ± 3 
22 ± 1 
36 ± 2 
25 ± 1 
26 ± 1 
57 ± 2 
50 ± 3 
87 
 
Both components were amplified to over 300% of their concentration in the 
blank DCL, at the expense of nearly all other competing hydrazones (Figure 1.52. C). 
Additionaly, the anisyl sulphonylhydrazone 5j underwent ~100% amplification using 
His6-hGST P1-1 as the only other positively selected component. The most significant 
reductions in equilibrium concentrations occurred for 5b, f and i (SjGST) and 5f, g and i 
(His6-hGST P1-1). 
Interestingly, the presence of either mGST A4-4 or His6-mGST M1-1 with the 
GS-conjugated DCL did not induce any amplification. It is known that these two 
isozymes have a relatively narrow active site due to the presence of a mu loop (mGST 
M1-1) or an alpha helix (mGST A4-4) on the top of it. Potentially, the ten hydrazides 
present in the library may not be accommodated in the active sites. It is also possible that 
the affinities of all the library members for these enzymes are so similar that no 
selectivity could be detected. It would be of interest to try performing conjugation 
experiments with GSH to find out whether the library components can bind to the active 
sites of these two isoforms. 
To verify the amplification results were not due to a kinetic selection by means 
of target-accelerated synthesis, a control experiment in which GS-conjugated DCLs 
were synthesised with the SjGST present from the beginning of the experiment was 
performed. The same equilibrium distribution was achieved, with hydrazone 5g strongly 
amplified, indicating that the amplified components are the result of genuine 
thermodynamic selection. Further controls involved a BSA control experiment, which 
was negative, and DCL synthesis in the presence of a large excess of the non-selective 
GST inhibitor ethacrynic acid (EA) as discussed earlier. Component amplification was 
completely suppressed for both SjGST and His6-hGST P1-1 DCLs, indicating that the 
GST active site is saturated by the EA inhibitor and cannot influence the DCL 
equilibrium composition. 
I generated a catalytically inactive SjGST mutant to test whether a catalytically 
inactive enzyme would exert the same control and selectivity on DCL composition as 
the wild-type enzyme. Essentially zero activity was observed with this mutant in CDNB 
conjugation when compared with the wild-type SjGST. However, SjGST Y7F proved 
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equally effective in controlling DCL composition, showing a clear preference for the 
same thiophene derivative 5g as was amplified by the wild-type SjGST (Figure 1.53.). 
This again provided evidence that the observed amplification was under thermodynamic 
and not kinetic control. 
 






















Figure 1.53. HPLC analyses of GST-templated DCLs. A, DCL hydrazone composition 
in the absence of any target (blank). B, When the DCL is constituted in the presence of 




1.2.3.2. Biological assays 
 
I performed biological assays to establish whether the best binding compounds 
in the GST-directed DCLs were also the best inhibitors of the SjGST and His6-hGST P1-
1 enzymes. To fully explore the isozyme-specific amplification effects of the two DCLs, 

















1.2.3.2.1. Binding studies 
 
I first confirmed that the amplified ligands 5c and 5g bound to SjGST and His6-
hGST P1-1 using isothermal calorimetry (ITC) and compared the thermodynamic results 
with those of SjGST binding to the building block 1. ITC is a well-establish method 
used to measure the stoichiometry (N), the dissociation constant (K), the enthalpy (∆H) 
and the entropy (∆S) changes of a binding reaction. Typical experimental data, raw and 
fitted, are given in Figures 1.54. and 1.55.; the thermodynamic parameters are tabulated 
in Table 1.8. The interactions between the ligands and the enzymes are exothermic. 
Analyses of the data yielded a binding affinity (Kd) of 5.8 µM for SjGST-5g, 6.5 µM for 
SjGST-5c, 6.6 µM for His6-hGSTP1-1-5g, 3.8 µM for His6-hGSTP1-1-5c. The 
conjugated aldehyde 1 bound to SjGST (41 µM) with an order of magnitude less than 
compounds 5g and 5c, suggesting that the selected building blocks extend into a binding 





















































Figure 1.54. ITC of SjGST (a and c) and His6-hGST P1-1 (b and d) in the presence and 
in the absence of 5c (c and d) and 5g (a and b). Top: Heats of injection of ~300 µM of 
ligand into a cell containing 10 M of enzyme. Bottom: Data from the upper panel 
integrated and plotted as a function of the molar ratio of ligand after subtraction of heats 



























































































































































Figure 1.55. ITC of SjGST in the presence and in the absence of 1. Top: Heats of 
injection of 627 M 1 into a cell containing 20 M SjGST. Bottom: Data from the upper 
panel integrated and plotted as a function of the molar ratio of 1 after subtraction of 
heats generated by injection of 627 M 1 into buffer.  
 
 
The stoichiometry of binding of 1.7, 1.7, 2.6 and 1.9 respectively revealed there 
are two ligands per dimer. The value greater than two for His6-hGSTP1-1-5g may be due 
in part to other complexation species such as three molecules of ligand 5g binding to a 
His6-hGSTP1-1 dimer.  
 
Table 1.8. Experimental thermodynamic data for 5c, 5g and 1 binding to SjGST and 
His6-hGST P1-1, determined by ITC at 25 ˚C. 
 
 
 SjGST-5c SjGST-5g hGST P1-1-5c hGST P1-1-5g SjGST-1 
Kd (µM) 6.5 ± 0.3 5.8 ± 0.5 3.8 ± 0.4 6.6 ± 1.0 41 ± 3.6 
N (stoichiometry) 1.71 ± 0.03 1.71 ± 0.05 2.60 ± 0.06 1.90 ± 0.1 2.02 ± 0.2 
∆H (kcal/mol) -11.4 ± 0.03 -16.9 ± 0.05 -16.9 ± 0.07 -13.4 ± 0.1 -5.0 ± 0.5 
∆S (cal/mol) -14.4 -33.1 -31.8 -21.4 3.2 






























1.2.3.2.2. Inhibition studies 
 
I studied the inhibitory activity of the ligands towards SjGST and His6-hGST 
P1-1 using the CDNB conjugation assay. The IC50 data are tabulated in Table 1.9. 
 














The IC50 values were slightly higher for all hydrazones against His6-hGST P1-1 
compared to SjGST (data ranging from 59 to 126 µM and 22 to 63 µM, respectively). 
Although all the data were found in the same micromolar range, for each isozyme, the 
DCC amplified hydrazone was the most active; thiophene 5g had the lowest IC50 value 
(22 µM) among all the library members against SjGST, and t-butylphenyl 5c had the 
lowest value among the four conjugates tested against His6-hGST P1-1 (57 µM). In 
summary, the DCL hydrazone/GST selection process has successfully extended inhibitor 
structure in the GST H-site, increasing potencies by sixfold for His6-hGST P1-1 (331 to 
57 µM ) and by over tenfold for SjGST (279 to 22 µM) relative to the starting anchored 
aldehyde 4.  
Hydrazone sjGST hGST P1-1 
4 279 ± 23 331 ± 20 
5a 24 ± 1 ND 
5b 40 ± 2 ND 
5c 50 ± 3 57 ± 2 
5d 26 ± 1 ND 
5e 36 ± 2 ND 
5f 61 ± 3 ND 
5g 22 ± 1 87 ± 3 
5h 34 ± 1 119 ± 8 
5i 37 ± 1 84 ± 4 
5j 25 ± 1 ND 
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Steady-state kinetic studies on the two amplified DCL components 5c (His6-
hGST P1-1) and 5g (SjGST) confirmed the expected competitive inhibition profile, with 
both compounds binding to the GST active sites. The inhibition data for SjGST and P1-1 
are plotted in Figures 1.56. and 1.57. respectively. The Ki data are presented in Table 
1.10., along with the corresponding Km and IC50 values. Firstly, we found that the Ki 
values were very close to the binding constants Kd determined previously by ITC and 
were well correlated to the IC50 data according to the Cheng-Prusoff equation: Ki = 
IC50/(1+[S]/Km), where the Ki can be estimated as IC50 = 4Ki for inhibitors which are 
competitive with both substrates [168].  
 










Secondly, it was interesting to note slightly higher Ki values for both 
compounds when assayed against CDNB, a substrate for the H-site of the enzyme, 
relative to the endogenous G-site ligand GSH. The affinity of the two hydrazone 
conjugates towards both GST G-sites was relatively close (data ranging from 5.25 to 






 His6-hGST P1-1 SjGST 
 CDNB GSH CDNB GSH 
Km (mM) 0.81 ± 0.04 0.20 ± 0.01 4.65 ± 0.92 0.35 ± 0.02 
Ki
5g (µM) 13.96 ± 0.78 7.19 ± 0.42 12.82 ± 0.68 5.25 ± 0.23 
Ki
5c (µM) 10.66 ± 0.67 6.61 ± 0.42 18.58 ± 1.05 6.33 ± 0.27 
IC50
5g (µM) 87 ± 3 22 ± 1 
IC50

























Figure 1.56. Inhibition of SjGST by 5g using GSH and CDNB as substrates. The IC50 
value is the concentration of inhibitor giving 50% inhibition of enzyme activity. Data are 
























Figure 1.57. Inhibition of hGSTP1-1 by 5c using GSH and CDNB as substrates. 
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5c = 6.6 µM 
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1.2.3.3. Structural insights into the dynamic combinatorial library 
amplification mechanism 
 
1.2.3.3.1. Docking studies 
 
To obtain some molecular insight into the selectivity of our GST isozymes 
towards the two hydrazone inhibitors 5c and g, I carried out a molecular modeling study 
with the collaboration of Dr. Ruth Brenk and Dr. Torsten Luksch (Dundee University). 
In a first experiment, the available GST structures were surveyed in the protein data 
bank (PDB) sharing more than 40% sequence identity to the target SjGST crystal 
structure (1M9A). 38 structures were retreived that contained a bound, GSH-based 
ligand. The binding sites of these structures, together with the bound ligands, were 
aligned, and as expected, it became evident that the GSH portions overlaid well, being 
bound in very similar conformations in the G-sites (Figure 1.58. a). In contrast, the 
conjugate parts of the various ligands showed great diversity in their conformations 
within the H-site, an unsurprising result given the respective functions of the G- and H-
sites. Detailed analysis of the superimposed crystal structures identified the GSH 
conjugate of 1,2-epoxy-3-(p-nitrophenoxy)propane (EPNP) bound to cGST M1-1 (PDB 
code 1C72) [169] as the ligand that projected functionality into the H-site with the most 
























Figure 1.58. GST ligands. a, Superposition of a selection of GST ligands from the PDB. 
b, Conformation of the GST-bound EPNP as found in the crystal structure of cGST M1-
1 (PDB code 1C72, green carbon atoms), relative to the energy-minimized structure of 
compound 5g (pink carbon atoms). 
 
 
Analysis of the GST–EPNP complex shows the EPNP moiety orienting towards 
R107 and Q165 in the H-site of the enzyme (Figure 1.59. C). The side chains of R107, 
F110, Q165, Q166 and F208 define the pocket that confines the EPNP moiety.  
On this basis, I could generate a binding model for SjGST with thiophene 
hydrazone 5g and for His6-hGST P1-1 with t-butyl hydrazone 5c (Figure 1.59. A and B). 
The interactions in the generated binding modes for SjGST in complex with 5g and for 
His6-hGST P1-1 in complex with 5c between the glutathione moiety and the proteins are 
identical to those reported in previous publications [103, 108]. The hydrazone group of 
5g is predicted forms hydrogen bonds to R103 and Q204 in SjGST, and equivalent 
interactions are observed for 5c in complex with His6-hGST P1-1. Residue V161 in 
SjGST and I161 in His6-hGST P1-1 make hydrophobic interactions in our models with 
the ligands 5c and 5g. As expected, the sub-pockets of both isoforms accommodating the 
hydrazones are rather hydrophobic, and complement the hydrophobic hydrazones 
amplified from the DCL. The thiophene hydrazone fits easily in the SjGST binding 




and crystal structure template), whereas the t-butylphenyl group would lead to a steric 
clash and would require some degree of induced fit in order to bind. Induced fit is also 
required to accommodate this ligand in the His6-hGST P1-1 pocket, but in that case the 
binding mode could be stabilized by additional lipophilic interactions of the t-butyl 
group with Y103, H162 and I161. It is worth noting that Chern and colleagues have 
reported that mutations in that region of the H-site had a great impact on EPNP binding, 
with mutation of cGST M1-1 Q165 to leucine (V161 in SjGST and I161 in hGST P1-1) 
reducing kcat
EPNP by 59%, although Km showed only small changes [169]. Because the 
amino acids in the equivalent pocket of SjGST and His6-hGST P1-1 are not highly 
conserved, these residues have such a great influence on ligand binding that it is likely 



















































Figure 1.59. Molecular modeling of amplified DCL components with the GST active 
site. A, Model of 5g bound to SjGST. B, Model of 5c bound to His6-hGST P1-1. The 
binding pocket surfaces are shown in light blue and key amino acids as blue sticks. The 
ligands are represented in salmon pink, with atoms coloured by type. Hydrogen bonds of 
the conjugated ligand parts are shown as yellow dotted lines. C, The EPNP–cGST M1-1 
crystal structure (PDB code 1C72). The binding pocket surface is shown in raspberry 
pink and key amino acids as red sticks. The ligand is represented in green, with atoms 









 1.2.3.3.2. Importance of the heteroatom in SjGST selection of a five-
membered heterocycle 
 
Looking back at the library members, we observed that compound 5f, 
containing an oxozole ring, was fairly similar to the thiophene hydrazone 5g selected by 
SjGST. Since the chemical groups of 5g involved in the predicted interactions with 
SjGST are the secondary amine of the hydrazone bond, the ketone common to all the 
library members and C4 of the thiophene ring, we noticed that the same types of 
interactions could occur with 5f and consequently it was surprising that this compound 
had not been amplified at all.  
 
1.2.3.3.2.1. Generation of a 3-member dynamic combinatorial library 
 
To study the importance of the heteroatom in the five-membered heterocycle, 
Venugopal Bhat generated a new library composed of the GSH conjugated aldehyde 4, 
the compounds 2f, 2g and another acyl hydrazone containing a pyrrole ring 2k (Figure 
1.60. A). Nitrogen has an intermediate size and electronegativity between oxygen and 
sulfur. The new DCL was equilibrated in the absence and in the presence of SjGST. The 
three peaks corresponding to 5k, 5f and 5g were clearly identified (Figure 1.60. B). 
After 16 hours with the target protein, a distinct amplification of around 50% was 
observed again for the same thiophene compound 5g. Both 5k and 5f decreased by 55 
and 50% respectively. In the acyl hydrazone 5k, the proton bound to the nitrogen may 
form a hydrogen bond with the oxygen of the ketone, making this molecule more rigid 
and preventing interactions with R103 and Q204 in SjGST’s hydrophobic pocket. 
Therefore binding of this compound would be less favoured among the three ligands. 





























Figure 1.60. HPLC analyses of GST-templated DCL of GSH conjugates. A, 3-
membered acyl hydrazone DCL based on GSH-conjugated aldehyde 4. B, DCL acyl 
hydrazone composition in the absence of target (blank) and in the presence of SjGST. 
Percentages of peak areas are specified above each peak.  
 
 
1.2.3.3.2.2. NMR studies 
 
The structures of the five-membered heterocycle acyl hydrazones were 
examined by NMR. In order to simplify the NMR analyses and since we were interested 
in the hydrazone moiety, I analysed the non-conjugated compounds 3f and 3g from the 
first generated library. 1H NMR spectra were firstly run for both compounds in DMSO 
at 25, 30, 35, 40 and 60˚C. The spectrum of 3f (Figure 1.61.) remained unchanged with 
A 
28.3 ± 0.4 % 20.8 ± 0.5 % 
50.9 ± 0.2 % 
12.8 ± 0.3 % 10.3 ± 0.5 % 
76.9 ± 0.4 % 























the increase in temperature. Whereas from 25 to 40˚C, proton peaks were too broad and 
coupling constants could not be determined from the 3g spectrum (Figure 1.62. A). At 
60˚C, the peaks became sharper allowing for determination of coupling constants 
(Figure 1.62. B), suggesting a faster rotation around the N-N bond. H7 proton was 
influenced most heavily by the bond delocalisation, as upon inter-conversion at higher 
temperature, both H7 peaks merge into an average peak hidden in the right shoulder of 
the peak of H3. Considering the broad peaks of H7 and H6 observed in the spectrum of 
3f, it is likely that the same dynamics occur at room temperature. The higher 
electronegativity of the oxygen atom may withdraw some of the electrons before the 
C=N-N delocalised system, allowing an easier rotation around the N-N bond. 
Unfortunately, 1H NMR could not be run at lower temperature due the high melting 
point of DMSO. I suggest that 3g may adopt a conformation more favourable to allow 
the thiophene ring to be accommodated within the SjGST hydrophobic pocket. 
 












Figure 1.62. A, Superposition of 3g 1H NMR spectra at room temperature (top) and at 
60˚C (bottom); B, Peak determination of the spectrum at 60˚C. 
 
Currently, there are more in-depth NMR studies underway on compound 3k to 





































1H NMR spectrum of 3g at 25˚C 



















GST enzymes are currently targeted in the development of new drugs against 
several important diseases such as cancer and schistosomiasis. In cancer therapy, they 
are mostly responsible for drug resistance in many cancer tissues, which often show 
elevated levels of theses enzymes compared to normal tissues. Many cancers also show 
different distribution of GST isozymes compared to those seen in healthy tissues. 
Therefore, elaboration of isoform-specific GST inhibitors would provide tumor-directed 
drugs and potentiate conventional chemotherapeutic agents.  
DCC was used as a new tool to explore the promiscuous H sites of various GST 
isoforms. The GST enzyme proved effective as a DCL template, with two isozymes 
from the GST family smoothly integrating with the small molecule assemblies and 
strongly amplifying the best binding components. The selected hydrazones showed 
increased inhibitory activity of over one order of magnitude from the starting GSH-
tagged nitro-benzaldehyde 4, validating the approach in the context of protein–ligand 
discovery. Interestingly, a single, small DCL composed of only ten members displayed 
isozyme selectivity according to which variant of the GST enzyme is used as the 
template. To gain insight into isoform selectivity, I found that each amplified molecule 
could be effectively docked into its respective GST H-site, although the fine structural 
features of the SjGST versus hGST P1-1 H-site that discriminate between thiophene 
hydrazone 5g and t-butylphenyl hydrazone 5c are unclear at the present time. Structural 
determination of the various GST:GS–hydrazone conjugates will be needed for a deeper 
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Chapter 2: Probing the active site of a bacterial 
















2.1.1. Bacterial glutathione transferases 
 
Bacterial GSTs have been studied since GST activity was reported in 
Escherichia coli in 1981 [1]. Since then, four different bacterial GST classes have 
been identified: Beta, Chi, Theta and Zeta. Most of them show poor catalytic activity 
and low specificity towards GST substrates such as CDNB. It has been proposed that 
these GSTs were not primarily involved in detoxification but were rather involved in 
primary metabolism. Their function may have changed during the course of 
evolution [1, 2, 3]. 
Bacterial theta class GSTs share high sequence similarity with eukaryotic 
theta class GSTs and the same properties. They are represented by dichloromethane 
(DCM) dehydrogenases which catalyse the glutathione dependant conversion of 
DCM to formaldehyde and allow facultative methylotrophic bacteria to use DCM as 
a carbon source. A tetrachlorohydroquinone (TCHQ) dehalogenase has been 
reported as belonging to the zeta class, based on amino-acid sequence alignments. 
This enzyme is involved in the degradation of pentachlorophenol and has isomerase 
activity like the eukaryotic zeta class GSTs. Beta-class GSTs have been isolated 
from several bacteria and are unusual in that they have two catalytic cysteine 
residues in their G-site. They are able to bind GSH-affinity matrices and they can 
conjugate GSH to CDNB. In contrast a new GST class called ‘Chi’ was isolated 
recently from cyanobacteria and they lack the two cysteine residues in their active 
site [1, 2, 3, 4, 5, 6]. 
 
 
2.1.2. The beta-class glutathione transferase BphK 
 
The bacterial GST BphK (Figure 2.1.) was expressed from a gene found in 
the genome of the species Burkholderia xenovorans LB400. This species is an 
environmental strain that was first isolated from a landfill site in the USA known to 
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contain a large concentration of polychlorinated biphenyls (PCBs) [7, 8]. It has a 
remarkable ability to detoxify PCBs, via the detoxification pathway known as the 
Bph pathway, which it then proceeds to use as a carbon source. The Bph pathway 
consists of a number of enzymes that catabolise PCBs. B. xenovorans’ ability to 
detoxify PCBs has been of great importance to the research community as a 
potential candidate for microbial degradation of pollutants [9]. 
The Bph pathway is coded by the Bph operon in the genome of B. 
xenovorans. This operon consists of a cluster of genes that code for enzymes that 
perform the various stages of the biphenyl catabolism eventually leading to the 
production of acetyl-CoA. When the Bph operon was characterised in detail the 
unexpected presence of a gene (bphK) coding for the GST enzyme mentioned above 
was observed. Although its function was unclear it was found not to be essential for 










Figure 2.1. Crystal structure of BphK from B. xenovorans (PDB 2GDR): a) 
homodimer (one subunit in grey, the other in orange) in complex with three 
molecules of GSH (shown in pink); b) active site residues (in green) interacting with 
the two molecules of GSH [157]. 
 
Subsequent studies have proposed that this GST may be responsible for the 
dechlorination of the chlorinated 2-hydroxy-6-oxo-6-phenyl-2,4-dienoate (HOPDA) 
metabolites of the PCB catabolic pathway (Figure 2.2.) [11, 12, 13]. In the proposed 
two-step mechanism for BphK’s function, two molecules of GSH are required. In 












catalytically active cysteine (Cys10) and the molecule of GSH used in the first step 
are regenerated.  
 
 
Figure 2.2. Proposed mechanism for the dehalogenation of 3-Cl HOPDA by BphK 
[15]. 
 
Subsequent searches on genomes of other bacteria resulted in the discovery 
of GST proteins with high sequence identity to that of BphK. Many bacteria of the 
genus Burkholderia, Pseudomonas and Sphingomonas have been shown to have 
proteins sharing sequence identity to the BphK GST [15]. B. cenocepacia belongs to 
the Burkholderia cepacia complex (Bcc) which is used to describe some nine 
species of the genus Burkholderia. Members of the Bcc are known to exist in the 
environment and are also pathogens of both humans and plants. They are most 
notorious as pathogens in sufferers of cystic fibrosis (CF) where they are 
opportunistic colonisers of the patient’s lungs [14].  
118 
 
The J2315 strain of the ET-12 lineage of Burkholderia cenocepacia was 
isolated from the lungs of CF patients. It is a known member of the Bcc and has 
spread among patients in Edinburgh, Scotland and Toronto, Canada during an 
epidemic outbreak in the 1990’s. As well as being able to survive in the CF lung 
B.cenocepacia inhabits the rhizosphere and has an impressive ability to detoxify 
hostile environments [14]. Studies have shown that the J2315 strain of B. 
cenocepacia, is capable of surviving murine macrophages, where a mechanism is in 
place that delays the maturation of phagosomes [15]. This ability to escape host 
cell’s fundamental immune responses along with J2315’s known occurrence in CF 
patients lungs shows conclusively that is has a very impressive detoxification 
system.  
 
2.1.3. Aims and research strategy 
 
BphK isolated from B. xenovorans is one of the most extensively 
investigated bacterial glutathione transferase for bioremediation since it is capable of 
degrading a broad spectrum of polychlorinated biphenyls (PCBs). It has an 
interesting mechanism of reaction which differs from the other GSTs by using two 
molecules of GSH instead of one.  
A bacterial strain from the same genus as B. xenovorans, B. cenocepacia 
J2315 can infect CF patients and is resistant to antibiotics. As a detoxification and 
PCB degrading enzyme, BphK from J2315 may be partly responsible for the 
bacteria’s resistance to a highly hostile environment. Therefore, the aims of this 
project were to: 
- search the genome of B. cenocepacia J2315 for a gene similar to the BphK gene 
found in B. xenovrans; 
- isolate the gene from J2315; 
- express the new GST protein; 
- characterise the activity of the BphK_J2315 protein with a CDNB assay; 
- probe the enzyme active site with a DCC approach.  
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2.2. Results and Discussion 
2.2.1. BphK_J2315 isolation and purification 
 
The BphK protein sequence from B. xenovorans strain LB400 was used to 
search the genome of B. cenocepacia for a similar translated sequences and a match 
of 45% identity was observed with the translated gene BCAM0431. Importantly, the 
active site residues were conserved and the C-terminal motif Ser/Thr-Xaa-Xaa-Asp 
common to all GSTs from PCB degrading operons was present (Figure 2.3.). Site-
directed mutagenesis of this motif in LB400 BphK affected GST activity towards the 




               10        20        30        40        50        60 
BphK   MKLYYSPGACSLSPHIALREAGLNFELVQVDLASKKTASGQDYLEINPAGYVPCLQLDDG 
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Figure 2.3. Alignment of the protein sequences of BphK from B. xenovorans 
(BphK) with the translation of the gene BCAM0431 from B. cenocepacia J2315 
(BphK_J). Alignment was made with LALIGN and gave 45.2% of identity between 
the two sequences. The conserved catalytic residues are shown in red; the conserved 













The gene was isolated from the B. cenocepacia J2315 genome, sequenced, 
and cloned into the expression plasmid pET22b as described in section 5.2.4.9.5. 
The protein of 23769 Da was named BphK_J2315 and expressed in E. coli BL21 
(DE3) at 37 ˚C. After 3 hours of induction with IPTG, a clear expression of the 
protein could be observed by SDS-PAGE analysis (Figure 2.4.). 
 
 










Figure 2.4. SDS-PAGE showing expression of BphK_J2315 from E. coli before (-) 
and after (+) induction with IPTG. From comparison with the marker (M) bands it is 




Purification of BphK_J2315 was performed by affinity chromatography, 
using a 20 ml GSTPrep FF 16/10 column (Figure 2.5.), followed by size exclusion 
chromatography using a 360 ml Superdex S200 column (Figure 2.6.). Specific 

















Figure 2.5. Elution profile of BphK_J2315 from the GSTPrep column showing the 
A280. The collected fractions were analysed by SDS-PAGE (M: low molecular 
weight marker; E: cell free extract; F: flow through; W: wash; collected fractions are 

















Figure 2.6. Elution profile of BphK_J2315 from the Sephacryl S-200 column 
showing the A280. Calibration markers are specified at the top of the S-200 UV trace, 
V0 is a void volume, VC is the column volume. Collected fractions were analysed by 
SDS-PAGE (M: low molecular weight marker). 
 

















Cell free extract 50 336 6.7 16.8 ± 1.8 2.5 ± 0.3 100 
S-200 eluate 40 104 2.6 11.4 ± 1.2 4.4 ± 0.5 68 
M    E   F   W   6   9  12 15  18  21 
30 kDa 






























A yield of ~ 100 mg of recombinant protein was obtained from 3 liters of E. 
coli BL21(DE3) culture. The molecular mass of native BphK_J2315 was estimated 
to be 40 kDa by calibrated gel filtration chromatography, which is close to the 
dimeric molecular mass of ~ 47.5 kDa. Murphy and co-workers purified BphK from 
Burkholderia xenovorans strain LB400 with a glutathione affinity resin and 
determined a mass of approximately 33.9 kDa for the native enzyme. 
Crystallographic analyses revealed that the enzyme is dimeric [11]. BphK_J2315 
was purified to its complete homogeneity with a total recovery of 68 % of the total 
activity using the CDNB assay. The specific activity of the purified enzyme towards 
the reporter substrate CDNB, 4.4 µmol/min/mg, was 1.8-fold higher than that of the 
raw extract. A similar specific activity of 7.4 µmol/min/mg was found for BphK 
from Burkholderia xenovorans strain LB400 [13]. 
In order to estimate the purity of the sample eluted from the gel filtration 
column and to determine the mass of the purified GST, MALDI-TOF MS analysis 
was carried on after dialysis against a 20 mM Tris/HCl buffer. Two major fused 
peaks of 23,761.68 and 24,076.09 m/z were observed (Figure 2.7.). The first peak 
corresponds to the BphK_J2315 monomer which has a theoretical mass of 23,769 
Da. The second peak has an additional 314 Da which is relatively close to the mass 
of glutathione (307 Da). Since BphK is known to have a catalytically active cysteine 
in its active site which binds GSH covalently, we can assume that this peak 
corresponds to BphK_J2315 bound to one molecule of glutathione. This hypothesis 
is verified by the appearance of a third peak at 48,145.13 m/z, matching with the 
molecular weight of the dimeric form of BphK_J2315 (47,538 Da) plus two 























Steady-state kinetics with variable concentrations of substrates (GSH: 1.0 
µM to 2.0 mM; CDNB: 0.5 µM to 1.0 mM) were performed. Data were plotted 
using the Michaelis-Menten and Lineweaver-Burk equations, and kinetic parameters 
such as kcat and KM were determined for each substrate. kcat was calculated using the 
monomeric molecular weight. The same results were obtained with the two models; 
Michaelis-Menten plots are shown in Figure 2.8. and kinetic data are summarised in 


















[2 Bphk_J2315 + 2GSH + H] 
23,761.68 Da 
[BphK_J2315 + H] 
24,076.09 Da 

















Figure 2.8. Michaelis-Menten representation of BphK_J2315 activity towards the 
substrates GSH (A) and CDNB (B). GSH and CDNB concentrations were varied 
from 1 µM to 2 mM and 0.5 µM to 1 mM, respectively. 
 
 
Table 2.1. Kinetic parameters of BphK_J2315 
 
 
 KM (mM) Vmax (µmol/min/mg) kcat (s
-1) kcat/KM (mM
-1.s-1) 
GSH 0.42 ± 0.03 2.92 ± 0.31 1.15 ± 0.12 2.74 
CDNB 1.40 ± 0.23 4.43 ± 0.49 1.75 ± 0.19 1.25 
 
KM and kcat for BphK from B. xenovorans has not been reported in the 
literature. However, similar data were obtained for another beta class GST from 
Proteus mirabilis, GST B1-1, which has KM values of 0.69 and 0.73 mM and kcat of 
0.97 and 1.16 towards GSH and CDNB respectively [17]. 
Since BphK_J2315 was able to conjugate GSH to CDNB, we decided to 























































2.2.2. Exploration of BphK_J2315’s active site using DCC 
 
Venughopal Bhat interfaced the glutathione-conjugated 10-membered 
library presented in Figure 2.9. with the enzyme for 16h and measured the 
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Figure 2.9. Aniline-catalysed acyl hydrazone formation. Conditions: Aldehyde (5 
µM), hydrazides (20 µM) in NH4OAc Buffer (50 mM, pH 6.2) containing 15% 









































Figure 2.10. HPLC analyses of BphK_J2315-templated DCL of GSH conjugates. A, 
DCL acyl hydrazone composition in the absence of target (blank) and in the 
presence of BphK_J2315. DCL conditions: GST (1 equiv.), aldehyde (5 µM), 
hydrazides (20 µM) and aniline (10 mM) in NH4OAc buffer (50 mM, pH 6.2) 
containing 15% DMSO for 16 h. B, Changes in DCL component concentration for 
blank and BphK_J2315 DCLs. 
 
 
The ten peaks corresponding to the 10 hydrazones were identified in both 
the blank and the GST-templated DCLs. Three compounds 5b, 5e and 5c were found 




















which was amplified to almost 200% as compared to 5e (~20%) and 5c (~15%). The 
seven remaining members decreased in proportion. The three selected ligands are all 
hydrophobic. The hydrazone 5b shares some structural features with the well-known 
substrate of BphK, HOPDA (Figure 2.11.). In particular, both molecules are planar 
and have a benzene ring at one extremity. Murphy and co-workers have crystallised 
BphK from LB400 in complex with glutathione and HOPDA [11]. These structures 
revealed the presence of a solvent-exposed H-site, where the benzene ring of 
HOPDA makes hydrophobic contacts with Trp164, Tyr167 and Phe113. These three 
residues are conserved in BphK_J2315. Therefore, one can hypothesise that the 
benzene ring of 5b is accommodated in the corresponding hydrophobic pocket of 
BphK_J2315. Similarly, 5e and 5c, which also have hydrophobic aromatic rings, 




















A BphK enzyme was isolated from the B. cenocepacia genome, expressed 
in E. coli and purified using glutathione-affinity chromatography. Kinetic 
parameters were determined and were comparable to the data found for some other 
bacterial beta class GSTs. They also showed that BphK_J2315 is able to conjugate 
CDNB to glutathione. The enzyme successfully amplified three hydrazones from the 
glutathione-conjugated DCL. The highest amplified member was found to share 
some structural features with a known substrate of BphK and could possibly bind to 
a hydrophobic pocket located in the active site of the enzyme. Although these results 
strengthen the credibility of the use of DCC as a tool in drug discovery, structural 
analyses of the complex BphK:5b/5e/5c as well as inhibition studies remain to be 
done to provide insight into the protein/ligand interactions involved and a rationale 
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Chapter 3: Preliminary work on the exploration of a 

















3.1.1. Eukaryotic translation elongation factor 1Bγ (eEF1Bγ) from 
Saccharomyces cerevisiae 
 
Protein biosynthesis is divided into three phases: initiation, elongation and 
termination. During initiation, a Met-tRNAi
Met is based paired with a starting AUG 
codon of an mRNA within the ribosome. In the elongation phase, one amino-acid 
is added at a time to a growing polypeptide; the ribosome selects the 
aminoacylated-tRNA (aa-tRNA) according to the sequence of codons in the 
mRNA. This process is assisted by several protein elongation factors. In 
eukaryotes, aa-tRNAs are brought to the ribosome by eukaryotic elongation factor 
1A (eEF1A), in the form of a ternary complex aa-tRNA-eEF1A-GTP. Upon 
cognate recognition, GTP is hydrolysed to GDP and eEF1A leaves the ribosome. 
Finally, nucleotide exchange of eEF1A is catalysed by the eukaryotic elongation 
factor 1B (eEF1B), so that inactive eEF1A-GDP is converted into active eEF1A-
GTP which can then bring another aa-tRNA to the ribosome [1].  
In Saccharomyces cerevisiae, eEF1B contains three subunits, α, β and γ. 
The last two interact with each other through their N-termini [2]. α and β are the 
catalytic subunits in the guanine exchange process [3]. eEF1Bγ has been shown to 
bind tubulin [4], the membrane of the endoplasmic reticulum [5] and mRNA [6] 
and is therefore thought to play a role in directing the protein synthetic apparatus 
towards cytoplasmic structures in the cell. Two eEF1Bγ isoforms, Tef3p and 
Tef4p, have been isolated from Saccharomyces cerevisiae [7]. Although its 
function is still unclear, Tef3p has been identified as a calcium-dependant 
membrane binding protein and as a gene dosage suppressor of a 40S ribosomal 
subunit assembly mutant [8].  It is also suspected to play a role in the oxidative 
stress pathway [9] and in the regulation of expression of methionine sulfoxide 
reductase [10].  
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Valencia and co-workers have shown by computational methods that the 
N-terminal domain of eEF1Bγ has sequence motifs characteristic to the theta class 
GSTs [11]. GST activity has been detected in rice eEF1Bγ  [12] and a related 
trypanothione transferase activity has been ascribed to eEF1Bγ  from the protozoa 
Leishmania major [13]. Yeast eEF1Bγ consists of two structural domains 
connected by a flexible peptide linker [2, 3]. The C-terminal domain 2 is 
monomeric and does not interact with eEF1Bα. The structure of the N-terminus of 
Tef3p from S. cerevisiae has been solved by Jeppesen et al. [3] and revealed a clear 
structural conservation to GST (Figure 3.1.). Since the full-length Tef3p tends to 
aggregate at physiological conditions, they constructed two deletion mutants, based 
on trypsin digestion and sequence alignment with the human theta class GST T2-2 
sequence. The two resulting recombinant fragments, domain 1 (1-219 residues) and 
domain 1’ (1-242 residues) respectively, had both sequence homology with GST 
and were highly soluble. Interestingly, domain 1 was found to be monomeric, 
whereas domain 1’ was purified as a dimer, suggesting that residues 220-242 were 










Figure 3.1. A, the eEF1Bγ domain 1 monomer viewed from the dimer interface 
side. The N-terminal subdomain 1N containing the sulphate ion is shown in purple, 
the C-terminal subdomain 1C in yellow, the extra-helix between α-6 and α-7 is 
shown in red. B, the human GST T2-2 monomer with GSH shown in pink bound in 






Only the crystal structure of domain 1 could be solved. Similar to other 
GST structures, domain 1 consists of 2 sub-domains connected by a short peptide 
linker with sub-domain 1N adopting a topology similar to a thioredoxin fold and 
sub-domain 1C containing a hydrophobic core created by interactions between the 
aromatic rings of Trp99, Phe143, Phe169, Phe173, Trp181, Trp191, and Phe192. 
Compared to the human GST T2-2 structure, there is an additional helix between 
α-6 and α-7 similar to that found in the Arabidopsis thaliana GST theta class 
structure. Domain 1 crystallised as a dimer, showing mainly hydrophobic and polar 
interactions between the two monomers, including a hydrophobic ‘lock and key’ 
motif described for mammalian GST structures. In the putative active site, several 
conserved residues involved in GSH binding were identified and a potential 
catalytic Tyr7, although orientated away from the active site, was pointed out.  
Despite these observations, domain 1 did not bind to GSH affinity resin nor did it 
show any activity towards CDNB in vitro [3]. 
It has been suggested that domain 1’ of eEF1Bγ  mediates the dimerisation 
of the eEF1 complex. Based on high sequence identity after alignment with other 
eEF1Bγ isoforms, an interaction site with eEF1Bα has been proposed to be located 
close to the putative GST active site. A communication may then occur between 
the exchange activity and the putative GST activity of eEF1Bγ. Moreover, it has 
been suggested that eEF1Bβ could interact with the loop located between α-2 and 
β-2, which would alternatively become part of the GST active site, giving it more 
flexibility and allowing substrate binding and catalysis. Although Tef3p did not 
show any GST activity towards CDNB, catalytic activity with a more specific 











3.1.2. Aims and research strategy 
 
eEF1Bγ is a protein homologous to GSTs, likely active, for which a 
potential secondary substrate remains to be characterised. Since its putative active 
site shares common structural features with CDNB-conjugating GSTs, the DCL 
created by Venugopal Bhat, based on the CDNB scaffold, was used to probe the 
“H-site” binding pocket in the hope of identifying an amplified ligand. Moreover, 
finding a ligand for the longer domain 1’ could help for a more qualitative 





















3.2. Results and Discussion 
3.2.1. Expression and purification 
 
Genes coding for domain 1 and domain 1’ were both cloned in pET11-d by 
Dr. Andersen and co-workers and both contained an N-terminal 6-histidine tag [3]. 
The resulting theoretical molecular weights of the tagged proteins were 24,876.65 
Da for domain 1 and 28,042.26 Da for the longer domain 1’. Plasmids were named 
pTKB588 and pTKB611 respectively.  
The two proteins were expressed at 37 °C in E. coli BL21 (DE) host cells, 
using the expression vectors pTKB588 and pTKB611. After induction with IPTG 
for 5 hours, an increase in expression of the recombinant proteins of the expected 













Figure 3.2. SDS-PAGE gels showing expression of proteins from E. coli before (-) 
and after (+) induction with IPTG. From comparison with the marker (M) bands it 




Domains 1 and 1’ were purified using a nickel column, followed by gel 
filtration chromatography, a 120 ml Superdex S-75 column and a 360 ml Sephacryl 
S-200 column were used respectively. Cell free extracts, affinity columns flow-
throughs (containing unbound proteins) and washes, and the collected fractions 
were used for SDS-PAGE analysis (Figures 3.3. and 3.4.). 
 
Domain 1 
M     -     + 
Domain 1’ 
M     +    - 
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Figure 3.3. Elution profiles of domain 1 from the Ni column (A) and from the 
Superdex S-75 (B) showing the A280. Calibration markers are specified at the top of 
the S-75 UV trace, V0 is a void volume, VC is the column volume. Collected 
fractions were analysed by SDS-PAGE (M: low molecular weight marker; E: cell 





































































Figure 3.4. Elution profiles of domain 1’ from the Ni column (A) and from the 
Sephacryl S-200 (B) showing the A280. Calibration markers are specified at the top 
of the S-200 UV trace, V0 is a void volume, VC is the column volume. Collected 
fractions were analysed by SDS-PAGE.  
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UV-vis traces from the nickel columns showed large amounts of protein 
contaminants eluting from fraction 1 to fraction 12 in both purifications. Nickel is 
the most widely available metal ion for purifying histidine-tagged protein and 
generally provides good binding efficiency but also tends to bind non-specifically 
to endogenous proteins that contain histidine clusters. Jeppesen et al. used a cobalt 
resin to purify the same two proteins. Cobalt exhibits a more specific interaction 
with histidine-tags, resulting in a less non-specific interaction. 
The molecular masses of the native proteins were estimated to be 25 kDa 
for domain 1 and 55 kDa for domain 1’ by calibrated gel filtration 
chromatography, indicating that domain 1 is monomeric (theoretical mass of 
24,876.65 Da) and domain 1’ is dimeric (56,084 Da). A yield of ~ 40 µg was 
obtained for domain 1, which was not enough material for LC ESI-MS analysis 
and for protein directed DCC. Therefore, my work focused on domain 1’ for which 
a yield of ~ 1 mg per litre of cell culture was obtained.  
Eluted fractions from the Sephacryl S-200 containing domain 1’ (F14 and 
15) were pooled and dialysed against a 20 mM Tris/HCl buffer prior to analysis by 
MALDI-TOF mass spectrometry. The resulting spectrum is presented in figure 3.4. 
A fused peak showing two masses of 27,914.12 Da and 28,044.60 Da was 
observed. The first mass corresponded to the theoretical mass of domain 1’ without 
one methionine plus one proton (27,912 Da), the second mass to domain 1’ plus 
one proton (28,043 Da). These data suggest that a part of the proteins had their N-
terminal methionine cleaved by E. coli during their synthesis. A third peak of 
56,086.20 Da was relatively close to the dimeric theoretical molecular weight of 


















3.2.2. Probing domain 1’ using dynamic combinatorial chemistry 
 
The glutathione-conjugated 10-membered library described in chapters 1 
and 2 was used to probe domain 1’. Venugopal Bhat interfaced the DCL with the 
protein for 16h and compared the acyl hydrazone composition with that of the 
same DCL in the absence of the target protein, in order to identify any 

















[2Domain 1’ + H] 
27,914.12 Da 
[Domain 1’ – Met + H] 
28,044.60 Da 



















Figure 3.5. HPLC analyses of Domain 1’-templated DCL of GSH conjugates; 
DCL acyl hydrazone composition in the absence of target (blank) and in the 
presence of Domain 1’. DCL conditions: Domain 1’ (1 equiv.), aldehyde (5 µM), 
hydrazides (20 µM) and aniline (10 mM) in NH4OAc buffer (50 mM, pH 6.2) 
containing 15% DMSO for 16 h. 
 
 
By comparing the two UV traces from the HPLC analyses, we observed 
that all the peaks remained unchanged in both chromatograms. Therefore, the 
presence of domain 1’ did not promote any change in the library composition. 
Since CDNB is not a substrate for eEF1Bγ, it is possible that none of the members 
were able to bind the protein. Binding studies such as isothermal calorimetry will 
be necessary to confirm these results.  
Since the putative GST active site of domain 1’ resembles that of the 
human GST T2-2, I searched for the literature-known substrates for this enzyme in 
order to be able to design a more appropriate library for domain 1’. Interestingly, 
hGST T2-2 does not have any activity towards CDNB and does not bind to 
glutathione-affinity resins either [14, 15]. Although it has a low affinity for GSH 
(KM ~ 0.8 mM), hGST T2-2 is able to activate the tripeptide with an efficiency 
similar to that of other mammalian GSTs [16, 17]. Moreover, it has been shown 














various carcinogenic sulfate esters and in particular to 1-menaphthyl-sulfate (MSu) 
[14, 18]. Similar to the hGST T2-2 crystal structure, a sulfate ion has been found 
bound in the putative active site of domain 1, suggesting the possibility of a 
sulfatase activity [3, 18]. Considering this information, one could imagine probing 
domain 1’ with a new library based on the MSu scaffold (Figure 3.6. A). For 
instance, a DCL could be developed based on the commercially available 











































The N-terminal part of eEF1Bγ from S. cerevisiae is a GST-like protein for 
which no biological function has been assigned so far. Two truncated forms from this 
region, the monomeric domain 1 and the dimeric domain 1’, have been purified using a 
nickel resin. However, the yields obtained for the two proteins were relatively low and 
the method needs to be improved. Domain 1’ did not influence the CDNB-based DCL 
composition and is possibly unlikely to bind any CDNB derivative. A potential 
substrate for this protein was suggested, and a structurally similar commercially 
available aldehyde has been found to be a good candidate for the generation of a new 
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Chapter 4: Biotechnological applications of glutathione 

















4.1.1. Quantum dots and their applications in biology 
 
Quantum dots (QDs) are colloidal nanocrystals of semiconductors with a 
size range of 1 to 10 nm [1]. They have recently emerged as powerful fluorescent 
probes for biomolecular and cellular imaging applications. QDs have several 
advantages over small organic dyes and fluorescent proteins such as size-tuneable 
photoluminescence, wide excitation range spanning the UV to near infra-red 
(Figure 4.1.), narrow emission, strong brightness, and high resistance to 
photobleaching and degradation. QD fluorophores are mainly used in biological 
imaging, in vitro for fixed cells and tissues as well as in vivo for live cells and 
animal imaging [2-4].  
 
Figure 4.1.  Tuning fluorescence emission based on quantum dot size (A) and 
composition (B) (adapted from Bailey et al.; [1]) 
 
Cellular labelling with QDs permits extended visualisation of cells under 
continuous illumination and multicolour imaging. QDs have been used for antigen 
detection, and labelling of plasma membrane, cytoplasmic and nuclear proteins in 
fixed cells [5-7]. In live cells, the process is more delicate because cellular viability 
has to be maintained. QDs are generally taken-up into the live cell by endocytosis, 
microinjection or electroporation. Targeted-uptake, implying delivery to a specific 
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cell compartment, is also possible through QDs labelled with specific peptides. 
Inside live cells, they can be tolerated for extended amounts of time [1, 2]. Using 
QDs with a long absorption wavelength, one can achieve a deeper penetration of 
live tissues than the existing dyes. They have been used for mapping, visualising 
and tracking cancer cells in animals in vivo [8, 9]. 
QD labelling assays have also been developed for detection of DNA, 
proteins and other biomolecules in vitro. DNA-coated QDs have been employed 
for in situ hybridizations [10], probes for human metaphase chromosomes [11], and 
in single-nucleotide polymorphism and multi-allele DNA detection [12]; while 
protein-coated QDs have been used in numerous immunoassays [13]. 
Finally, QDs have been reported as fluorescence resonance energy 
transfer (FRET) donors. Self-assembling acceptor dye-labelled proteins are 
attached onto QD donor surfaces, QD donor emission can be size-tuned to improve 
spectral overlap with a particular acceptor dye. To further improve FRET efficacy, 
one can use multiple acceptors [14]. 
QDs for biological applications are generally made of a CdSe core coated 
over with a protective layer of ZnS. This hydrophobic surface is then modified to 
make them more water-soluble and to allow attachment of biomolecules. The 
conjugation of a biomolecule to a QD is generally achieved through a covalent 
bond, electrostatic or hydrophobic interactions [1, 2]. The ability to control the site 
of attachment is important to ensure that the biomolecule bound to the QD is still 
active. Site-specific noncovalent binding of QDs to biomolecules has been 
achieved and examples include those that exploit carbohydrate-lectin and 
streptavidin-biotin interactions [15, 16]. 
 
 
4.1.2. Metal-mediated labeling of hexahistidine-tagged proteins 
 
The method to purify proteins with histidine residues was first described 
in 1987 by Schacher and co-workers [17]. The number of six histidine units was 
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found to be the most efficient under native conditions and in low or high salt 
concentrations. Hexahistidine (His6) tags can generally be incorporated at the 
termini of proteins with little or no impact on protein function and folding. Since 
His6-tags are known to tightly interact with nitrilotriacetic acid (NTA) complexes 
of transition metal ions such as Cd2+, Hg2+, Co2+ and Ni2+ (Kd ~ 10 M), 
purification of histidine-tagged proteins is accomplished using NTA metal 
complexes immobilized on resins. After binding, the target protein can be eluted by 
a gradient of imidazole [18]. 
Binding affinity between metal-NTA complexes and His6-tagged proteins 
was applied to fluorescence labeling of proteins. The first example was reported by 
Ebright and co-workers who attached the widely used fluorochromes Cy3 and Cy5 
to Ni2+:NTA units [19]. Binding of the His6-tagged transcription factor catabolite 
activator protein (CAP) to a (Ni2+:NTA)2-Cy3 or (Ni
2+:NTA)2-Cy5 resulted in a 
large increase in fluorescence. The Ni2+:NTA constructs were highly specific for 
the hexahistidine region. However, these constructs had relatively poor emission, 
limiting their applications in biological systems. More recently, Lippard and co-
workers selectively labeled a His6-tagged extracellular protein using a fluorescein-
NTA conjugate, increasing fluorescence efficiency [20].  
 
 
4.1.3. SjGST as a tool in biotechnology 
 
GST gene fusion proteins are widely used in proteomics and genomics. 
Two years after the identification of a Mr 26,000 antigen in mice as a functional 
GST of the parasitic worm Schistosoma japonicum in 1986 [21], Smith and 
Johnson first described the use of SjGST as a fusion tag for single-step purification 
of polypeptides [22]. SjGST was cloned in a pGEX E. coli expression vector. 
Bound fusion proteins can be purified from crude lysate by affinity 
chromatography on immobilized GSH or GSH derivatives, and eluted with GSH. 
In most cases, the fusion proteins have good aqueous solubility and are therefore 
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easy to purify. Generally, the fusion proteins are released from the GST-tag by 
using site specific proteases such as thrombin or the blood coagulation factor Xa, 
after which the GST carrier and the GST-tagged protease are removed by 
absorption by GSH affinity chromatography [18]. 
In the late eighties, this expression system was used to generate 
recombinant antigens targeting the GST fusion protein. For instance, Rickard and 
co-workers prepared an antigen useful for vaccinating sheep against ovine 
cysticercosis [23]. Later, Brunham and co-workers used the same technique in the 
aim to develop a vaccine against several serovars of Chlamydia trachomatis, a 
bacterium responsible for the chlamydiose disease [24]. 
More recently, pull-down or affinity precipitation assays using GST 
fusion proteins have been developed to study protein-protein interactions [25]. A 
GST fusion protein is expressed, purified and then immobilised on a GSH affinity 
resin. Once bound, the fusion protein is incubated with cell extracts to pull down 
the interacting target protein. This technique is widely used for identifying 
unknown protein-protein interactions or specific regions involved in these 
interactions. Using this process, Livingstone and co-workers identified a group of 
proteins interacting with a tumour gene suppressor [26]. In another study, Kaelin 
and co-workers characterised the sequence-specific DNA binding site domain of 
the retinoblastoma protein which plays a role in cell growth regulation [27].  
 
 
4.1.4. Aims and research strategy 
 
The fluorescent labelling of specific proteins using a His6-tags fusion 
strategy coupled to the recognition of these tags by Ni-NTA has been recently 
extended to QDs. During this study, Song and co-workers showed that Ni-NTA-
containing QDs can be applied to imaging His6-tagged proteins in live cells [28]. In 
a previous study, Mattousi and co-workers showed that Hisn-tags can also bind 
with very high affinity to QDs with carboxylic acid functionalities requiring fewer 
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synthetic steps and cheaper reagents [29]. However, it was also reported that these 
QDs bind His6-tagged proteins only in the presence of Ni
2+ cations [30]. Therefore, 
it is useful to look at the advantages, disadvantages and applicability of this fairly 
new technique. In this study, Manish Gupta and Dr. Juan Mareque-Rivas 
(University of Edinburgh) investigated binding of the well characterised His6-
tagged and untagged SjGST as model protein to CdSe-ZnS core-shell nanoparticles 
with carboxylates, NTA, and Ni2+-bound NTA at the surface. For this purpose, I 
purified and characterised both His6-tagged and untagged SjGSTs. QDs-GST 
conjugates are interesting because GSTs catalyze the nucleophilic addition of GSH 
to the electrophilic center of a range of nonpolar substrates as a way of detoxifying 
a wide range of harmful endogenous and xenobiotic compounds, and in drug 
resistance mechanisms. Since GST activity requires not only the formation of a 
dimeric structure (i.e. protein-protein interactions) but also binding of both GSH 
and an acceptor substrate (i.e., protein-substrate interactions), it is a good enzyme 



























4.2. Results and discussion 
4.2.1. Expression, purification and characterisation of SjGST and His6-
SjGST 
 
The untagged SjGST was expressed and purified as described in chapter 1. 
The N-terminal 6 histidine-tagged-SjGST was expressed at 37 °C in E. coli. BL21 
(DE3) host cells, using the expression vector pET-6His-SjGST. After induction 
with IPTG for 3 hours, an increase in expression of the recombinant protein of the 








Figure 4.2. SDS-PAGE gel showing expression of His6-SjGST from E. coli before 
(-) and after (+) induction with IPTG. Clear overexpression of the GST protein 
(~28 kDa) is observed. 
 
Although pET-6His-SjGST contains a lacI gene, a relatively high 
expression of the recombinant protein is already observed without IPTG. It is likely 
that the lac I repressor does not bind properly to the lac O operator of the same 
plasmid, allowing expression without inducer. The His6-SjGST was purified using 
a nickel column (immobilized metal affinity chromatography, IMAC), followed by 
gel filtration chromatography with a 320 ml Sephacryl S-200 gel filtration column. 
Cell free extracts, affinity columns flow-throughs (containing unbound protein) 
and washes, and the collected fractions were used for SDS-PAGE analysis (Figure 
4.3.). 
M     -     + 
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After the first purification step with a Ni column, a relatively small 
amount of unbound recombinant protein was found in the flow-through. The bound 
His6-SjGST eluted in ten fractions (fractions 19 to 29) which were pooled, 
concentrated and loaded on a Sephacryl-S200. Three fractions of highly 
concentrated enzyme were collected from the gel filtration column and a yield of ~ 
48 mg was obtained. Despite the two purification steps, two bands of impurities 
were found in fractions 14 and 15 of the gel filtration column. MALDI-TOF mass 
spectrometry analysis of the pooled collected fraction was carried out after dialysis 
against a 20 mM Tris/HCl buffer, containing 1.4 mM of β-mercaptoethanol. The 















































Figure 4.3. Elution profiles of His6-SjGST from the Ni column (A) and from the 
Sephacryl-S200 (B) showing the A280. Calibration markers are specified at the top 
of the S-200 UV trace, V0 is a void volume, VC is the column volume. Collected 
fractions were analysed by SDS-PAGE (M: low molecular weight marker; E: cell 







































Figure 4.4. MALDI-TOF mass spectrum of His6-SjGST from 20,000 to 65,000 
m/z.  
 
Mass spectrometry analysis revealed that the sample was relatively pure. 
A first peak showing a mass of 28,060.37 Da was observed which was really close 
to the theoretical mass of His6-SjGST plus one proton (28,058 Da). A second peak 
with a mass of 56,118.62 Da corresponded to the dimeric form of His6-SjGST plus 
one proton (56,117 Da).  
Kinetic parameters were determined for both the untagged and the His6-
tagged SjGSTs using a CDNB assays. His6-SjGST data were plotted with 
Michaelis-Menten and are shown in Figure 4.5. Kinetic parameters towards CDNB 
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Figure 4.5. Michaelis-Menten representation of His6-SjGST activity towards the 
substrates GSH (A) and CDNB (B). GSH and CDNB concentrations were varied 

















SjGST 0.35 +/- 0.03 4.65 +/- 0.92 50.0 +/- 8.3 10.8 105.1 +/- 17.6 
His6-SjGST 0.39 +/- 0.01 4.32 +/- 0.64 54.6 +/- 7.3 1.3 116.8 +/- 15.6 
 
Kinetic results show that both the untagged and the tagged SjGSTs are 
active. Moreover, His6-SjGST displayed similar parameters to the untagged 
enzyme, meaning that the presence of a histidine tag at the N-terminus of SjGST 
does not affect its function. 
 
4.2.2. Investigation on His6-SjGST binding to Ni-NTA capped quantum 
dots 
 
QDs decorated with Ni-NTA were prepared by Manish Gupta from CdSe-
ZnS core-shell dihydrolipoic acid (DHLA)-capped QDs (Figure 4.6.). He used QDs 
with a maximum fluorescence emission at 614 nm; and found that the 
[GSH] (µM)













































photoluminescence intensity of the Ni-NTA-capped QD is ~ 85% that of the NTA-
capped QD. This is an important feature as the photoluminescence is not quenched 


















Figure 4.6. Schematic representation of a DHLA-capped QD (top) and a Ni-NTA-
capped QD (bottom). Maximum fluorescence emission at 597 nm. 
 
 
A solution of QDs or PBS buffer (as a control) was incubated with either 
the untagged or His6-tagged SjGST for two hours at room temperature. The 
enzyme-QDs complexes were separated from the unbound enzyme molecules by 
passing this solution through a 35 nm pore size membrane. The retentate 
containing the QD-bound enzyme was dissolved in a PBS solution of imidazole to 
release the enzyme, and both retentate and filtrate were analysed by SDS-PAGE 

























Figure 4.7. SDS-PAGE of the retentate (R) and filtrate (F) after ultrafiltration 
through a Nanosep 300K filter of His6-GST (a), untagged GST (b), His6-GST 
incubated with QD (c), and untagged GST incubated with QD (d). In each case, the 
enzyme and QD concentrations were 16.5 M and 9.0 M, respectively. 
 
 
In the absence of the QD, His6-tagged and untagged GST were found only 
in the filtrate. It has been shown in several studies that DHLA-capped CdSe-ZnS 
core-shell QDs are able to bind histidine-tagged protein by coordination to Zn2+ 
ions at the nanocrystal surface [29, 31-33]. However, interestingly in this study, no 
protein was found in the retentate when incubating DHLA-capped QDs with GSTs. 
Lack of binding could be due to steric hindrance at the N-terminal domain of the 
histidine tag, preventing access and therefore interaction with the Zn2+ of the QD’s 
shell. It is also possible that the different synthetic procedures used to prepare QDs 
lead to subtle changes at the QD surface which affect binding of biomolecules. It is 
also important to note that His-tagged proteins can behave differently depending on 
whether the histidine tag is located at the N- or C-terminus, and that in the studies 
reporting direct His-tag binding to carboxylate-coated QDs the histidine tag was 
located at the C-terminus. In contrast, using the same experimental conditions the 
Ni-NTA-capped QDs immobilized both enzymes and more His6-tagged than 
untagged GST was found in the retentate. Binding was also investigated in the 
presence of high salt concentrations. His6-GST binding to Ni-NTA-capped QDs 
was not affected by 1 M NaCl. In contrast, untagged GST did not bind to the QDs 
under these conditions, which suggests it is predominantly electrostatic. Therefore, 
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high salt concentrations can be used to avoid binding of untagged proteins while 
ensuring binding of the desired His6-tagged target.  
The enzyme was easily released from the QD surface upon addition of 0.5 
M imidazole, which competes for the Ni2+ binding sites. Thus, decorating the 
surface of the QD with Ni2+ complexes of NTA seems a good approach for 
noncovalent site-specific fluorescent labeling of proteins, which can be used for 
instance if carboxylate-functionalized QDs lacking Ni2+ ions fail. Potential 
advantages of attaching Ni-NTA units to QDs could be stronger interactions with 
the His-tag (Kd  10-10 M) [34] and less sensitivity to steric hindrance and surface 
properties by being further away from the nanocrystal surface.  
Recently, the value of magnetic nanoparticles as affinity probes to 
selectively trap and separate His-tagged proteins from cell lysates has been 
elegantly demonstrated [35-38]. The protein purification efficiency of the Ni-NTA-
capped QDs was investigated by incubating cell lysates containing His6-tagged 
SjGST for 2 hours. Remarkably, pure fluorescently labelled GST was obtained 
simply by ultracentrifugaton of this mixture (Figure 4.8.). Thus, by using the Ni-
NTA-capped QDs it is possible to purify and fluorescently label His-tagged 
proteins in a single step. Current methods for efficiently purifying and 
fluorescently labeling His-tagged proteins need various labour-intensive and 
expensive steps, such as conjugation of NTA derivatives on support materials or 
the preparation of suitable magnetic nanoparticles for purification purposes, 
followed by the attachment of fluorescent tags. Another construct suitable for one-
step protein purification and site-specific labelling was recently developed and 






























Figure 4.8. A, SDS-PAGE studies of the cell lysate containing His6-tagged SjGST 
(lane 2) and proteins released from the Ni-NTA-coated QDs treated with PBS 
containing 0.5 M imidazole (lane 3) and supernatant (lane 4) after 
ultracentrifugation. Lane 1 is the molecular weight marker. B, Images of the cell 
lysate after ultracentrifugation and of the pure QD-bound His6-tagged SjGST. 
 
In order to obtain information about the effect of QD binding on the 
catalytic activity of GST, Manish Gupta performed GST assays using CDNB. His6-
SjGST and untagged SjGST were incubated with the same concentration of Ni-
NTA-capped QD. He found that His6-tagged GST retained its activity after binding 
to the QD, whereas the untagged GST lost approximately 22% of its activity 
(Figure 4.9.). It is suggested that the ability of the His6-tag to control the position 
of the Ni-NTA-capped QD relative to the GST active site is responsible for 


































Figure 4.9. Activity of His6-tagged and untagged SjGST in the absence and in the 
presence of Ni-NTA coated QDs. The QD alone did not have any activity. 
 
 
The X-ray crystal structure of SjGST [40] shows that the N-terminus, 
which is where the His6-tag was placed, is approximately 25 Å away from the 
essential catalytic residue Tyr7 (Figure 4.10.). I have examined the distribution of 
positively and negatively charged residues and found that there are positive and 
negative regions close to the active site. These are sites where in the absence of the 
His6-tag nonspecific electrostatic binding could occur, disrupting the enzyme 
activity. By comparing the activity of the enzyme which did not bind to the QD 
with that of the enzyme before incubation with QD, Manish Gupta estimated the 
protein binding capacity and number of His6-GST molecules immobilized on each 
QD (
16). This surface coverage correlates well with that found for QDs and 








































Figure 4.10. X-ray crystal structure of the SjGST homodimer highlighting the 
catalytically crucial Tyr7 residue in red, and the N-terminus site for the His6-tag in 
































Ni-NTA-coated QDs provide a straightforward method to, in one step, purify 
and reversibly label proteins fluorescently. By using these QDs, the N-terminal His6-
tagged SjGST was selectively labelled and purified, which was not possible using QDs 
with carboxylates at the surface. Moreover, it was found that Ni2+ provides a docking 
site which helps to precisely orient the fluorescent nanoparticle on the protein surface 
and that, as a result, GST retained its activity. The use of histidine tags has been 
broadly adopted in the molecular biology and biochemistry communities, and therefore 
this specific conjugation strategy should enable widespread use of these QDs for a 
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5.1. General Materials 
5.1.1. General reagents 
 
All reagents, chemicals and media were purchased from Sigma, Aldrich, 
Fisher, Biorad, Pharmacia or Oxoid unless otherwise stated. All competent cells and 
plasmids were purchased from Novagen and all chromatography columns were from 
GE Healthcare unless otherwise indicated. The pET-6His-SjGST plasmid was 
constructed in the laboratory, prior to this work, by Dr. Dominic Campopiano. 
Plasmids pET15-b-mGSTM1 and pET9-a-mGSTA4 were generously supplied by 
Prof. John Hayes (University of Dundee, UK). Plasmid pET15-b-hGSTP1 was a kind 
gift from Dr. Sylvie Blond (University of Illinois, USA). Pasmids pET11-d-TKB587 
and pET11-d-TKB611 were provided by Dr. Gregers Andersen (University of Arhus, 
Denmark). 
 
5.1.2. Media and Solutions 
 
Sterilisation of media: all media were autoclaved at 121°C for 20 minutes prior to 
use. 
 
Luria Bertani (LB): tryptone (10 g.l-1), yeast extract (5 g.l-1), sodium chloride (10 g.l-
1); pH adjusted to 7.5 with sodium hydroxide. 
 
2 x YT: tryptone (16 g.l-1), yeast extract (10 g.l-1), sodium chloride (5 g.l-1); pH 
adjusted to 7.5 with sodium hydroxide. 
 
SOC: tryptone (20 g.l-1), yeast extract (5 g.l-1), sodium chloride (0.5 g.l-1), magnesium 
sulfate (5 g.l-1), glucose (3.2 g.l-1); pH adjusted to 7.5 with sodium hydroxide. 
 
Agar plates: LB Agar (35 g.l-1) was dissolved in the appropriate volume of deionised 
water. The specific antibiotic was added prior to making plates. 
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X-Gal plates: S-Gal™/LB Agar Blend from Sigma-Aldrich containing tryptone (10 
g.l-1), yeast extract (5 g.l-1), sodium chloride (10 g.l-1), agar (12 g.l-1), S-Gal (0.3 g.l-1), 
ferric ammonium citrate (0.5 g.l-1), IPTG (0.03 g.l-1) was dissolved in the appropriate 
amount of deionised water according to the manufacturer’s instructions. The specific 
antibiotic was added prior to making plates. 
 
DNA-running buffer: TAE buffer – 40 mM Tris, 20 mM Acetic acid, 1 mM EDTA 
(pH 8.3). 
 
Protein-running buffer: TGS buffer – 25 mM Tris, 192 mM glycine, 0.1% (w / v) 
SDS (pH 8.3). 
 
5.1.3. Purification buffers 
 
Purification of His6-hGSTP1-1, His6-mGSTM1-1, His6-SjGST, His6-TKB587 and 
His6-TKB611 
• Buffer A (binding buffer): 20 mM Tris-HCl, 0.5 M NaCl, 5 mM imidazole (pH 
6.8) 
• Buffer B (elution buffer): 20 mM Tris- HCl, 0.5 M NaCl, 0.5 M imidazole (pH 
6.8) 
• Buffer C (gel filtration buffer) : 0.1 M KPhos buffer (0.0503 M KH2PO4, 
0.0497 M K2HPO4), 150 mM NaCl (pH 6.8) 
• Buffer D (dialysis buffer): 0.1 M KPhos buffer (pH 6.8) 
 
Purification of SjGST, SjGST-Y7F, mGSTA4-4 and BphK_J2315 
• Buffer E (binding buffer): 20 mM Tris-HCl (pH 7) 
• Buffer F (elution buffer): 20 mM Tris-HCl, 10 mM glutathione (pH 8) 
• Buffer C (gel filtration buffer) : 0.1 M KPhos buffer (0.0503 M KH2PO4, 
0.0497 M K2HPO4), 150 mM NaCl (pH 6.8) 
• Buffer D (dialysis buffer): 0.1 M KPhos buffer (pH 6.8) 
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5.2. Molecular Biology 
5.2.1. Bacterial cell lines 
 
Strain Genotype Applications 
Top 10™ 
(Competent) 
F- mcrA ,(mrr-hsdRMS-mcrBC) 
80lacZ,M15 ,lacX74 deoR 
recA1 araD139 ,(ara-leu)7697 




F- 80lacZ,M15 ,(lacZYA-argF) 
U169 deoR recA1 endA1 hsdR17 






endA1 recA1 gyrA96 thi hsdR17 
(rk-, mk+) relA1 supE44, ,(lac-proAB),  
[F’ traD36 proAB, laqIqZ,M15] 
Protein expression 
Transformation of DNA ligations 
BL21(DE3) 
(Competent) 
F- ompT hsdSB (rB
- mB
-) gal dcm (DE3) Protein expression 
 
 
5.2.2. Plasmids pGEX6P-1, pET-6His-SjGST, pET9-a-mGSTA4, pET15-b-
mGSTM1, pET15-b-hGSTP1, pET11-d-TKB588 and pET11-d-TKB611 
 
The plasmid pGEX-6P-1 used for expression of SjGST was obtained from 

















Figure 5.1. The plasmid pGEX6P-1 used for expression of SjGST. 
 
Plasmid pET-6His-SjGST used for expression of the N-terminal 6-histidine 
tagged SjGST was generated previously from the modification of pGEX6P-1, in our 


































































Plasmids pET9-a-mGSTA4 and pET15-b-mGSTM1 were kindly provided by 
Prof. John Hayes and his research group based in the University of Dundee (Figures 

























































































































Plasmid pET15-b-His6-hGSTP1 was kindly provided by Dr. Sylvie Blond and 













Figure 5.5. The plasmid pET15-b-His6-hGSTP1 used for expression of His6-hGST 
P1-1. 
 
Plasmids pET11-d-TKB588 and pET11-d-TKB611 were generously provided 
by Dr. Gregers Andersen and his research group based in the University of Aahrus, 













































Figure 5.6. The plasmid pET11-d-TKB588 used for expression of the 588 N terminus 













Figure 5.7. The plasmid pET11-d-TKB611 used for expression of the 611 N terminus 
truncated eEf1bγ from Saccharomyces cereviseae. 
 
 
5.2.3. Oligonucleotide primers 
 
The following oligonuclotide primers were used in this study. Restriction 




























Name Sequence (5’-3’) 
BphK_J2315 Forward  GAC ACC CAC GAA GGA ACC ATA TGA AGC T 
BphK_J2315 Reverse  GCA CCG CTG CGG CGG CCA CGC GTC ATC G 
BphK_J2315_NcoI Forward  CCT GTT GCG ATG ACC CAT GGC CGC CGC A 
BphK_J2315_NcoI Reverse  TGC GGC GGC CAT GGG TCA TCG CAA CAG G 
pGEX Forward GGG CTG GCA AGC CAC GTT TGG TG 
pGEX Reverse CCG GGA GCT GCA TGT GTC AGA GG 
pUC/M13 Forward  GTT TTC CCA GTC ACG AC 
pUC/M13 Reverse  CAG GAA ACA GCT ATG AC 
SjGST_Y7F Forward  CCT ATA CTA GGT TTT TGG AAA ATT AAG 
SjGST_Y7F Reverse  CTT AAT TTT CCA AAA ACC TAG TAT AGG  
T7 Promoter  TAA TAC GAC TCA CTA TAG 
T7 Terminator  CTA GTT ATT GCT CAG CGG 
 
 
5.2.4. DNA manipulation 
5.2.4.1. Purification of plasmid DNA 
   
Plasmid DNA was prepared using QIAprep® Spin Miniprep Kit (Qiagen) 
following the manufacturer’s instructions, provided with the kit and summarized 
below. 
An over-night culture (1.5 mL) was transferred to a sterile epindorf (1.5 mL) 
and centrifuged (13,000 rpm, 5 minutes) using a bench-top centrifuge. The supernatant 
was discarded and the procedure repeated with a further 1.5 mL of culture. The pellet 
was resuspended in P1 buffer (250 µL) and P2 buffer (250 µL) was added. This was 
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followed by immediate invertion of the epindorf 4-6 times. Subsequently, N3 buffer 
(350 µl) was added and the mixture inverted immediately (4-6 times). The resultant 
cloudy mixture was centrifuged (13,000 rpm, 10 minutes) after which, the supernatant 
was transferred to a QIAprep spin column and centrifuged (13,000 rpm, 1 minute). 
The flow-through was discarded and the spin column washed with PB buffer (500 µL) 
and centrifuged (13,000 rpm, 1 minute). The column was washed further with PB 
buffer (750 µL) and centrifuged (13,000 rpm, 1 minute). The column was centrifuged 
for one more minute to remove any residual wash buffer before the purified DNA was 
eluted with sterile water (100 µL) and stored at -20˚C until required. 
 
5.2.4.2. Tranformation of E. coli competent cells with recombinant DNA 
   
Competent cells were transformed according to the manufacturer’s 
instructions. DNA (up to 40 ng) was added to an aliquot of competent cells and gently 
mixed. This was left on ice for 2 minutes before the cells were heat shocked (42°C, 30 
sec). The cells were then grown in 80 l SOC medium at 37°C for 1 hr. Finally, the 
cells were spread to dryness on selective agar plates and incubated at 37°C overnight. 
 
5.2.4.3. Electrophoresis of DNA 
   
The required amount of agarose was added to TAE buffer (typically 1 g / 100 
ml) and heated at 100°C until dissolved. The solution was allowed to cool to 55°C and 
ethidium bromide was added to a final concentration of 0.5 g.ml-1. The gel was then 
poured into a casting mould and allowed to set at room temperature. Loading dye 
(Promega) was added to the sample prior to loading the DNA migrated using a 
potential difference of 100 V for an adequate time to achieve separation. The gels were 
viewed and photographed under UV-light. HyperLadder I and IV (Bioline) were used 




5.2.4.4. Digestion of DNA with restriction endonucleases 
   
The required amount of DNA (0.5 – 1 g) was treated with the appropriate 
amount of endonuclease and buffer, and incubated for at least 3 hours at 37°C before 
analysis by electrophoresis on agarose. The restriction enzyme EcoRI was used as a 
control for the digestion of pGEM-T easy plasmids. 
 
5.2.4.5. Gel-extraction of DNA 
   
DNA was purified from agarose using QIAquick® Gel Extraction Kit 
(Qiagen) following the manufacturers’ instructions which are summerised below. 
Agarose, containing the DNA, was covered of QG buffer (600 µL – 1 mL) 
and incubated at 50 ˚C until the agarose had completely dissolved. This solution was 
transferred to a spin column and centrifuged (13,000 rpm, 1 minute) and the 
supernatant discarded. QG buffer (500 µL) was added and the column centrifuged 
again (13,000 rpm, 1 minute). The supernatant was discarded and PE buffer (750 µL) 
added to the column and incubated for 2-5 minutes. The column was centrifuged 
(13,000 rpm, 1 minute), the supernatant discarded, and the column centrifuged again 
to remove any residual buffer. The purified DNA was eluted with sterile water (30 µL) 
and stored at -20˚C until required. 
 
5.2.4.6. Direct cloning of PCR products 
   
All PCR products were cloned into the pGEM-T easy vector (Promega) using 
the manufacturers’ instructions. 2x rapid T4 DNA ligase buffer (2 l), pGEM-T easy 
vector (1 l), PCR product (3 l) and T4 DNA ligase from Promega (1 l) were gently 
mixed and incubated for one hour at room temperature. 2 l of the reaction mixture 




5.2.4.7. Cloning into plasmid vectors 
   
The DNA fragment cut with suitable restriction enzymes (8 l), the host 
vector cut with suitable restriction enzymes (2 l), 2x Quick ligation buffer (2 l) and 
Quick T4 DNA ligase from New England Biolabs (1 l) were gently mixed and 
incubated for 10 min at room temperature. The reaction mixture (3 l) was used to 
transform JM109 competent cells as described in section 5.2.4.2. 
 
5.2.4.8. Storage of bacterial stocks 
   
LB medium (5 mL) containing the appropriate antibiotic was inoculated with 
the strain of interest and incubated over-night at 37 °C. Subsequently, 225 µL of sterile 
80% glycerol and 1 mL of bacterial culture were placed into a labeled 1.5 mL 
cryotube, giving a final bacterial stock containing 15% glycerol. The tube was quickly 
vortexed and placed at -80°C until required.   
 
5.2.4.9. Polymerase chain reactions 
 
Polymerase chain reactions (PCRs) were performed using a Techne TC-3000 
thermal cycler.  
 
5.2.4.9.1. Amplification of DNA 
   
A typical amplification PCR contained two Ready to Go PCR™ beads 
(Amersham Biosciences), DNA template (2 l), primer-forward 10 M (5 l), primer-
reverse 10 M (5 l), and distilled water (final volume of 50 l). The cycling 






PCR steps Temperature (°C) Time (min) Number of 
cycles 
Initial denaturation 95 2 1 
Denaturation 95 1 25 
Annealing 55 1 25 
Extension 72 2 25 
Termination 72 10 1 
  
The PCR product was then subjected to agarose gel electrophoresis and the 
required band was excised. DNA was purified as described in section 5.2.4.5. 
 
 
5.2.4.9.2. DNA sequencing 
   
The sequencing reactions were performed using the BigDye® Terminator 
v3.1 Cycle sequencing kit (PE Applied Biosystems). The PCR mixtures contained 
DNA template ~5 pmol (5 l), 5x reaction buffer (2 l), primer 10 M (1 l) and Big 
Dye 3.1 (2 l). The pET, pUC/M13 and pGEX primers were used to sequence the 
pET, pGEM and pGEX inserts, respectively. Sequencing of the 5’-end of the DNA 
template was carried out with the primer forward while the sequencing of the 3’-end 
was carried out with the primer reverse. The cycling parameters of the PCR are listed 
below. 
 
PCR steps Temperature (°C) Time Number of cycles 
Denaturation 95 30 sec 16 
Annealing 60 20 sec 16 




Automated DNA sequencing was performed on an ABI prism 377 DNA 
sequencer using the Sanger dideoxy chain termination method. Sequence data were 
analysed using Contig Express within Vector NTI Advance™ V10 software package. 
 
 
5.2.4.9.3. Site-directed mutagenesis  
 
Mutations were performed by using Stratagene site-directed mutagnenesis kit. 
Each reaction contained plasmid DNA (5 l), 10x reaction buffer (5 l), primer-
forward (1 l), primer-reverse (1 l), dNTP mix (1 l), distilled water (final volume 50 
l) and Pfu DNA polymerase 2.5 u / l (1 l). The amplification parameters are listed 
below. One microliter (5 U) of DpnI restriction enzyme was added to the PCR product 
and incubated at 37°C for 2 h. The reaction products were used to transform competent 
E. coli cells DH5 (DE3).  
 
PCR steps Temperature (°C) Time Number of cycles 
Initial denaturation 95 2 min 1 
Denaturation 95 30 sec 16 
Annealing 55 60 sec 16 
Extension 68 1 min / 1000 bp 16 




5.2.4.9.4. Generation of a SjGST_Y7F mutant 
 
A site-directed mutagenesis was carried out as described in section 5.2.4.9.3, 
using plasmid pGEX-6P-1 as a template. SjGST_Y7F Forward and Reverse primers 





























tyrosine amino-acid residue was replaced by a phenylalanine (SjGST_Y7F). 
Transformed DH5α were spread on agar plates containing ampicillin (100 µg/mL). 
Resulting colonies were used to inoculate 5 mL LB liquid media with ampicillin (100 
µg/mL) and cultured over-night at 37 ˚C. Subsequently, plasmid vectors were purified 
as described in section 5.2.4.1. and sequenced as described in section 5.2.4.9.2. 
pGEX6P-1 vectors containing the mutation were named pGEX-6P-1-Y7F (Figure 5.8.) 










Figure 5.8. The plasmid pGEX6P-1-Y7F used for expression of SjGST_Y7F 
 
5.2.4.9.5. Isolation and cloning of bphK_J2315 in pET22-b  
 
Isolation of bphK_J2315 from Burkholderia cenocepacia genome 
 
B. cenocepacia J2315 genomic DNA was provided by Dr. Josefin 
Bartholdson from our laboratory. The known BphK protein sequence from B. 
xenovorans strain LB400 was used to search the genome of B. cenocepacia for similar 
translated sequences. The highest match was obtained with the gene BCAM0431 
sharing 45% identity. The BphK_J2315 Forward and Reverse primers were designed 
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subsequently and used to amplify bphK_J2315 from the J2315 genome as described in 
section 5.2.4.9.1. 
The PCR product was ligated into pGEM®-T Easy vector according to the 
manufacturer’s instructions summarized below. The PCR product (2 µL, ~25 ng) was 
added to 5 µL of 2X rapid ligation buffer, 1 µL of pGEM®-T Easy plasmid, 1 µL of 
T4 DNA ligase and 11 µL of distilled and filtered water. The reaction was mixed by 
pipetting and incubated for 1 h at room temperature.  
After incubation, 2 µl of reaction were used to transfom JM109 competent 
cells as described in section 5.2.4.2. Transformed cells were spread on X-Gal plates 
containing ampicillin (100 µg/mL) for a subsequent blue:white screening. After over-
night incubation at 37˚C, several white colonies were used to inoculate 5 mL LB liquid 
media with ampicillin (100 µg/mL) and cultured over-night at 37 ˚C. Subsequently, 
plasmid vectors were isolated as described in section 5.2.4.1. and sequenced as 
described in section 5.2.4.9.2. pGEM vectors containing bphk_J2315 were kept at -
20˚C until required. 
 
Cloning of bphk_J2315 in pET22-b 
 
In order to insert the gene in a pET22-b expression vector, a site-directed 
mutagenesis was carried out to introduce an NcoI restriction site at its C-terminus, 
using BphK_J2315_NcoI Forward and Reverse primers as described in section 
5.2.4.9.3. The PCR product was used to transform DH5α (DE3) competent cells 
which were subsequently spread on agar plates containing ampicillin (100 µg/mL). 
After over-night incubation at 37 ˚C, several colonies were picked and used to 
inoculate 5 mL of LB medium with ampicillin (100 µg/mL) each.  Plasmids were 
isolated with a QIAprep® Spin Miniprep Kit as described in section 5.2.4.1. and 
subjected to digestion using NdeI and NcoI restriction enzymes as described in section 
5.2.4.4. Restriction products were separated by gel electrophoresis. DNA fragments 
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with a size corresponding to that of bphk_J2315 (624 bp) were extracted from the 
agarose gel as described in section 5.2.4.5. and cloned in pET22-b as described in 
section 5.2.4.7. The insertion was confirmed by restriction analyses using NdeI and 
NcoI restriction enzymes and DNA sequencing. The resulting vector containing the 


















5.3. Protein work 
5.3.1. Polyacrylamide Gel Electrophoresis (PAGE) 
   
SDS-PAGE was used to analyse proteins on the basis of their molecular mass 
with a Tris-Glycine or “Laemmli” discontinuous buffering system [3]. 
SDS sample 2x loading buffer contained Tris/HCl (1.5 M, pH 8.0, 1 ml), 
glycerol (2 ml), bromophenol blue (0.05%, 2 ml), SDS (10%, 1.6 ml) and -
mercaptoethanol (0.4 ml). Samples for analysis by SDS-PAGE were prepared by 
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addition of appropriate volume of this buffer, followed by heating (100°C, 5 min) and 
centrifugation (13,000 rpm, 5 min). 
A standard method was used for the production of acrylamide gels with a 
running gel containing 15% acrylamide and a stacking gel of 4% acrylamide. Briefly, 
the running gel (acrylamide/bis (29:1) 15% w/v, SDS 0.1 % w/v, TEMED 0.15% v/v 
and APS 0.1% w/v in Tris buffer (375 mM, pH 8.8)) and was poured between glass 
plates, levelled and set at room temperature. The stacking gel (acrylamide/bis (29:1) 
4% w/v, SDS 0.1 % w/v, TEMED 0.15 % v/v and APS 0.1% w/v in Tris buffer (375 
mM, pH 6.8)) was then added and set at room temperature using a mould to produce 
the wells in the finished gel. Gels were run in protein-running buffer at 150 V and then 
visualised using Coomassie Brilliant Blue R250, GelCode (Pierce) in accordance with 
manufacturers’ instructions. 
 
5.3.2. Expression and purification of glutathione transferases 
5.3.2.1. Large scale expression  
   
A general method, as follows, was used to express the GST isoforms and the 
GST-like proteins. 
The appropriate plasmid vector was used to transform E. coli expression 
strain BL21 (DE3). One colony was picked and used to inoculate 200 ml of LB broth 
containing ampicillin (100 g/ml) or kanamycin (30 g/ml) and grown overnight at 
37°C with agitation (250 rpm). The 200 ml overnight culture was used to inoculate 3/5 
L of appropriate media, grown to an OD600 of 0.6 at 37°C and induced with IPTG for 
three to five hours at the appropriate temperature. The conditions of expression for 














































































































































































































































































































































































































Cells were harvested by refrigerated centrifugation at 5 000 x g for 10 min 
immediately after induction. Cell pellets were stored at -20°C until required. 
 
5.3.2.2. Purification of SjGST, SjGST_Y7F, mGSTA4-4 and BphK_J2315 
   
The expressing pellet was resuspended (4 ml/g wet cell pellet) in buffer E 
containing one protease inhibitor cocktail tablet (EDTA-free). The resuspended pellet 
was sonicated for 15 min (30 s on / 30 s off) on ice and was then centrifuged at 27 000 
x g for 30 min at 4°C to remove insoluble debris. The supernatant was filtered through 
a 0.45 m membrane prior to chromatography at 4°C. The cell lysate was loaded onto 
a 20 ml GSTPrep FF 16/10 column (GE Healthcare) previously equilibrated with 
binding buffer E. The column was then washed with 5 column volumes of buffer A 
before elution using a linear gradient of glutathione (0 – 100% buffer F) over 5 column 
volumes. Fractions were analysed by SDS-PAGE and proteins that did not bind to the 
column were shown to be in the flow-through fraction with the rest of the unbound 
material. Fractions containing the protein of interest were pooled, dialysed twice 
against 4 L of buffer D, using a Spectra/Por® 8,000 molecular-weight-cutoff dialysis 
tubing, and fractionated into aliquots of 1 mL. 225 µl of sterile 80% glycerol were 
added to each 1 mL protein aliquot in a 1.5 mL cryotube. Tubes were frozen in liquid 
nitrogen and stored at -20°C until required. 
 
5.3.2.3. Purification of His6-SjGST, His6-hGSTP1-1, His6-mGSTM1-1, 
TKB587 and TKB611  
 
The expressing pellets were resuspended in binding buffer A (4 ml per gram 
of wet cell paste) with one protease inhibitor cocktail tablet (EDTA-free) and 
disrupted by sonication (15 pulses of 30 s at 30 s intervals) at 4°C. The cell debris 
were removed by centrifugation at 27 000 x g for 30 minutes at 4°C, after which the 
supernatant was filtered through a 0.45 m membrane prior to chromatography. The 
cell lysate was loaded onto a 5 ml HisTrap™ HP column (GE Healthcare) previously 
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equilibrated with buffer A. The column was then washed with 5 column volumes of 
buffer A before the bound material was eluted using a linear gradient of imidazole (0 – 
100% buffer B) over 20 column volumes at 4°C. Fractions were analysed by SDS-
PAGE and those containing the protein of interest were pooled and applied onto a 320 
ml HiPrep Sephacryl S-200 HR column (GE Healthcare) pre-equilibrated with buffer 
C, except for TKB587 which was applied to a 120 ml HiLoad Superdex S-75 column 
(GE Healthcare). The column was then washed with one column volume of buffer C. 
Fractions containing the protein of interest were pooled, dialysed twice against 4 L of 
buffer D, using a Spectra/Por® 8,000 molecular-weight-cutoff dialysis tubing, and 
fractionated into aliquots of 1 mL. 225 µl of sterile 80% glycerol were added to each 1 
mL protein aliquot in a 1.5 mL cryotube. Tubes were frozen in liquid nitrogen and 
stored at -20°C until required. 
 
5.3.2.4. Sephacryl 200 and Superdex 75 columns calibration 
 
Calibrations were performed with low and high molecular weight calibration 
kits (GE Healthcare) according to the manufacturer’s guide lines. Columns were 
preequilibrated with 20 mM Tris buffer containing 150 mM NaCl, pH 7.5 and then run 
with Blue Dextran 2000 (1 mg/ml). Elution volumes were referred as the void 
volumes, V0. Mixture of low and high molecular weight standards (5 mg/ml each) were 
successively run and the elution volumes noted Ve. The gel phase distribution 
coefficient (Kav) of the protein was calculated as (Ve – V0)/(Vc – V0), where Vc is the 
total volume of the column (320 ml). Kav was plotted against log(Mw) of each sample 
injected (Figure 5.10. and 5.11.) and a linear equation was fitted by Sigmaplot software 






























Figure 5.11. Calibration curve of Superdex 75 Hiprep 16/60 column. 
 
5.3.3. Analyses of purified proteins 
5.3.3.1. Bradford assay  
   
Protein concentrations of cell lysates, soluble fractions and purified GSTs 
were determined by the method of Bradford [4] using a Quick StartTM Bradford 
Protein Assay (Bio-Rad). This method is based on the change in absorbance of 
Coomassie Blue G-250 upon binding of protein. The dye exists in three forms: cationic 
(red), neutral (green), and anionic (blue). Under acidic conditions, the dye is 
Log (Mw)




























predominantly in the doubly protonated red cationic form (λmax = 470 nm). However, 
when the dye binds to protein, it is converted to a stable unprotonated blue form 
(λmax = 595 nm). It is this blue protein-dye form that is detected at 595 nm in the 
protein assay. A standard curve was produced from serial dilutions (Table 5.1) of a 
known stock concentration of BSA (2 mg/mL). 
1 mL of 1X Dye Reagent was added to a clean, dry cuvette containing the 
protein sample (20 µL). The solution was mixed by inverting the cuvette 3-4 times and 
incubated at room temperature for 10 minutes. Each sample was carried out in 
duplicate. The absorbance of the standards and unknown samples was measured at 595 
nm. The concentration of protein was calculated according to the standard curve. 
 











Table 5.1. Standard curve concentrations. 
 
5.3.3.2. Liquid chromatography-mass spectrometry (LC-ESI-MS) 
   
LC-ESI-MS was performed on a MicroMass Platform II quadrupole mass 
spectrometer equipped with an electrospray ion source. The spectrometer cone voltage 
was ramped from 40 to 70 V and the source temperature set to 140°C. Protein samples 
were separated on a Jupiter C5 reverse phase column (5 m, 250 x 4.6 mm, 
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Phenomenex) with a Waters HPLC 2690 directly connected to the spectrometer. 
Proteins were eluted from the column with a 5-95% acetonitrile (containing 0.01% 
TFA) gradient at a flow rate of 0.1 ml.min-1. The total ion count in the range 400-1980 
m/z was scanned at 0.1 s intervals. The scans were accumulated, spectra combined and 
the molecular mass determined by the MaxEnt and Transform algorithm of the Mass 
Lynx software (Micromass, U.K.). 
 
5.3.3.3. MALDI-TOF Mass Spectrometry 
 
Proteins were buffer-exchanged against a Tris-HCl buffer (20 mM) using a 
10000 MWCO centrifuge filter (Vivaspin) and co-crystallised with sinapinic acid used 
as a matrix, directly on MALDI plate. A volume of 0.5 µl was deposited on a MALDI 
plate and was kept at room temperature until dried. MALDI-MS spectra (two 
replicates) were measured on a Voyager DE-STR MALDI-TOF mass spectrometer. 
Spectra were acquired in the range of 20,000 to 65,000 Da. Other variables were set as 
follows: accelerating voltage = 25,000 V, grid voltage = 96%, guide wire = 0.15%, 
extraction delay time = 800 nsec. Typically, 100 shots were taken for each sample 
combined and analysed using the DataExplorer software from Applied Biosystems. 
 
5.3.3.4. In vitro glutathione transferase assays 
 
Activity assays were performed on a Varian’s Cary 50 UV-Vis 
spectrophotometer and inhibition assays were carried out on a Molecular Devices 
SpectraMax M5 UV-visible 96 well-plates spectrophotometer.  
 
5.3.3.4.1. Activity assays 
   
The initial rates of GST-catalyzed conjugation of GSH with CDNB were 
determined spectrophotometrically according to the method of Habig et al. [5]. The 
Km
CDNB for the CDNB-GSH conjugation reaction was determined using a range of 
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CDNB concentrations while the GSH concentration was fixed at 2 mM. Determination 
of the Km
GSH was conducted using a range of GSH concentrations, while the CDNB 
concentration was constant (1 mM final concentration). Enzymatic reactions were 
carried out in potassium phosphate, 0.1 M, pH 6.8 (reaction buffer) containing 2.5% 
ethanol. 
 
Preparation of stock solutions 
 
GST samples and a GSH stock solution (40 mM) were prepared in reaction 
buffer. A CDNB stock solution (20 mM) was prepared in 50% ethanol. 
 
A set of 12 substrate concentrations was prepared as a two-fold serial dilution 
set for each substrate as follows. 
- GSH:  
1 mL of GSH stock solution (40 mM) was added to 9 mL of reaction buffer, giving a 
second GSH stock solution of 4 mM. 5.6 mL of this second stock solution were added 
to 4.4 mL of reaction buffer, giving a GSH concentration of 2222.2 µM.  
From this solution, 5 mL were serially added 11 times to 5 mL of reaction buffer, 
giving the concentrations presented in the table below. 
- CDNB:  
1 mL of CDNB stock solution (20 mM) was added to 9 mL reaction buffer, giving a 
second CDNB stock solution of 2 mM.  
5.6 mL of this second stock solution were added to 4.4 mL of reaction, giving a CDNB 
concentration of 1111.1 µM in reaction buffer containing 2.8% ethanol.  
From this solution, 5 mL were serially added 11 times to 5 mL of reaction buffer with 


















the reaction (µM) 
2222.2 2000 1111.1 1000 
1111.1 1000 555.6 500 
555.6 500 277.8 250 
277.8 250 138.3 125 
138.3 125 69.4 62.5 
69.4 62.5 34.7 31.3 
34.7 31.3 17.4 15.6 
17.4 15.6 8.7 7.8 
8.7 7.8 4.4 3.9 
4.4 3.9 2.2 2 
2.2 2 1.1 1 
1.1 1 0.51 0.5 
 













the reaction (µM) 
22.2 20 88.8 80 
11.1 10 44.4 40 
5.6 5 22.2 20 
2.8 2.5 11.1 10 
1.4 1.25 5.6 5 
0.7 0.625 2.8 2.5 
0.35 0.31 1.4 1.25 
0.17 0.15 0.7 0.625 
0.085 0.08 0.35 0.31 







The reactions were maintained at 25°C, and the conditions were generally 
saturating for the invariant substrate. 
To a 1 ml cuvette were added: 
- 900 µl of either CDNB (8.7 to 1111.1 µM) or GSH (17.4 to 2222.2 µM); 
- GST (50 l, ~0.15 mg.ml-1); 
The solution was mixed well and after incubation at 25°C for 5 minutes, GSH 
or CDNB (50 l, 40 or 20 mM, respectively) was added quickly and mixed. The 
enzymatic reactions were monitored at 340 nm (∆ε = 9.6 mM-1.cm-1) for 5 minutes.  
Each reaction was carried out in triplicate. Controls were performed without 
enzyme for each substrate concentration. The specific activity of the enzymes was 
expressed as micromoles of substrate per minute per milligram of enzyme and was 
corrected for the rate of the spontaneous non-enzymatic conjugation reaction of CDNB 
and GSH. Kinetic data were analysed using the graphing software SigmaPlot®. 
 
5.3.3.4.2. Inhibition studies 
     
Inhibition studies were carried out on SjGST and hGST P1-1. In these 
experiments, enzymatic reactions were carried out in potassium phosphate, 0.1 M, pH 
6.8 (reaction buffer) containing 10% DMSO.  
GST samples and a stock solution of GSH (40 mM) were prepared in reaction 
buffer. Stock solutions CDNB (20 mM) and inhibitors (20 mM) were prepared in 
DMSO. 
Each reaction was carried out in triplicate. Controls were performed in the 
same conditions without enzyme and initial rates were corrected for the rate of the 
spontaneous non-enzymatic conjugation of CDNB and GSH. Data were collected and 




Measure of IC50s 
 
IC50 values, with respect to the GSH-CDNB conjugation reaction, were 
determined for SjGST assayed with compounds 4, 5a to 5j; and hGST P1-1 assayed 
with compounds 4, 5c, 5g, 5h and 5i.  
Sets of 17 inhibitor concentrations were prepared in DMSO, spanning a range 




4 8 12 16 20 40 80 120 160 200 400 
Inhibitor final 
concentrations in 
the reaction (µM) 





800 1200 1600 2000 3000 4000 10,000 20,000 
Inhibitor final 
concentrations in 
the reaction (µM) 
40 60 80 100 150 200 500 1,000 
 
To a 360 l well were added 240 L of reaction buffer, GST (15 L, ~ 0.15 
mg.mL-1) and inhibitor (15 L, 17 concentrations spanning from 4 M to 20 mM). The 
solution was mixed well and incubated at 25°C for 5 minutes. CDNB (15 L, 20 mM) 
and GSH (15 L, 40 mM) were added and the plate was quickly shaked. Absorbance 
was measured at 340 nm, 25°C for 5 minutes.  
 
Measure of Kis 
 
The Ki values with respect to both GSH and CDNB were determined for 
SjGST and hGST P1-1 with compounds 5c and 5g.  
Solutions of CDNB were prepared in 50% DMSO. 
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Sets of 8 substrate concentrations were serially prepared from the stock 













the reaction (µM) 
40 2000 20 1000 
20 1000 10 500 
10 500 5 250 
5 250 2.5 125 
2.5 125 1.25 62.5 
1.25 62.5 0.625 31.3 
0.625 31.3 0.313 15.6 
0.313 15.7 0.157 7.8 
 
Sets of 5 inhibitor concentrations were used spanning a range from 2.5 to 200 
µM (final concentrations) as a three-fold serial dilution set. Dilutions were made 
directly in the 96-well plate. 340 µL of a 235 µM stock solution prepared in reaction 
buffer with 6% DMSO were pipetted into 4 wells (3 replicates + blank). Subsequently, 
85 µL were serially added 4 times to 170 µL of reacion buffer containing 6% DMSO, 






235 78.4 26.1 8.7 2.9 
Final inhibitor 
concentrations 
in the reaction 
(µM) 
200 66.7 22.2 7.4 2.5 
 
To the wells containing inhibitor (255 µL) were added 15 µL of GST (~0.15 
mg.mL-1) and the solution was incubated at 25˚C for 5 minutes. Subseqently, 15 µL of 
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GSH (0.313 to 4 mM) and 15 µl of CDNB (0.157 to 2 mM) were added to the 
reaction. The plates were quickly shaked and absorbance was measured at 340 nm, 
25˚C for 5 minutes.   
 
5.3.3.4.3. Isothermal Calorimetry 
 
Isothermal calorimetry (ITC) was carried out in collaboration with Prof. Alan 
Cooper and the Glasgow Biological Microcalorimetry Facility. The ITC measurements 
were performed on a VP-ITC calorimeter (Microcal Inc Northampton, USA) at 25°C.  
SjGST and hGST P1-1 were dialysed against a 0.1 M potassium phosphate 
buffer, pH 6.8 containing 10 % DMSO. The concentrations of SjGST and hGSTP1-1 
(~10 M for titrations with 5c and 5g; ~20 µM for titrations with 4) were determined 
by measuring absorption at 280 nm [∆ε280(SjGST) = 41.2 mM
-1.cm-1 ; ∆ε280(hGST P1-
1) = 38.8 mM-1.cm-1].  
Compounds 5c, 5g and 4 were provided as solids by Venughopal Bhat 
(University of Edinburgh). The right amounts of compounds were accurately weighed 
out using an AnD FX-200 benchtop balance and dissolved in the same dialysis buffer. 
Ligand concentrations were approximately 600 µM.The same buffer was used for 
titration, instrument calibration and baseline controls.  
The proteins SjGST and hGST P1-1 were placed in the 2 ml sample chamber 
and 5c, 5g or 4 in the syringe. A typical ITC measurement consisted of a first control 
injection of 1 l followed by 29 successive injections of 10 l for 20 s with a 3 
minutes interval between each injection.  
Control experiments in which ligands were directly injected in the buffer 
without enzyme were performed in order to evaluate the heat contributions due to 
coupled protonation events upon binding. The observed heat effects were identical to 
the heat signals after complete saturation of the proteins. Therefore, the non-specific 
background was usually estimated by averaging the small heats at the end of the 
SjGST and hGST P1-1 titrations. 
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Raw data were collected and the baseline was corrected for ligand heats 
dilution. The peaks generated were integrated using ORIGIN software (Microcal Inc) 
by plotting the values in microcalories against the molar ratio of injectant to reactant 
within the cell.  
Data were fitted using the one single-site binding model. From the 
dissociation constant KD and the reaction enthalpy value 	H, the change in free Gibbs 
energy (	G°) and entropy change (	S°) can be calculated using the equation 	G° = -
RT ln(1/KD) = 	H - T	S° where R is the universal gas constant and T the absolute 
temperature. 
 
5.4. Molecular docking  
5.4.1. Ligand alignments  
 
The superimposition of glutathione S-transferase ligands was carried out by 
using Relibase+3.0.0 [6]. First, a search was performed to find binding sites that share 
a sequence identity between 40% and 100% to the target SjGST crystal structure 
1M9A [7]. The 38 structures with bound ligand were superimposed by using binding 
site residues only. Finally, the ligands from the superimposed structures were extracted 
and analysed. 
 
5.4.2. Binding mode prediction of SjGST with 5g 
 
The SjGST crystal structure 1M9A [8] was used as initial conformation for 
binding mode generation. The glutathione group of 5g was mapped onto the 1M9A 
ligand coordinates. The thiophen hydrazone group of 5g was oriented towards the 
cavity, lying at the end of the S-hexyl site, as observed for the ligand bound to 
cGSTM1-1 with pdb code 1C72 [7]. In the next step, the protein in complex with 5g 
was minimized, considering the ligand as fully flexible. For the protein all residues 
were kept rigid, except the amino acids that define the pocket at the end of the S-hexyl 
site (R103, V106, V161, V162, Q204). 
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5.4.3. Binding mode prediction of hGST P1-1 with 5c 
 
The hGST P1-1 crystal structure 6GSS [9] was used as initial conformation 
for binding mode generation. The glutathione group of 5c was mapped onto the 6GSS 
ligand coordinates. The tertbutyl hydrazone fragment of 5c was oriented towards the 
cavity, lying at the end of the S-hexyl site, as observed for the ligand bound to 
cGSTM1-1 with PDB code 1C72 [7]. In the next step, the protein in complex with 5c 
was minimized, considering the ligand as fully flexible. For the protein all residues 
were kept rigid, except the amino acids that define the pocket at the end of the S-hexyl 
site (R100, Y103, I161, H162, N204). 
 
 
5.5. NMR analyses on 3f and 3g 
 
1H NMR spectra were recorded in DMSO on a Brüker dpx600 (600 MHz) 
instrument and calibrated to residual solvent peaks (CDCl3 7.26 ppm). The data are 
presented as follows: chemical shift (in ppm on the 
 scale), multiplicity (s=singlet, 
d=doublet), the coupling constant (J, in Hertz) and integration.  
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hGST P1-1 assayed with 4, 5c, 5g, 5h and 5i: 
[4] (M)
















 = 331 +/- 20 M
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 = 57 +/- 2 M
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 = 87 +/- 3 M
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 = 119 +/- 8 M
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SjGST assayed with 4 and 5a to 5j: 
 
[4] (M)

















 = 279 +/- 23 M
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 = 50 +/- 3 M
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 = 26 +/- 1 M
 
[5e] (M)

















 = 36 +/- 2 M
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 = 22 +/- 1 M
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 = 34 +/- 1 M
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 = 37 +/- 1 M
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ITC control experiments: heat signals generated by injection of a ligand (~600 M; 
A: 5c; B: 5g; C: 4) directly into buffer without enzyme. The observed heat effects 

















































H NMR δH 12.16 (s, 1H), 8.50 (s, 1H), 8.37 (d, J = 
1.96 Hz, 1H), 8. 37 (dd, J = 8.45, 2.02 Hz, 1H), 8.03 (d, J = 0.98 
Hz, 1H), 7.85 (d, J = 8.42 Hz, 1H), 7.36 (s, 1H), 6.73 (dd, J = 3.52, 





H NMR δH 12.00 (s, 1H), 8.38 (s, 1H), 8.00 (d, J = 
1.96 Hz, 1H), 7.08 (dd, J = 8.45, 2.02 Hz, 1H), 8.07 (d, J = 0.98 Hz, 
1H), 7.85 (d, J = 8.42 Hz, 1H), 7.24 (s, 1H), 7.24 (dd, J = 3.52, 1.74 
Hz, 1H).  
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Nucleophilic catalysis of acylhydrazone
equilibration for protein-directed dynamic
covalent chemistry
Venugopal T. Bhat1†, Anne M. Caniard1†, Torsten Luksch2, Ruth Brenk2, Dominic J. Campopiano1* and
Michael F. Greaney1*
Dynamic covalent chemistry uses reversible chemical reactions to set up an equilibrating network of molecules at
thermodynamic equilibrium, which can adjust its composition in response to any agent capable of altering the free energy
of the system. When the target is a biological macromolecule, such as a protein, the process corresponds to the protein
directing the synthesis of its own best ligand. Here, we demonstrate that reversible acylhydrazone formation is an
effective chemistry for biological dynamic combinatorial library formation. In the presence of aniline as a nucleophilic
catalyst, dynamic combinatorial libraries equilibrate rapidly at pH 6.2, are fully reversible, and may be switched on or off
by means of a change in pH. We have interfaced these hydrazone dynamic combinatorial libraries with two isozymes from
the glutathione S-transferase class of enzyme, and observed divergent amplification effects, where each protein selects
the best-fitting hydrazone for the hydrophobic region of its active site.
D
ynamic covalent chemistry (DCC) uses reversible chemical
reactions to set up equilibrating assemblies of molecules at
thermodynamic equilibrium1–4. The resultant dynamic com-
binatorial library (DCL) is responsive to the addition of a template,
which will selectively amplify the best binding compounds from the
equilibrium distribution. The essence of the concept lies in the sub-
sequent adjustment of the DCL equilibrium, which will express
more of the best binding compounds at the expense of the poorer
ones. A DCL is thus adaptive and capable of evolutionary behaviour,
whereby individual components are either amplified or reduced in
response to template-directed binding events. These concepts have
been applied to diverse problems in biological and medicinal chem-
istry5–11, synthetic receptor–ligand interactions12–16, self-replica-
tion17–19, complex molecule synthesis20–22 and materials
science23,24. Taken together, they represent the best characterized
examples to date of systems chemistry, which looks to synthesize
complex molecular networks and study their properties and behav-
iour in macrocosm, rather than as a sum of their individual
components25,26.
We are interested in DCC systems that use a biological molecule,
such as a protein, to template assemblies of small molecules at
dynamic equilibrium27. Here, the DCC experiment provides a
method for discovering, studying and ranking novel protein
ligands, concepts fundamental to medicinal chemistry. In these
terms, the DCC process bridges the gap between targeted chemical
synthesis of drug candidates and their biological binding assay,
meshing the two processes into a single step in which the structure
of the biological target directs the assembly of its own best inhibitor
in situ.
A particular challenge for DCC in biological systems lies in the
implementation of a suitable reversible reaction that can operate
effectively under the physiological conditions required by the bio-
template. Lehn has defined two limiting cases for DCL construction:
adaptive and pre-equilibrated DCC28. The adaptive DCL represents
the ideal scenario, where the DCL chemistry is fully compatible with
the biological target and the ensuing binding events control the
evolution of the DCL composition. Pre-equilibrated DCL refers to




































Figure 1 | Transimination reactions for DCC. a, Imine DCLs: reversible
addition of amines to aldehydes gives unstable imines that cannot be
isolated or analysed directly, necessitating an in situ reduction step. The
resultant static library of amines may or may not share the binding profile of
the imine precursors. b, Acyl hydrazone DCLs: reaction of aldehydes with
hydrazides gives acylhydrazones that have good stability and are amenable
to analysis. Equilibration requires acidic conditions that are incompatible with
biological targets—a nucleophilic catalyst such as aniline may enable DCL
formation at biocompatible pH.
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DCL is not compatible with the biological target, meaning that the
DCL and the target must be separated in some manner. This results
in static libraries in which the molecular recognition events that
control DCL composition are lost. Given the challenges associated
with conducting fast, freely reversible chemistry under physiological
conditions, it is not surprising that methods for true adaptive DCL
generation are limited, with the majority of successful systems using
sulfur-based transformations such as disulfide bond formation or
thiol conjugate addition29–32. The development of new methods
for adaptive DCLs is thus central to the application of DCC to bio-
logical systems, as the chemistry will define the target scope and
range of available DCL components.
The reversible formation of C¼N imine-type linkages emerged
early on as a DCL-forming reaction33. The ready availability of
diverse carbonyl and amine building blocks, plus the extensive pre-
cedent of imine formation in biochemical systems, makes it an ideal
candidate reaction. However, the inherent instability of imines in
aqueous solution presents serious analytical and isolation problems
in the DCC context. The solution to this in the field of biological
DCC has been to construct pseudo-adaptive DCLs where the
imine linkage is reduced in situ to an amine with an external
hydride source. The resulting library contains static amine com-
ponents that can correspond to the imines in binding affinity,
although both false-positive and false-negative results are possible.
In addition, the introduction of an in situ reduction step complicates
the DCL equilibration and makes it difficult to distinguish between
genuine thermodynamic selection of the best binders and selection
of those compounds that are kinetically favoured.
An advance on simple imine formation in DCC came from the
Sanders group, who introduced acylhydrazones as reversible lin-
kages34. The reaction has proven to be an excellent balance
between facile reversibility and product stability; the acylhydrazone
products formed are stable to analysis and isolation, and the reac-
tion has very good equilibration properties, as is made evident by
its application to a large number of elegant abiological DCC
studies subsequently reported by the Sanders group35–37. It has
not, however, been generally possible to apply this reaction directly
to adaptive biological DCC systems because of the acidic pH
required for reversibility to occur in a reasonable timeframe
(pH , 4)38,39. A single elegant study from Poulsen has shown that
slow equilibration of acylhydrazones, taking one week at pH 7.2,
can be accelerated in the presence of the enzyme carbonic anhy-
drase, enabling in situ identification of binders using mass spec-
trometry40. We were keen to apply this proven reaction to our
DCC studies of enzymes, and reasoned that it could be harnessed
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Figure 2 | Aniline-catalysed acylhydrazone formation. a, Aldehyde equilibration with hydrazide to form an acylhydrazone. b, Hydrazide components of the
ten-membered DCL. c, DCL established in the absence of aniline. Conditions: aldehyde (5mM), hydrazides (20 mM each) in NH4OAc buffer (50 mM, pH¼
6.2) containing 15% DMSO. d, DCL established in the presence of aniline (10 mM).
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could be found to accelerate the equilibration. Nucleophilic catalysis
of semicarbazone formation using aniline derivatives was estab-
lished in classic work from Jencks in the 1960s, and recently
applied to hydrazone and oxime formation in peptide ligation
systems by Dawson41–44. We reasoned that an additive such as
aniline could promote the equilibration of acylhydrazides and alde-
hydes at pH values closer to the physiological window required by
biological targets in DCC (Fig. 1).
We began by reacting aldehyde 1 (Fig. 2), related to the known
glutathione S-transferase (GST) substrate chlorodinitrobenzene
(CDNB, see below), with an excess of the ten aryl hydrazides
2a–2j at room temperature. The hydrazides were chosen to randomly
display aryl and heteroaryl groups and featured eight acyl and two
sulfonyl hydrazides (2d and j). Equilibration at pH 6.2 was
slow, and only two of the ten possible hydrazones could be observed
by high-performance liquid chromatography (HPLC) after 1 h
(Fig. 2c). Notably, there was a significant amount of free aldehyde 1
present throughout the reaction, despite the presence of excess
amounts of the ten different hydrazides. Equilibrium was not com-
plete after 48 h, and required incubation for a further 5 days until
the library composition reached a steady-state composition with
signals for each of the ten hydrazones 3a–3j being clearly identified.
In contrast, repeating the experiment in the presence of excess
aniline produced a far higher rate of equilibration. A distribution of
acylhydrazones was observed after initial mixing and HPLC sampling,
and complete equilibration of the ten components was observed after
just 6 h (Fig. 2d). Aldehyde 1 could not be detected following initial
mixing, indicating that it was continually being sequestered as an acyl-
hydrazone component, reflecting the faster exchange processes oper-
ating in the presence of aniline (see Supplementary Information for a
study on the effect of varying aniline concentration on rates of hydra-
zone formation). We demonstrated the reversibility of the DCL by
generating it from a different starting composition, hydrazone 3g
plus the nine other hydrazides and aniline. An identical equilibrium
distribution to Fig. 2 was observed, indicating true thermodynamic
equilibrium. A second control experiment confirmed the reversibility
of the DCL through the addition of excess hydrazide 2b to the pre-
equilibrated DCL, which resulted in a large amplification of the corre-
sponding acylhydrazone 3b (see Supplementary Information).
Having established that aniline could act as an effective nucleo-
philic catalyst for hydrazone DCC formation at both a pH and time-
frame reasonable for biomolecule stability, our next step was to
introduce proteins to the DCL. Our target chosen for DCC interrog-
ation was the GST enzyme superfamily45. The GSTs are responsible
for cell detoxification, catalysing the conjugation of glutathione
(GSH) to a wide variety of xenobiotic electrophiles, thereby
protecting the cell from cytotoxic and oxidative stress. We have
previously developed thiol conjugate addition DCLs directed
towards GST inhibition, and successfully interfaced the enzyme
with small molecules so that it controlled library evolution27. The
GSTs are well suited to exploration using DCC methods, being
well-characterized, robust proteins having nascent medicinal chem-
istry application46,47. There are relatively few ligands reported in the
literature for GST binding—a plus point, as it would enable us to use
DCC as a genuine discovery tool for new binding motifs, rather than
as a proof-of-principle process for confirming the binding ability of
known ligands. The cytoplasmic GSTs are inherent dimers with
active sites composed of residues from both monomers, bifurcating
between a highly conserved G-site, which binds the endogenous
ligand GSH, and an H-site, which binds hydrophobic substrates
for GSH conjugation (Fig. 3). This bisubstrate architecture is
particularly appropriate for DCC interrogation, given that the
method essentially uses a reversible linkage to couple two sets of
fragment structures together48. Furthermore, within the GST super-
family, the large, heterogeneous H-sites are functionally evolved
to accommodate many different hydrophobic substrates for
conjugation, a classically difficult architecture to investigate using
orthodox structure-based drug-design methods.
We prepared two recombinant GST isozymes as targets, SjGST
from the helminth worm Schistosoma japonicum, a drug target in
tropical disease49, and hGST P1-1, a human isoform that has been
targeted in the treatment of chemotherapy drug resistance50. An
initial control experiment with SjGST established that the enzyme
retained GSH conjugation activity in the presence of aniline (up
to 20 mM). The acylhydrazone DCL prepared in Fig. 2 was then
interfaced with the two protein targets and amplification was
measured (Fig. 4). Both DCLs demonstrated strikingly clear ampli-
fication of hydrazone components; thiophene acylhydrazone 3g was
selected by SjGST and t-butylphenyl hydrazone 3c by hGST P1-1.
Synthesizing the DCL in the presence of bovine serum albumin
(BSA, 1 equiv.) as a control experiment produced no measurable
amplification of any component, indicating the GST enzymes as
being responsible for component amplification. We further demon-
strated that amplified components were bound in the target
H-region of the active site of the enzyme by performing conjugation
experiments with GSH. Conjugation of GSH to the aryl chloride
group in hydrazones 3 by means of SNAr substitution is a slow reaction
at pH 6.2, taking several days. In the presence of catalytic amounts of
SjGST, however, rapid formation of the SNAr conjugation adduct for
hydrazone 3g was observed at pH 6.2. The amplified hydrazone can
thus act as a substrate for SjGST and binds in the targeted H-site.
The amplified hydrazones were re-synthesized and assayed
against both GSTs and found to be inhibitors of GSH conjugation
of CDNB, but poor solubility prevented the determination of accu-
rate IC50 values at the higher concentrations necessary to assay weak
binding compounds. To solve this problem, and simultaneously
increase the potency of our DCL components, we conjugated
GSH to aldehyde 1 using an SNAr reaction. We anticipated that
the highly soluble GSH tripeptide motif would act as an ‘anchor’
at the G-site, enabling exploration of the H-site with assorted hydra-
zide fragments. This approach, in which a known enzyme–substrate
interaction is used for inhibitor discovery, is well exemplified in clas-
sical medicinal chemistry drug design, GST inhibition51 and DCC
methods. The IC50 value for SjGST inhibition of the anchored frag-
ment 4 was measured in the CDNB conjugation assay as 280 mM.
Initial DCC experiments using GS-conjugated aldehyde 4 and
the same ten hydrazides used previously confirmed the utility of
aniline as a nucleophilic catalyst (Fig. 5). Equilibration was complete
in 6 h, compared to 4 days in the absence of aniline, and each of the
ten acylhydrazones were clearly identified by liquid chromatography-
mass spectrometry (LC-MS) (see Supplementary Information).
As before, clear amplifications could be observed for both GST
Figure 3 | Structure of GST illustrating H- and G-sites. Grey, monomer 1;
yellow, monomer 2; green, G-site; red, H-site.
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targets: in each case the same hydrazide fragment was selected as the
best binder, thiophene (5g) for SjGST and t-butylphenyl (5c).
Both components were amplified to over 300% of their con-
centrations in the blank DCL, at the expense of nearly all other com-
peting hydrazones. Also of note, the anisyl sulfonylhydrazone 5j
underwent 100% amplification using hGST P1-1 as the only
other positively selected component. The most significant
reductions in equilibrium concentrations occurred for 5b, f and i
(SjGST) and 5f, g and i (hGST P1-1).
The GST-directed DCLs were synthesized with the protein present
from the beginning of the experiment, that is, in the presence of alde-
hyde 4 and the ten hydrazides 2a–2j. To verify that the amplification
results were not due to a kinetic selection by means of target-acceler-
ated synthesis, we added SjGST to the pre-equilibrated DCL. The
same equilibrium distribution was achieved as is shown in Fig. 5,
with hydrazone 5g strongly amplified, indicating that the amplified
components are the result of genuine thermodynamic selection.
Further controls involved a BSA control experiment, which was nega-
tive, and DCL synthesis in the presence of a large excess of the non-
selective GST inhibitor ethacrynic acid. Component amplification
was completely suppressed for both SjGST and hGST P1-1 DCLs,
indicating that the GST active site is saturated by the ethacrynic
acid and cannot influence the DCL equilibrium composition.
We completed our protein-directed DCL studies by preparing a
catalytically inactive SjGST mutant. It was of interest to see whether
a functionally disabled enzyme would exert the same control and
selectivity on DCL composition as the wild-type enzyme. The con-
served Tyr 7 active site residue is known to play a critical role in
GSH conjugation for the Sj class of GSTs, stabilizing the GSH thio-
late anion through H-bonding from the phenol group, with
enzymes lacking this residue being catalytically inactive52. We pre-
pared a Y7F mutant of SjGST, in which the crucial tyrosine
residue is replaced with phenylalanine. We observed essentially
zero activity with this mutant in CDNB conjugation when com-
pared with the wild-type SjGST. However, SjGST Y7F proved
equally effective in controlling DCL composition, showing a clear
preference for the same thiophene derivative 5g as was amplified
by the wild-type SjGST (see Supplementary Information).
Biological assay was then performed to establish whether the best
binding compounds in the GST-directed DCLs were also the best
inhibitors of the GST enzyme. To fully explore the isozyme-specific
amplification effects of the two DCLs, we separately synthesized
hydrazone conjugates 5a–5j for study. We first confirmed that the
amplified ligands 5c and 5g bound to SjGST and hGST P1-1 by iso-
thermal calorimetry (ITC) (see Supplementary Information). We
then studied their inhibitory activity towards SjGST and hGST
P1-1 using the CDNB conjugation assay. The IC50 values were
slightly higher for all hydrazones against hGST P1-1 compared to
SjGST (data ranging from 59 to 126 mM and 22 to 63 mM, respect-
ively; see Supplementary Information). For each isozyme, the DCC
amplified hydrazone was the most active; thiophene 5g had the
lowest IC50 value (22 mM) among all the library members against
SjGST, and t-butylphenyl 5c had the lowest value among the four
conjugates tested against hGST P1-1 (57 mM). The DCL hydrazone
selection process has successfully extended inhibitor structure in the
GST H-site, increasing potencies by sixfold for hGST P1-1 (331 to
57 mM ) and by over tenfold for SjGST (279 to 22 mM) relative to
the starting anchored aldehyde 4.
Steady-state kinetic studies on the two amplified DCL com-
ponents 5c (hGST P1-1) and 5g (SjGST) confirmed the expected
competitive inhibition profile, with both compounds binding to
the GST active sites. It was interesting to note slightly higher Ki
values for both compounds when assayed against CDNB, a substrate
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Figure 4 | GST-templated DCLs. a, DCL hydrazone composition in the absence of any target (blank). b, When the DCL is constituted in the presence of
SjGST, the thiophene hydrazone 3g is clearly amplified. c, Changing the target protein to hGSTP1-1 produces a different distrubution, in which the
t-butylphenyl derivative 3c is amplified. Targeted DCL conditions: GST (1 equiv.), aldehyde (5mM), hydrazides (20mM) and aniline (10 mM) in NH4OAc
buffer (50 mM, pH¼ 6.2) containing 15% DMSO for 16 h.
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ligand GSH. The affinity of the two hydrazone conjugates towards
both GST G-sites was relatively close (data ranging from 5.25 to
7.19 mM), as would be expected for two compounds sharing a
common GSH-tagged nitrobenzene fragment.
To obtain some molecular insight into the selectivity of our iso-
zymes towards the two hydrazone inhibitors 5c and g, we carried
out a molecular modelling study. We surveyed the available GST
structures in the protein data bank (PDB) and retrieved those that
contained a bound GSH-based ligand. The binding sites of these
structures, together with the bound ligands, were aligned, and
it became evident that the glutathione portions overlaid well,
being bound in very similar conformations in the G-sites (Fig. 6a).
In contrast, the conjugate parts of the various ligands showed great
diversity in their conformations within the H-site, an unsurprising
result given the respective functions of the G- and H-sites. Detailed
analysis of the superimposed crystal structures identified the GSH
conjugate of 1,2-epoxy-3-( p-nitrophenoxy)propane (EPNP) (6)
bound to cGST M1-1 (PDB code 1c72)53 as the ligand that projected
functionality into the H-site with the most similar geometry to the
energy-minimized structure of hydrazone 5g (Fig. 6b).
Analysis of the GST–EPNP complex shows the EPNP moiety
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Figure 5 | GST-templated DCLs of GSH conjugates. a, Acyl hydrazone DCL based on GSH-conjugated aldehyde 4 (GS¼ S-linked glutathione). b, DCL
hydrazone composition in the absence of target (blank), in the presence of SjGST and in the presence of hGSTP1-1. DCL conditions: GST (1 equiv.), aldehyde
(5mM), hydrazides (20mM) and aniline (10 mM) in NH4OAc buffer (50 mM, pH¼ 6.2) containing 15% DMSO for 16 h. c, Changes in DCL component
concentration for blank, SjGST and hGST P1-1 DCLs. The error bars represent the standard deviation over three experiments.
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(Fig. 7c). The side chains of R107, F110, Q165, Q166 and F208
define the pocket that confines the EPNP moiety. On this basis,
we could generate a binding model for SjGST with thiophene hydra-
zone 5g and for hGST P1-1 with t-butyl hydrazone 5c (Fig. 7). The
interactions in the generated binding modes for SjGST in complex
with 5g (Fig. 7a) and for hGST P1-1 in complex with 5c (Fig. 7b)
between the glutathione moiety and the proteins are identical to
those reported in previous publications54,55. We predict that the
hydrazone group of 5g forms hydrogen bonds to R103 and Q204
in SjGST, and equivalent interactions are observed for 5c in
complex with hGST P1-1. Residue V161 in SjGST and I161 in
hGST P1-1 make hydrophobic interactions in our models with
the ligands 5c and 5g.
As expected, the sub-pockets of both isoforms accommodating
the hydrazones are rather hydrophobic, and complement the hydro-
phobic hydrazones amplified from the DCL. The thiophene hydra-
zone fits easily in the SjGST binding pocket, with only minor side-
chain adjustments necessary (root mean square deviation (RMSD)
0.3 Å between model and crystal structure template), whereas the
t-butylphenyl group would lead to a steric clash and would
require some degree of induced fit in order to bind. Induced fit is
also required to accommodate this ligand in the hGST P1-1
pocket, but in that case the binding mode could be stabilized by
additional lipophilic interactions of the t-butyl group with Y103,
H162 and I161. It is worth noting that Chern and colleagues have
reported that mutations in that region of the H-site had a great
impact on EPNP binding as a substrate, with mutation of cGST
M1-1 Q165 to leucine (V161 in SjGST and I161 in hGST P1-1)
reducing k cat
EPNP by 59%, although Km showed only small
changes53. Because the amino acids in the equivalent pocket of
SjGST and hGST P1-1 are not highly conserved, these residues
have such a great influence on ligand binding that it is likely that
these amino-acid exchanges across the isoforms are critical in deter-
mining ligand selectivity.
Conclusions
We have demonstrated that reversible synthesis of acylhydrazones
can be compatible with protein targets by using aniline as a nucleo-
philic catalyst. The many advantages of this DCC tool (ready avail-
ability of easily customized building blocks, good kinetic and
thermodynamic properties leading to ease of analysis, good biologi-
cal compatibility forming amide-like linkages) may now be realized
with biological targets. Most importantly, the acylhydrazone DCLs
are truly adaptive, allowing amplification effects to be simply and
directly related to structures present at equilibrium.
The GST enzyme proved extremely effective as a DCL template,
with two isozymes from the GST family smoothly integrating
with the small molecule assemblies and strongly amplifying the
best binding components. The selected hydrazones showed
increased inhibitory activity of over one order of magnitude from
the starting GSH-tagged benzaldehyde 4, validating the approach
in the context of protein–ligand discovery. Interestingly, a single,
small DCL composed of only ten members displays isozyme
selectivity according to which variant of the GST enzyme is used
as the template.
The study at hand has been deliberately confined to a small
number of DCL components so as to thoroughly characterize equi-
librium distributions and quantify amplifications with the aniline-
catalysed hydrazone method. In principle, much larger hydrazone
DCLs may be accessed to thoroughly explore chemical space, both
within the GST H-site and for other biological targets9,15. It may
not be possible, or even desirable, to accurately characterize the
equilibrium distribution of such complex DCLs, but this will not
be necessary if one simply seeks to identify prominently amplified
components from a ligand discovery perspective.
To gain insight into isoform selectivity, we found that each
amplified molecule could be effectively docked into its respective
GST H-site, although the fine structural features of the SjGST
versus hGST P1-1 H-site that discriminate between thiophene
hydrazone 5g and t-butylphenyl hydrazone 5c are unclear at the
present time. Structural determination of the complexes of various
GST:GS–hydrazone conjugates will be needed for a deeper under-




























Figure 7 | Molecular modelling of amplified DCL components with the GST active site. a, Model of 5g bound to SjGST. b, Model of 5c bound to hGST P1-1.
The binding pocket surfaces are shown in light blue and key amino acids as blue sticks. The ligands are represented in salmon pink, with atoms coloured by
type. Hydrogen bonds of the conjugated ligand parts are shown as yellow dotted lines. c, The EPNP–cGST M1-1 crystal structure (PDB code 1c72). The
binding pocket surface is shown in raspberry pink and key amino acids as red sticks. The ligand is represented in green, with atoms coloured by type.













Figure 6 | GST ligands. a, Superposition of a selection of GST ligands from
the PDB. b, Conformation of the GST-bound EPNP ligand 6 as found in the
crystal structure of cGST M1-1 (PDB code 1c72, green carbon atoms), relative
to the energy-minimized structure of compound 5g (pink carbon atoms).
ARTICLES NATURE CHEMISTRY DOI: 10.1038/NCHEM.658
NATURE CHEMISTRY | ADVANCE ONLINE PUBLICATION | www.nature.com/naturechemistry6
© 2010 Macmillan Publishers Limited.  All rights reserved. 
 
area, together with applications of acylhydrazone DCC to other bio-
logical targets, is the subject of our current research.
Methods
Aniline catalysis of reversible hydrazone formation. The ten hydrazides 2a–j
(10 × 5 ml, 10 mM, DMSO), aldehyde 1 (2 ml, 10 mM, DMSO) and aniline (10 ml,
1 M, DMSO) were added to a mixture of DMSO (93 ml) and ammonium acetate
buffer (845 ml, 50 mM, pH 6.2). The DCL was allowed to stand at room temperature
with occasional shaking, and was monitored periodically by HPLC to establish the
blank composition until the relative populations of the hydrazones became constant.
The pH of all samples was raised to 8 by the addition of NaOH (15 ml, 1 M,
aqueous). LC-MS verified that each of the expected hydrazones was present in the
DCL (HPLC conditions: column, Luna 5 m C18(2), 30 mm × 4.6 mm, and Luna 5 m
C18(2), 50 mm × 4.6 mm, in sequence; flow rate, 1 ml min21; wavelength, 254 nm;
temperature, 23 8C; gradient, H2O/MeCN (0.01% TFA) from 95% to 80% over
6 min, then to 45% over 30 min, and eventually to 5% over 5 min) (Fig. 2d). The
DCL was then re-synthesized in the absence of aniline, and the HPLC traces at
different time intervals were compared (Fig. 2c).
Templated DCL aldehyde 1. SjGST (111 ml, 180 mM, in potassium phosphate
buffer 0.1 M, pH 6.8), the ten hydrazides 2a–j (10 × 5 ml, 10 mM, DMSO), aldehyde
1 (2 ml, 10 mM, DMSO) and aniline (10 ml, 1 M, DMSO) were added to a mixture of
DMSO (93 ml) and ammonium acetate buffer (734 ml, 50 mM, pH 6.2). The DCL
was allowed to stand at room temperature, with occasional shaking, for 12 h. The pH
of the sample was raised to 8 by the addition of NaOH (15 ml, 1 M, aqueous), and
the protein was removed by ultrafiltration using a 10,000 MWCO filter (Vivaspin).
HPLC analysis was performed and the traces were compared with the blank
composition (HPLC conditions: column, Luna 5 m C18(2), 30 mm × 4.6 mm, and
Luna 5 m C18(2), 50 mm × 4.6 mm, in sequence; flow rate, 1 ml min21; wavelength,
254 nm; temperature, 23 8C; gradient H2O/MeCN (0.01% TFA) from 95% to 80%
over 6 min, then to 45% over 30 min, and eventually to 5% over 5 min).
DCL composition was identical, regardless of whether the SjGST was present
from the beginning or added after pre-equilibration, but equilibration took more
than 24 h in the latter case.
For the hGST P1-1 templated library, the ten hydrazides 2a–j (10 × 5 ml, 10 mM,
DMSO), aldehyde 1 (2 ml, 10 mM, DMSO), aniline (10 ml, 1 M, DMSO) and hGST
P1-1 (100 ml, 200 mM, in potassium phosphate buffer 0.1 M, pH 6.8) were added to a
mixture of DMSO (93 ml) and ammonium acetate buffer (734 ml, 50 mM, pH 6.2).
After equilibration for 12 h, the DCL was analysed using HPLC. Control experiments
were performed using the same equivalents of BSA in place of GST.
Conjugate DCLs. To establish the blank DCL composition, the ten hydrazides 2a–j
(10 × 5 ml, 10 mM, DMSO), aldehyde 5 (5 ml, 10 mM, aqueous) and aniline (10 ml,
1 M, DMSO) were added to a mixture of DMSO (96 ml) and ammonium acetate
buffer (839 ml, 50 mM, pH 6.2). The DCL was allowed to stand at room temperature,
with occasional shaking, and was monitored periodically by HPLC to establish the
blank composition until the relative populations of the hydrazones became constant.
The pH of all the samples was increased to 8 by the addition of NaOH (15 ml, 1 M,
aqueous). LC-MS verified that each of the expected hydrazones was present in the
DCL (Fig. 5) (HPLC conditions: column, Luna 5 m C18(2), 50 mm × 4.6 mm, and
Luna 5 m C18(2), 250 mm × 4.6 mm, in sequence; flow rate, 1 ml min21;
wavelength, 254 nm; temperature, 23 8C; gradient H2O/MeCN (0.01% TFA) from
95% to 5% over 40 min).
For re-synthesizing the DCL in the presence of the protein SjGST (278 ml,
180 mM, in potassium phosphate buffer 0.1 M, pH 6.8), the ten hydrazides 2a–j
(10 × 5 ml, 10 mM, DMSO), aldehyde 5 (5 ml, 10 mM, DMSO) and aniline (10 ml,
1 M, DMSO) were added to a mixture of DMSO (96 ml) and ammonium acetate
buffer (561 ml, 50 mM, pH 6.2). The DCL templated by hGST P1-1 was synthesized
by adding the ten hydrazides 2a–j (10 × 5 ml, 10 mM, DMSO), aldehyde 5 (5 ml,
10 mM, DMSO), aniline (10 ml, 1 M, DMSO) and hGST P1-1 (250 ml, 200 mM, in
potassium phosphate buffer 0.1 M, pH 6.8) to a mixture of DMSO (96 ml) and
ammonium acetate buffer (589 ml, 50 mM, pH 6.2). The DCLs were allowed to stand
at room temperature for 12 h, after which the pH was raised to 8 by the addition of
NaOH (15 ml, 1 M). The protein was filtered off using a centrifuge filter of MWCO
10,000 followed by analysis of the filtrate by HPLC using conditions similar to those
listed above.
Molecular modelling. To establish ligand alignment, the superposition of GST
ligands was carried out using Relibaseþ 3.0.0 (ref. 56). A search was first performed
to find binding sites that share a sequence identity between 40 and 100% with the
target GST crystal structure 1m9a. The resulting 38 structures with bound ligand
were superimposed by using binding site residues only. Finally, the ligands from the
superimposed structures were extracted and visually analysed.
To carry out a binding mode prediction with Moloc57, the SjGST crystal
structure (PDB code 1m9a SjGST – S-hexyl–GSH complex) and the hGST
P1-1–GSH complex crystal structure (PDB code 6gss)54 were used as starting
conformations for binding mode generation. The glutathione groups of the
synthesized ligands were mapped onto the glutathione groups of the ligands bound
to the crystal structures. The hydrophobic hydrazone groups of the synthesized
ligands were oriented towards the cavity, lying at the end of the S-hexyl site, as
observed for the EPNP ligand bound to cGSTM1-1 (PDB code 1c72). In the next
step, the protein in complex with the modelled ligand was minimized, considering
the ligand as fully flexible. For the protein all residues were kept rigid, except for the
amino acids that define the pocket at the end of the S-hexyl site (R103, V106, V161,
V162, Q204 for SjGST and R100, Y103, I161, H162, N204 for hGST P1-1).
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Nitrilotriacetic Acid-Derivatized Quantum Dots for Simple Purification and
Site-Selective Fluorescent Labeling of Active Proteins in a Single Step
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We demonstrate that QDs coated with nitrilotriacetic acid (NTA) bound to Ni2+ can be used to reversibly and
selectively bind, purify, and fluorescently label His6-tagged (N-terminal) glutathione S-transferase (GST) in one
step with retention of enzymatic activity. We find binding to be less effective in the absence of the His6-tag or
Ni2+ ions.
Colloidal semiconductor nanocrystals (quantum dots, QDs)
have emerged as powerful fluorescent probes for biological
imaging applications (1-5). QDs have several advantages over
small organic dyes and fluorescent proteins such as size-tuneable
photoluminescence, wide excitation-narrow emission proper-
ties, improved brightness, and high resistance to photobleaching
and degradation. To conjugate QDs to biomolecules, the QD
surface is derivatized in such a way as to allow the attachment
of the biomolecule through a covalent bond, electrostatic, or
hydrophobic interactions. A typical biomolecule contains many
residues capable of forming covalent and noncovalent linkages
with the QD. The ability to control the site of attachment is
important to ensure that the biomolecule bound to the QD is
still active. Site-specific noncovalent binding of QDs to bio-
molecules has been achieved by exploiting carbohydrate-lectin
and streptavidin-biotin interactions (6, 7).
A common approach to facilitate protein purification involves
the use of genetically encoded oligohistidine (Hisn) tags (8-10).
Since Hisn-tags are recognized by nitrilotriacetic acid (NTA)
complexes of nickel(II) (Scheme 1), purification of these proteins
is achieved by passing the protein mixture through chromatog-
raphy columns containing Ni-NTA resins (11-13). Given the
widespread use of Hisn-tags and the fact that they can be
introduced into regions of peptides where they do not disturb
protein structure and function such as at the termini or in loops,
they provide a convenient way to achieve site-specific binding
for many applications (14-18). Hence, the fluorescent labeling
of specific proteins by encoding Hisn-tags on them coupled to
the recognition of these tags by Ni-NTA has become popular.
Initially, this was done using organic dye-NTA conjugates
(19, 20), but very recently it has been extended to QDs. Thus,
during the final stages of preparation of this manuscript the first
study showing that Ni-NTA-containing QDs that can be applied
to imaging His6-tagged proteins in live cells has appeared (21).
This is interesting because it has been shown that Hisn-tags can
also bind with very high affinity (Kd ≈ 1 nM) to QDs with
carboxylic acid functionalities requiring fewer synthetic steps
and cheaper reagents (22). In another study, however, it was
reported that QDs with carboxylic acids presented at the surface
bind His-tagged proteins only in the presence of Ni2+ cations
(23). Thus, it is interesting to investigate the advantages,
disadvantages and applicability of each of these functionalities
for the formation of QD-protein conjugates.
Here, we investigate binding of His6-tagged and untagged
GST as model protein to CdSe-ZnS core-shell nanoparticles
with carboxylates, NTA, and Ni2+-bound NTA at the surface.
QDs-GST conjugates are interesting because GSTs catalyze
the nucleophilic addition of GSH to the electrophilic center of
a range of nonpolar substrates as a way of detoxifying a wide
range of harmful endogenous and xenobiotic compounds (24),
and in drug resistance mechanisms (25). Since GST activity
requires not only the formation of a dimeric structure (i.e.,
protein-protein interactions) but also binding of both GSH and
an acceptor substrate (i.e., protein-substrate interactions), it is
a good enzyme to investigate the effect of specific and
nonspecific binding of QDs on enzymatic activity. We report
that the combination of His6-tagged GST with CdSe-ZnS
core-shell nanoparticles coated with Ni2+-bound NTA gives
the best results. The resulting QD-protein conjugate is strongly
fluorescent and readily purified by filtration or ultracentrifuga-
tion, which should enable widespread use of these QDs as a
“two-in-one” purification-fluorescence labeling tool. Moreover,
the QD binds the His6-tagged GST with little disruption of its
enzymatic activity, whereas QD binding is weaker and disrupts
enzymatic activity when GST lacks a His-tag or when Ni2+ is
unavailable. This is a significant result in that it shows that by
using this simple construct protein purification, fluorescent
tagging, and precise positioning of the fluorescent probe to
preserve structural/functional properties are all accomplished
in a single, inexpensive step. It shows also that QDs presenting
Ni-NTA at the surface provide a good alternative to site-
specifically binding His-tagged proteins if, like in this case, the
easier-to-make QDs with carboxylic acids at the surface fail to
do so (Vide infra).
The QDs decorated with NTA were easily prepared from the
reaction of CdSe-ZnS core-shell dihydrolipoic acid (DHLA)-* Corresponding author. E-mail: juan.mareque@ed.ac.uk.
Scheme 1a
a (A) Reversible binding between a His-tagged protein and Ni(NTA).
(B) Synthesis of the QD functionalized with NTA.
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capped QDs (26) with commercially available N,N-bis(car-
boxymethyl)-L-lysine hydrate using EDC and N-hydroxysuc-
cinimide as coupling agents in phosphate buffer solution
(Scheme 1). The product is purified by filtration with a Nanosep
100K centrifugal device (Pall Corporation). The composition
of the QDs was examined by X-ray photoelectron spectroscopy
(XPS). The XPS spectra showed the main diagnostic peaks of
the product QDs: a 2s peak at 400.1 eV due to N, and 2p3 and
2p1 peaks at 857.1 and 874.1 eV, respectively, due to Ni2+
(Supporting Information).
The photoluminescence intensity of the Ni-NTA-capped QD
is ca. 85% that of the NTA-capped QD (Figure 1). This is
important because the paramagnetic Ni2+ was found to strongly
quench the photoluminescence of some organic dyes, limiting
their applications (19).
We selected GST from the helminth worm Schistosoma
japonica (SjGST, 26 kDa monomer) as our target enzyme
because it is amenable to recombinant overexpression in E. coli
as a His6-tagged construct and has been well-characterized (9).
It is important to note that the His6-tag was genetically fused at
the N-terminus. The noncovalent attachment of His6-tagged and
untagged GST to the QD surface before and after derivatization
with Ni-NTA was analyzed by SDS-PAGE. A solution of the
QD or PBS (as control) was incubated with the corresponding
enzyme for 2 h and passed through a Nanosep 300K centrifugal
device. The retenate was redissolved in PBS buffer, and both
retenate and filtrate were analyzed by SDS-PAGE. In the
absence of the QD, His6-tagged and untagged GST were found
only in the filtrate. Several reports have shown that the DHLA-
coated CdSe-ZnS core-shell QDs are capable of binding His-
tagged proteins by coordination to Zn2+ ions at the nanocrystal
surface (22, 26-28). Our SDS-PAGE studies, however, did not
find protein in the retenate (Figure 2). Lack of binding could
be due to steric hindrance at the N-terminus location of the His6-
tag preventing access to the Zn2+ atoms of the nanoparticle. It
is also possible that the different synthetic procedures used to
prepare QDs lead to subtle changes at the QD surface which
affect binding of biomolecules. However, it is worth noting that
it is not rare for His-tagged proteins to exhibit different
properties depending on whether the His-tag is at the N- or
C-terminus, and that in the studies reporting direct His-tag
binding to carboxylate-coated QDs the His-tag was located at
the C-terminus (22, 26-28). In contrast, using the same
experimental conditions the Ni-NTA-capped QDs immobilized
both enzymes. Moreover, we found more His6-tagged than
untagged GST in the retenate. Binding was also investigated in
the presence of high salt concentrations. His6-GST binding to
Ni-NTA-capped QDs was not affected by 1 M NaCl. In contrast,
untagged GST did not bind to the QDs under these conditions,
which suggests it is predominantly electrostatic. Thus, high salt
concentrations can be used to avoid binding of untagged proteins
while ensuring binding of the desired His6-tagged target. The
enzyme was easily released from the QD surface upon addition
of 0.5 M imidazole, which competes for the Ni2+ binding sites.
Thus, decorating the surface of the QD with Ni2+ complexes
of NTA seems a good approach for noncovalent site-specific
fluorescent labeling of proteins, which can be used for instance
if carboxylate-functionalized QDs lacking Ni2+ ions fail.
Potential advantages of attaching Ni-NTA units to QDs could
be stronger interactions with the His-tag (Kd ≈ 10-13 M) (18)
and less sensitivity to steric hindrance and surface properties
by being further away from the nanocrystal surface.
Recently, the value of magnetic nanoparticles as affinity
probes to selectively trap and separate His-tagged proteins from
cell lysates has been elegantly demonstrated (29-32). The
protein purification efficiency of the Ni-NTA-capped QDs was
investigated by incubating cell lysates containing His6-tagged
GST for 2 h. Remarkably, pure fluorescently labeled GST was
obtained simply by ultracentrifugaton of this mixture (Figure
3). Thus, by using the Ni-NTA-capped QDs it is possible to
purify and fluorescently label His-tagged proteins in a single
step. Current methods for efficiently purifying and fluorescently
labeling His-tagged proteins need various labor-intensive and
expensive steps, such as conjugation of NTA derivatives on
support materials or the preparation of suitable magnetic
nanoparticles for purification purposes, followed by the attach-
ment of fluorescent tags. Another construct suitable for one-
step protein purification and site-specific labeling was recently
developed and involves organic fluorophore-doped Ni-NTA-
modified silica nanoparticles (33).
In order to obtain information about the effect of QD binding
on the catalytic activity of GST, we have used 1-chloro-2,4-
dinitrobenzene (CDNB) as substrate. The GST-catalyzed reac-
tion of GSH with CDNB produces a dinitrophenyl thioether
Figure 1. Photoluminescence spectra for CdSe-ZnS core-shell QDs
coated with DHLA-NTA and DHLA-Ni(NTA) (spectra were acquired
in 20 mM PBS pH 6.7, excitation at 350 nm; T ) 293 K). The integrated
emission decreases 15% upon Ni2+ addition.
Figure 2. SDS-PAGE of the retenate (R) and filtrate (F) after
ultrafiltration through a Nanosep 300K filter of His6-GST (a), untagged
GST (b), His6-GST incubated with QD (c), and untagged GST incubated
with QD (d). In each case, the enzyme and QD concentrations were
16.5 µM and 9.0 µM, respectively.
Figure 3. (A) SDS-PAGE studies of the cell lysate containing His6-
tagged GST (lane 2) and proteins released from the Ni-NTA-coated
QDs treated with PBS containing 0.5 M imidazole (lane 3) and
supernatant (lane 4) after ultracentrifugation. Lane 1 is the molecular
weight marker. (B) Images of the cell lysate after ultracentrifugation
and of the pure QD-bound His6-tagged GST.









































































which can be conveniently detected spectrophotometrically at
340 nm (34). His6-tagged GST and untagged GST were
incubated with the same concentration of Ni-NTA-capped QD.
We have found that His6-tagged GST retains its activity after
binding to the QD, whereas the untagged GST loses activity
(Figure 4). We suggest that the ability of the His6-tag to control
the position of the Ni-NTA-capped QD relative to the GST
active site is responsible for preserving the activity of the
enzyme. The X-ray crystal structure of SjGST (35) shows that
the N terminus, which is where the His6 tag was placed, is ca.
25 Å away from the essential catalytic residue Tyr7 (Figure 4).
We have examined the distribution of positively and negatively
charged residues and found that there are positive and negative
regions close to the active site. These are sites where in the
absence of the His6 tag nonspecific electrostatic binding could
occur, disrupting the enzyme activity. By comparing the activity
of the enzyme which did not bind to the QD with that of the
enzyme before incubation with QD, we estimated the protein
binding capacity and number of His6-GST molecules im-
mobilized on each QD (∼16). This surface coverage correlates
well with that found for QDs and proteins of similar size (26, 27).
In summary, we have shown that Ni-NTA-coated QDs
provide a straightforward method to, in one step, purify and
fluorescently reversibly label proteins. By using these QDs, we
have selectively purified and labeled an N-terminal His6-tagged
GST, which was not possible using QDs with carboxylates at
the surface. Moreover, we have found that Ni2+ provides a
docking site which helps to precisely orient the fluorescent
nanoparticle on the protein surface and that, as a result, GST
retained its activity. The use of His-tags has been broadly
adopted in the molecular biology and biochemistry communities,
and therefore this specific conjugation strategy should enable
widespread use of these QDs for a broad range of biological
applications.
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